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Abstract 
 
Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a 
devastating fatal neurodegenerative condition. Mutations in CCNF, the gene 
encoding the E3 ubiquitin ligase cyclin F, have been recently identified to cause 
ALS.  To examine the effects of the CCNFS621G mutation, three new induced 
pluripotent stem cell (iPSC) lines from two siblings with the same CCNFS621G 
mutation, and a healthy control, were generated through the employment of mRNA 
reprogramming. Characterisation of these stem cells indicated expression of 
pluripotency factors NANOG, and Oct4 (encoded by POU5F1) using 
immunocytochemistry and/or qRT-PCR.  Karyotyping of the reprogrammed stem 
cells revealed no chromosomal abnormalities, and comparison to other established 
stem cell lines via bioinformatics assay (the PluriTest) indicated cells with typical 
iPSC characteristics. The stem cells used in this study were all capable of 
differentiating to cell types from each of the three germ layers, as characterised by 
morphology and marker expression.  Using these stem cell lines, as well as three 
established iPSC lines, a robust motor neuron differentiation protocol was generated 
to produce a high yield of patient derived motor neurons to model ALS ‘in a dish’.  
These differentiated neuronal cultures had high expression of motor neuron markers, 
which were on average 88±1.4% Islet 1 positive, 90.5±1.4% neurofilament heavy 
(SMI32) positive, and 83.87 ± 2.48% HB9 positive.  Using these motor neuron 
models, it was possible to detect and quantify endogenous ALS relevant proteins 
including cyclin F, and the hallmark protein TAR DNA-Binding Protein-43 (TDP-
43). These proteins both localised in the nucleus, in aggregate structures consistent 
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with nuclear bodies. Quantification of both these proteins indicated a relative 
decrease in abundance in ALS patient derived motor neurons compared to those 
derived from healthy donors.  An additional TDP-43 species was also detected in the 
motor neurons differentiated from CCNFS621G patient iPSCs. These findings, 
combined with an increased retention of proteins tagged for degradations in the ALS 
patient derived motor neurons as determined by an UPS function assay, are 
consistent with a dysfunction in the UPS in CCNFS621G cells.  In further support of 
this proposed disease mechanism, proteomic analysis of ubiquitinated proteins 
revealed an increase in the proteins uniquely ubiquitinated in fibroblasts, iPSCs and 
motor neurons derived from a symptomatic CCNFS621G patient.  Together, these data 
are in agreement with the proposition that cyclin F substrate recognition is altered by 
the S621G mutation.  Ubiquitinomics analysis of motor neurons suggests that 
disruption to the normal activity of cyclin F likley causes downstream dysfunction to 
a number of downstream pathways including mitochondrial processes, the 
spliceosome, autophagy, heat shock, vesicles, extracellular matrix, and the UPS 
itself.  Comparison of the motor neuron ubiquitome to iPSCs and fibroblasts from 
which the neurons derive, serves to highlight the central nature of the UPS in 
regulating cellular processes such as the extracellular matrix and RNA processing. 
Examing the different cell types in this study, it is clear that ubiquitin also regulates 
cell type specific processes such as the cell cycle in iPSCs, and axogenesis in motor 
neurons reiterating the dynamic nature of the UPS. Together, the findings of these 
studies strongly implicate the UPS as a strong candidate for therapeutic target in 
ALS. 
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1. UBIQUITIN PROTEASOME SYSTEM DYSFUNCTION IN 
AMYOTROPHIC LATERAL SCLEROSIS 
 
1.1 Amyotrophic lateral sclerosis is a severe neurodegenerative 
disease 
Amyotrophic lateral sclerosis (ALS) is the most common of the devastating motor 
neurone diseases. ALS is characterised by the death of upper and lower motor 
neurons, which leads to an eventual loss of control over muscles responsible for 
voluntary movements, causing the muscles to harden and/or atrophy (Turner and 
Talbot, 2013).  Clinical presentation of ALS occurs in one of two manners; 75% of 
patients will first experience loss of motor control in their hands or feet, and muscle 
weakening advances through their arms or legs – referred to as limb onset.  One 
quarter of patients experience bulbar onset, wherein speech and swallowing difficulty 
are the first symptoms experienced, caused by muscle weakness in the tongue, 
pharynx, and larynx.   In both circumstances motor neuron death and subsequent 
muscle paresis spreads sequentially throughout the body; people living with ALS are 
rendered unable to utilise their hands, walk, speak, and will eventually experience 
difficulty breathing (Vucic et al., 2007).  In most cases of ALS, cause of death is 
usually the result of this respiratory failure, which can lead to broncho pneumonia 
(Corcia et al., 2008).  On average ALS is fatal within 27 months from the first 
clinical symptom presentation. There are 1,900 Australians currently suffering from 
ALS, though due to the speed of progression of the disease, the lifetime risk of 
having ALS has been estimated as high as 1:400 in Europeans (Shaw, 2010). 
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Currently no truly effective therapeutics are available (Parker et al., 2019). The first 
FDA approved therapeutic, Riluzole, will only extend patient life span by two to 
three months (Miller et al., 1996).  Edaravone, which was more recently approved for 
use, has been reported to cause a 33% reduced decline in patient physical ability 
(Abe et al., 2017; Parker et al., 2019; Rothstein, 2017). Accordingly, therapeutic 
development for ALS patients is greatly needed. 
 
A confounding factor in drug development for ALS is the variability of rate of 
progression and severity of symptom onset.  The average age for diagnosis of ALS is 
55 years old, however patients with juvenile forms of ALS have been reported as 
young as eight years old.  Patients have been known to rapidly decline, dying within 
months of diagnosis or conversely, living over 20 years with ALS (Cleveland and 
Rothstein, 2001). The affected biochemical pathways known to cause familial ALS 
dictate neither the speed of disease progression, nor age of onset.  For example, a 
mutation in the vesicle trafficking protein gene VABP has been documented to elicit 
disease onset in patients of the same family with the same mutation at a range of ages 
between 25 and 44 years old (Nishimura et al., 2004).  This variability strongly 
suggests that a combination of genetic and environmental factors play a role in 
pathogenesis (Robberecht and Philips, 2013).  Approximately 90-95% of ALS cases 
are sporadic, with no family history of the disease.  The remaining 10-5% of ALS 
cases are hereditary, referred to as familial ALS.  The majority of these patients will 
remain cognitively normal throughout the course of the disease, however, a subset of 
both sporadic and familial ALS patients has been identified with overlapping disease 
phenotypes between frontotemporal dementia (FTD) and ALS (Cleveland and 
Rothstein, 2001).  Patients experiencing behavioural and personality changes, 
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impairment in language comprehension and speech, and memory loss, as well as the 
degeneration of muscle, are now considered to be a part of the FTD-ALS spectrum 
(Neumann et al., 2006).  
 
1.2 ALS is a disease of proteostasis dysfunction 
 
The mutations in genes already known to cause ALS serve as our best clue in 
understanding the cellular mechanisms that lead to neurodegeneration.  A diverse 
array of gene mutations are known to cause ALS.  Genetic mutations in at least 33 
genes have been identified to cause ALS (Chen et al., 2013).  The normal functional 
roles of the affected proteins span a range of cellular mechanisms, including RNA 
binding and processing, mitochondrial function, cytoskeletal regulation, intracellular 
transport and protein homeostasis (Robberecht and Philips, 2013).  Mutations in 
these genes will, for some proteins, have indirect effects (via non-protein related 
mechanisms), or direclty affect the protein via a gain of toxic function or a loss of 
function in these proteins linked to motor neuron death in ALS (Ciechanover and 
Brundin, 2003).  
 
There is a recurring theme of protein homeostasis (proteostasis) dysfunction in ALS.  
Broadly, the healthy functioning of proteostasis mechanisms are particularly 
important as correctly folded proteins are required for all the aforementioned cellular 
mechanisms affected in ALS (Ciechanover and Brundin, 2003; Robberecht and 
Philips, 2013). More specifically, all genes with mutations that cause ALS are linked 
to proteostasis either through inclusion of the proteins in aggregates or through the 
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involvement of the gene product in proteostasis pathways (discussed later in this 
chapter). Mutant proteins arising from these genes are either incorporated, or 
increase the formation of, cellular aggregates. Many of these mutations affect 
proteins that are directly involved in proteostasis pathways. In both scenarios, 
disruption to the proteostasis machinery affects cellular viability.  Understanding 
cellular proteostasis is therefore crucial in delineating the events of ALS to establish 
viable therapeutic targets (Tanaka and Matsuda, 2014).   
 
Under normal conditions, an array of cellular proteostasis machinery prevents the 
accumulation and subsequent aggregation of misfolded and abnormal proteins.  
These undesirable proteins are removed via the ubiquitin proteasome system (UPS), 
the primary selective labelling and degrading mechanism of the cell, or via 
autophagy in the lysosome system. In some instances, proteins may be refolded into 
the correct conformation by cellular chaperones circumventing the need for protein 
degradation (Powers et al., 2009). Failure of the proteostasis machinery results in a 
build-up of abnormal proteins, which form aggregates within the cell.   
 
In ALS, protein aggregates form inclusions with a glassy (hyaline) or thread-like 
(skein) appearance in the spinal cord and brain stem (Mizusawa, 1993).  Inclusions 
are described in histology as eosinophilic or basophilic- staining positive with an 
acidic or basic dye, respectively. Inclusions including eosinophilic intraneuronal 
Bunina bodies, and Lewy-body-like inclusions are typical in ALS post mortem 
studies (Kato, et al., 1989; Okamoto et al., 2008).  These inclusions form via multiple 
cellular mechanisms (for review of the role of these proteostasis mechanisms in 
neurodegeneration see Yerbury et al. 2016), though are overwhelmingly positive for 
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ubiquitin, an essential posttranslational modification. Molecular investigations 
consistently identify ubiquitin-positive aggregates in ALS tissues, strongly 
implicating the UPS dysfunction in ALS (Arai et al., 2006).   
 
It is still not understood if these aggregates are protective or pathogenic.  The 
accumulation of aggregates can serve as a protective mechanism: aggregates 
minimise the exposure of the intracellular environment to misfolded proteins. 
Cellular mechanisms sequester these misfolded proteins/aggregates into cellular 
compartments to reduce inappropriate interactions such as the initiation of further 
aggregation.  The presence of compartmentalized aggregates therefore serves as a 
protection to the intracellular environment. Conversely, an increased presence of the 
aggregate prone species (reaching towards supersaturation) in the cell increases 
cellular aggregation (Ciryam et al., 2015). The presence of these aggregates 
contribute to intracellular crowding, which can affect proper protein structure and 
stability, protein activity, including protein-nucleic acid interactions, and also 
increases the likelihood of more protein misfolding events (Kuznetsova et al., 2014). 
Together, these features represent a likely pathogenic element to the presence of 
aggregates. It has been suggested that a healthy threshold of protein misfolding 
would exist within the cell to maintain proteostasis, however when proteostasis 
systems are overwhelmed, have deleterious effects.  (Hartl et al., 2011) 
Understanding the proteostasis mechanisms that maintain these levels, particularly 
the UPS, will be important for therapeutic intervention targeted at aggregate 
reduction in ALS (Webster et al., 2017). 
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1.3 The UPS is a central component of proteostasis, among other 
functions 
 
The UPS is the principal selective degradation pathway, involved in the degradation 
of up to 90% of intracellular proteins (Jansen et al., 2014; Lee and Goldberg, 1998). 
The UPS is comprised of both a labelling component: the ubiquitination system, and 
a degrading component: the proteasome system. In the ubiquitination system, the 
addition of ubiquitin, a highly conserved 8.5 kDa protein, acts as a posttranslational 
modification (Hershko and Ciechanover, 1998). When attached, the ubiquitin label 
signals proteins for specific relocation within the cell. The addition of an ubiquitin 
molecule was previously thought to act only as a protein degradation signal for the 
UPS, however ubiquitin signaling is now regarded as a much more complex cellular 
language (Ciechanover, 1994; Komander and Rape, 2012).  The addition of specific 
ubiquitin chains can affect protein function in proteasome-independent processes, 
referred to as the ubiquitin signaling system, thus this first component of the UPS is 
critical in ensuring the correct ubiquitin message is attached to the appropriate 
substrate protein (Atkin and Paulson, 2014; Komander and Rape, 2012). 
 
Proteins are subjected to a three-step process to label a target protein with ubiquitin: 
(1) the ubiquitin molecules are activated via binding to an ATP-dependent E1 
ubiquitin-activating enzyme, converting the C-terminal glycine residue to a high-
energy thiol ester intermediate; (2) the now active ubiquitin molecule is transferred 
to an E2 conjugating enzyme; (3) the E2-ubiquitin complex binds to a specific E3 
ubiquitin ligase, which also binds the protein of interest, attaching ubiquitin to the 
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target protein via the activated C-terminal glycine and a NH2 of the lysine on the 
substrate (Figure 1.1) (Ciechanover and Brundin, 2003; Hershko and Ciechanover, 
1998; Komander and Rape, 2012).  A single E3 ubiquitin ligase is capable of 
recognizing multiple target proteins, and conversely a single target protein may be 
ubiquitinated by more than one of the approximately 600 identified E3 ubiquitin 
ligases.  In recent years, commercial availability of ubiquitin immunoaffinity 
products combined with proteomic analysis techniques mean proteins ubiquitinated 
by the ubiquitin system can be qualified and quantified in a technique termed 
ubiquitinomics (Nagarajan et al., 2017).  
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Figure 1.1 Ubiquitin proteasome system schematic 
The addition of an ubiquitin (Ub) tag onto a protein substrate occurs through a three-
step process: Free ubiquitin is bound to an E1 enzyme, which delivers the ubiquitin 
to an E2 enzyme. The protein substrate is recognised by an E3 ubiquitin ligase. 
Binding of the E2-E3 complex permits the binding of ubiquitin to the protein 
substrate. This final step is repeated in the formation of a polyubiquitin chain. The 
type of ubiquitination (mono- or poly-ubiquitination) and the chain conformation 
indicates if a protein substrate is to be degraded by the proteasome, or is to serve 
another purpose in the cell. Ubiquitin is recycled following degradation or via 
deubiquitinating enzymes, back to the free pool. Figure adapted from Ciechanover 
and Brundin, 2003; Tai and Schuman 2008. 
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The redundancies in the UPS reiterate the importance of the system, particularly the 
final step (Hjerpe et al., 2016).  In the final rate-limiting step, the ubiquitin tag is 
covalently bound to an ubiquitin binding-domain on the protein substrate. If only a 
single ubiquitin tag is to be added to the protein (mono-ubiquitination) the protein 
will exit the cycle following this step (Hicke, 2001). Mono-ubiquitination usually 
acts as a localization signal, or a protein confirmation alteration for complex 
formation or activity modifying purposes, particularly as a histone modification for 
example for DNA transcription (Meas and Mao, 2015; Yau and Rape, 2016).  
Proteins requiring the addition of multiple ubiquitin molecules (multi-ubiquitination) 
or a chain of ubiquitin (poly-ubiquitination) will repeat this final step (Strieter and 
Korasick, 2012). Poly-ubiquitin chains are formed via a covalent isopeptide bond 
between a lysine residues or the N-terminal ubiquitin methionine (M1), and usually 
the C-terminal glycine of the following ubiquitin in the chain in an ATP-dependent 
manner (Lindquist and Kelly, 2011).  There is added complexity in the manner by 
which the poly-ubiquitin chains are linked, which affects the signaling properties of 
this post-translational modification (Figure 1.2).  The ubiquitin molecule contains 
seven lysine residues which act as linking points, including K6, K11, K27, K29, 
K33, K48, and K63 (Alfano et al., 2016).  Poly-ubiquitin chains may be linked 
repeatedly through the same lysine residues in a homologous chain, or can be linked 
by a combination of any of the seven lysine residues, or M1 in a heterologous chain 
(Meyer and Rape, 2014).  These heterologous chains are either single straight chains, 
or branched chains, diverging from a single ubiquitin molecule into two or more 
chains (Alfano et al., 2016; Kim et al., 2007; Peng et al., 2003). The diversity of 
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possible ubiquitin tags adds significant complexity to ubiquitin signaling (Yau and 
Rape, 2016).   
 
 
Figure 1.2 Ubiquitin post-translational modifications  
Ubiquitin can be bound to protein substrates in many forms - as a single ubiquitin 
tag, in multiple locations on a protein, and as complex chain structures. Chains form 
as ubiquitin binds to one another on one of the ubiquitin lysine (K) residues (K6, 
K11, K27, K29, K33, K48, K63) or on methionine 1 (M1). Chains may be 
consistently bound to the same lysine residues I.e. all K48 bound, or may bind to 
different residues; branching of the chains can also occur. These different types of 
ubiquitin chains (or mono ubiquitin) binding encode different signals. Figure adapted 
from Yau and Rape 2016. 
 
The idiosyncrasies of the different ubiquitin chain codes are currently not fully 
understood (Alfano et al., 2016). Some specific signals have been identified – for 
example, if a protein is destined for degradation, the final step is typically repeated to 
produce a poly-ubiquitin chain of four ubiquitin tags, joined by all K48 or all K11 
links, to signal degradation by the proteasome; this is the most common signal for 
ubiquitin chains (Yau and Rape, 2016).  Different chain codes are also responsible 
for signaling a range of fundamental cellular functions including cell cycling, DNA 
damage control, transcriptional regulation, cellular transport (including axonal 
transport) and cellular survival, in addition to protein degradation (Ciechanover and 
Brundin, 2003). However, most of the ubiquitin ‘code’ combinations have not been 
characterized (Alfano et al., 2016; Di Lello and Hymowitz, 2016; Komander and 
Rape, 2012). 
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Ubiquitin chains are typically formed from the pool of free ubiquitin in the cell 
(Groothuis et al., 2006). Ubiquitin chain lengths can however be modified following 
synthesis.  Deubiquitinating enzymes (DUB) are able to reduce chain length, and 
remove ubiquitin chains/monoubiquitin (Hershko and Ciechanover, 1998; Hicke, 
2001). In some cases, ubiquitin acts as an inhibitory post-translational modification, 
so the removal of ubiquitin by a DUB serves to alter enzyme activities (Groothuis et 
al., 2006).  This ubiquitin removal by DUB recycles the ubiquitin back to the free 
ubiquitin pool for reuse (Park and Ryu, 2014).  Interestingly, this reserve of ubiquitin 
is affected by cellular homeostasis.  Ubiquitin is redistributed in proteotoxic stress 
due to competition for the limited pool of free ubiquitin. Quantification of human 
frontal cortex by affinity chromatography and protein standard absolute 
quantification mass spectrometry indicated that 82% of ubiquitin in the brain is free 
ubiquitin (Dantuma et al., 2006).  It is therefore unsurprising that depletions to this 
ubiquitin pool would exacerbate cellular stress, and that free ubiquitin is considered 
neuroprotective (Farrawell et al., 2017; McKinnon and Tabrizi, 2014; Yerbury et al., 
2016; Ryu et al., 2014).  It has been speculated that as aggregates commonly 
sequester ubiquitin, that aggregate formation in neurons would lead to a reduction in 
free ubiquitin reserves, decreasing ubiquitin availability for other cellular functions, 
leading to an increase in cellular stress (Hallengren et al., 2013). 
 
Proteins fated for proteolysis by the UPS are degraded by the proteasome.  The 
predominant proteasome in mammals is the 26S proteasome, a cytosolic complex 
that is composed of two caps, and a central degradation unit.  The two caps (19S) are 
regulatory units, which recognize the ubiquitinated protein, which in turn is 
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internalized and undergoes proteolysis in the degradation unit (20S) (D. Voges et al., 
1999).  The 26S proteasome has been detected in three main conformations, which 
are hypothesized to correspond to a three-step process to selectively degrade 
proteins: (1) the substrate accepting state, wherein ubiquitin is recognized and 
recruited, along with the bound protein destined for degradation; (2) the intermediate 
state, which corresponds to point of no return for the proteolysis; (3) the 
translocating step, in which the protein is processed by the proteasome, degrading it 
to small peptides (Pickart and Eddins, 2004). 
 
1.4 Neurons are susceptible to proteostasis dysfunction 
 
Although every cell in the body must carry out selective protein degradation to 
maintain proteostasis, neurons appear more sensitive to cellular stress (including 
proteostasis dysfunction) than other cell types (Yerbury et al., 2016).  Neurons are 
some of the most metabolically and structurally complex cells in the human body.  
Neurons have a high metabolic demand, owing to the complex structure and 
requirement for constant activity in the cell type. Neuronal morphology is very 
distinct; neurons, particularly motor neurons, have an incredibly large surface area-
to-volume ratio relative to other cell types, owing to the specialist structures such as 
dendrites and the axon, some of which extend great distances throughout the body to 
innervate muscles (Holzbaur, 2009; Tai and Schuman, 2008).  This high surface 
area-to-volume ratio is taxing not only regarding the transport requirements of the 
cell, which alone is energetically taxing, but also causes an overwhelming 
requirement for the cell in terms of protein synthesis, including the needs for 
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membrane and scaffolding proteins.  In addition to these cellular needs, the primary 
function of neurons is reliant on the ability of the cell to compartmentalize.  Vesicle 
formation is essential for the primary role of communication in the neuron, and 
requires a plethora of proteins to function (Tai and Schuman, 2008).  As protein 
synthesis must be balanced by protein degradation in the cells, these high demands 
on the synthesis equally place high demands on the protein degradation system of 
neurons (McKinnon and Tabrizi, 2014).   Unlike many other cell types of the body, 
neurons are generally post-mitotic; most neurons must therefore endure a lifetime of 
stress upon these systems, with very limited capacity for turnover, unlike most other 
cell types (Tai and Schuman, 2008).  
 
Neurons are more susceptible to changes in UPS efficiency when compared to other 
neural cell types (Hallengren et al., 2013).  In a report by Ding et al. (2004) primary 
rat neurons from the cerebral cortex displayed a higher increase in nucleic acid 
oxidation than primary rat cerebral cortex astrocytes when treated with the same 
concentration of the proteasome inhibitor MG262 for 24 h.  The group used 
immunocytochemistry to assess the hydroxyl species 8-hydroxyguanosine and 8-
hydroxy-2’deoxyguanosine to indicate nucleic acid stress, and observed that neurons 
expressed higher levels of these hydroxyl species compared to other neural cells 
(Ding et al., 2004).  The authors noted differences in the level of immunoreactivity to 
the hydroxyl species in the different cell types based on general morphology, 
although unfortunately they did not quantify the differences between neurons and 
astrocytes, nor did they identify the types of neurons and astrocytes in the mixed 
culture other than by morphological observation.  Despite these flaws, the overall 
observation that neuronal cells elicits an increased stress response to proteasomal 
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inhibition is pertinent given the selective neuronal cell death in neurodegenerative 
diseases such as ALS. 
 
1.4.1 Motor neurons are particularly sensitive to UPS stresses 
Sensitivity of motor neurons to UPS stress has previously been indicated. Ocular 
motor neurons, which remain relatively free from degeneration during the course of 
ALS pathogenesis, were compared to spinal motor neurons in a study by 
Brockington et al. (2013).  A comparison of human ocular motor neurons and spinal 
motor neurons by microarray analysis indicated differences in expression of genes 
relating to ubiquitination, as well as mitochondrial function and RNA metabolism. 
The group detected an increase in the expression of 119 genes related to proteostasis 
in ocular motor neurons compared to the spinal motor neurons, including 25 genes 
deemed to belonged to the UPS (Brockington et al., 2013). The group suggested that 
it may be this increased expression of UPS genes that allows the ocular motor 
neurons to withstand the effects of ALS progression, compared to spinal motor 
neurons. 
 
Dysfunction of the UPS is already known to contribute to ALS, with a number of 
UPS gene mutations identified as causing the disease.  Ubiquitin is required as an 
essential protein for healthy neuronal function and survival (Park & Ryu 2014).  
Decreased function of the UPS leads to an increase in aggregated proteins and an 
increase in ubiquitin tagged proteins or “UPS substrates” (Bence et al., 2001). 
Deficits in the ubiquitin system in particular are detrimental to multiple facets of 
neuronal function (McKinnon and Tabrizi, 2014).  Cell membrane proteins, proteins 
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involved in vesicle formation, including pre- and post-synaptic terminal proteins, and 
microtubule proteins all require ubiquitin signaling to function (Tai and Schuman, 
2008).  Glycine receptors, for example, are thought to be degraded via internalization 
and cleavage by the lysosome following ubiquitination (Manuel and Sorkin, 2007).  
Disruption to these pathways would have dire consequences to general cellular 
functions, as well as neuron specific functional pathways (Tanaka and Matsuda, 
2014).  
 
1.5 Proteostasis genes that cause ALS provide valuable information 
for all forms of ALS 
 
A number of genes with ALS causing mutations code for proteins of the UPS (Chen 
et al., 2013; Table 1.1).  The effects of these mutations are varying, however, that 
these UPS associated gene mutations are amongst the ALS causing genes indicates 
that defects in the UPS system cause ALS.  Examination of these identified genetic 
causes and subsequent gene products provides insight into both the patient subsets 
with these mutations, while also providing a greater understanding of the general 
mechanisms that cause ALS. Such information is of undeniable benefit to the 
majority of ALS sufferers who have no genetic history to draw from (Robberecht and 
Philips, 2013). 
 
1.5.1 Network analysis reveals UPS genes dysregulated in ALS 
Recent gene co-expression analysis by Ferrari et al. (2016) identified proteostasis as 
a key pathway in the FTD spectrum. In an effort to understand the systems 
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implicated in the FTD spectrum, which includes ALS, a gene co-expression network 
analysis of 101 healthy individuals was performed.  Clustering of co-expression 
patterns in the frontal cortex, temporal cortex, putamen, thalamus, hippocampus, 
white matter, cerebellum and medulla obtained by microarray indicated that 
C9ORF72, VCP, UBQLN2, and OPTN, genes already associated with ALS, were 
central players in FTD. The group also identified a panel of potential novel genes 
that are likely to be associated with ALS/FTD, including nine proteins from the UPS 
pathway (Ferrari et al., 2016). These include proteins that form the E3 ubiquitin 
ligase complexes: CAND1, which codes for cullin associated neddylation dissociated 
1, a protein that assembles SKP1-CUL1-F-box complexes (Zheng et al., 2002), 
MYCBP2, which codes for an E3 ubiquitin ligase (Holland, 2011), CUL2, which 
codes for cullin 2, a component of an E3 ubiquitin ligase complex (Brower et al., 
2002), BTRC, which codes for F-box/WD repeat-containing protein 1A, an F-box 
protein (Mudhasani et al., 2016), COPS3, which codes for a component of a complex 
that deneddylates cullin in SCF-Cul1-F-box ligases and other SCF ligases (Lydeard 
et al., 2013). Other identified UPS associated genes include PLAA, the gene for 
phospholipase A-2-activating protein, which maintains ubiquitin levels (Fu et al., 
2009), UBQLN1, which codes for ubiquilin 1, a ubiquitin-like protein that associates 
with the proteasome and ubiquitin ligases (Kim et al., 2009), USP9X which codes for 
probable ubiquitin carboxyl-terminal hydrolase FAF-X, which serves to 
deubiquitinating proteins (Dupont et al., 2009), and PSMD12, which codes for a 
proteasome subunit (Küry et al., 2017).  Interestingly, the authors noted gene co-
expression network analysis did not strongly implicate a hallmark ALS protein, 
TDP-43 in the ubiquitin proteasome pathways, however they did find an increase in 
RNA regulation which is associated with TDP-43 (Strong et al., 2007). This network 
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analyses further implicated the ubiquitin proteasome system in ALS (Ferrari et al., 
2016). 
 
1.5.2 ALS causing mutations in UPS associated genes  
Mutations in UPS machinery-coding genes have been identified to cause ALS.  
Mutations in the genes for UPS proteins ubiquitin-like protein ubiquilin 2, 
(UBQLN2), valosin containing protein (VCP), sequestesome 1 (SQSTM1), 
optineuron (OPTN), TANK-binding kinase 1 (TBK1) and more recently, cyclin F 
(CCNF) have all been identified to cause ALS (Abel et al., 2012; Williams et al., 
2016).  These proteins normally serve a range of function in the UPS. Ubiquilin 2 
associates with ubiquitin ligases, poly-ubiquitin chains, and proteasome subunits and 
is thought to assist in transitioning proteins between the labelling and degradation 
systems of the UPS, including protein clearance mechanisms (Hjerpe et al., 2016; 
Schuberth and Buchberger, 2008).  VCP regulates ubiquitination via facilitating 
ubiquitination of proteins by bind directly to E3 ubiquitin ligases, and facilitates 
ubiquitin removal by binding to DUBs (Meyer et al., 2012). (Moscat et al., 2006; 
Sowa et al., 2009; Wang et al., 2006).  Sequestosome 1 is a ubiquitin binding protein 
which indirectly activate Nuclear Factor Kappa-Light-Chain-Enhancer of Activated 
B Cells (NF-κB) through ubiquitination of an E3 ubiquitin ligase (Moscat et al., 
2006).  Dorfin is an E3 ubiquitin ligase - which interestingly ubiquitinates SOD1 for 
degradation  (linking SOD1 accumulation and UPS dysfunction) (Niwa et al., 2002; 
Sone et al., 2010).  These UPS proteins act on a wide range of proteins, implicating 
the downstream effects of these mutations are vast, and due to UPS redundancies, are 
still largely unknown.  Importantly, this in turn also suggests that targeting 
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proteostasis proteins is a valid path for therapeutics in ALS caused by mutations 
other than those directly linked to the UPS (Ishigaki et al., 2004). 
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Table 1.1 ALS associated mutations and proteostasis dysfunction 
Gene Protein Normal Function ALS Proteostasis dysfunction  Reference 
SOD1 
Superoxide dismutase 1  Destroying free superoxide radicals Ubiquitin positive JUNQ inclusion formation  Farrawell et al., 2017; Valentine et 
al., 2005; Wong et al., 1995 
ALS2 
Alsin  
Guanine Nucleotide Exchange Factor (Rab5 
and Rac1) Loss of function increases aggregate formation. Hadano et al., 2001; Li et al., 2011 
SETX 
Senataxin 
DNA/RNA helicase, RNA transcription and 
DNA repair 
Present in ubiquitin positive inclusions, including in 
axonal spheroids 
Rabin et al., 1999; Suraweera et 
al., 2009 
SPG11 
Spatacsin  Axonal maintenance and cargo trafficking Hyaline inclusions present in a patient post mortem 
study. 
Orlacchio et al., 2010; Pérez-
Brangulí et al., 2014 
FUS 
Fused in sarcoma RNA transcription and processing Ubiquitin positive aggregate formation and 
increased rate of aggregate formation. 
Kwiatkowski et al., 2009; Zinszner 
et al., 1997 
VAPB 
VAMP- associated 
protein B 
Protein transport; Implicated in the unfolded 
protein response 
Altered unfolded protein response and increase 
aggregate formation. 
Nishimura et al., 2004; Tokutake et 
al., 2015 
ANG 
Angiogenin Blood vessel stimulator Involved in stress granule formation. Dewey et al., 2012; Gao and Xu, 
2008; Greenway et al., 2006 
TARDBP 
TAR DNA binding 
protein-43 (TDP-43) 
DNA and RNA binding protein to regulate 
transcription and splicing. 
Present in aggregates, including ubiquitin positive 
aggregates. Wild type TDP-43 is ubiquitinated. 
Johnson et al., 2009; Sephton et 
al., 2010; Strong et al., 2007 
FIG4 
Phosphoionositide-
5phosphatase (via factor 
induced gene 4) 
Hydrolyzes D5-phosphorylated 
polyphosphoinositide substrates; biogenesis of 
vesicular bodies  
Impairs protein trafficking.  Increases protein 
aggregation when mutations accompanied by 
Vac14 mutation. 
Chow et al., 2009; Michell and 
Dove, 2009; Sbrissa et al., 2007 
OPTN 
Optineurin 
Golgi complex maintenance, membrane 
trafficking and exocytosis.  Links myosin VI to 
the golgi complex. 
Found in inclusion bodies, and mutant forms impair 
protein trafficking including to the lysosome. 
Ubiquitin positive aggregates. 
Maruyama et al., 2010; Sahlender 
et al., 2005 
 52 
 
ATXN2 
Ataxin-2 Stress granule and P body formation. Modifies TDP-43 toxicity, mutation increases 
formation of TDP-43 positive aggregates.  
Elden et al., 2010; Nonhoff et al., 
2007 
VCP 
Valosin containing 
protein 
Part of a complex that binds ubiquitinated 
proteins and exports misfolded proteins from 
the ER to the cytoplasm. 
Impairs the unfolded protein response, which leads 
to protein aggregation and the UPS. Found in 
ubiquitin positive inclusions. 
Ishigaki et al., 2004; Johnson et al., 
2010; Weihl et al., 2008 
UBQLN2 
Ubiquitin-like protein-2 
UBQLN2 recognizes aggregated and 
misfolded proteins for delivery to the 
proteasome for degradation. 
Protein degradation impairment and increase in 
misfolded proteins leading to increase in 
aggregates. 
Deng et al., 2011; Hjerpe et al., 
2016 
SIGMAR1 
Sigma non-opioid 
intracellular receptor 1 
Inter-organelle signaling modulator at ER 
including Ca
2+ 
Reduces aggregation formation 
- via chaperone activity  
Aggregates in vitro. TDP-43 and FUS positive 
cytoplasmic inclusions in detected in ALS patient 
tissue. 
Al-Saif et al., 2011; Gregianin et 
al., 2016; Miki et al., 2018; Su et 
al., 2010 
CHMP2B 
Charged multivesicular 
body protein 2b 
Subunit of endosomal sorting complexes 
required for transport (ESCRTs), which 
regulate protein trafficking in lysosomal 
degradation. 
Mutation in CHMP2B results in ubiquitin positive 
inclusion body formation. Protein trafficking 
disrupted. 
Cox and Mann, 2008 
PFN1 
Profilin 1 
Regulates the assembly of actin monomers to 
filaments. 
Formation of ubiquitin positive inclusions and 
cytoskeletal dysfunction. 
Poggetto et al., 2015; Wu et al., 
2012; Yang et al., 2013 
C9orf72 
C9ORF72 Regulates endosomal trafficking. p62/ubiquitin- and TDP-43 positive inclusions form 
in C9ORF72 patients. Farg et al., 2014; Mori et al., 2013 
CHCHD10 
Coiled-coil helix-coiled-
coil-helix domain 
containing 10 
Unconfirmed. Predicted to be involved in 
oxidative phosphorylation. Localised in the 
mitochondria. 
Not yet detected.  Bannwarth et al., 2014 
DCNT1 
Dynactin 
Retrograde transport of vesicles and 
organelles along microtubules 
Axonal protein trafficking dysfunction. Included in 
ubiquitin positive aggregates with SOD1 in 
SOD1G93A mouse model. 
Ayloo et al., 2014; Puls et al., 
2003; Teuling et al., 2008 
TUBa4a 
Tubulin Alpha 4a Cytoskeletal protein  
Forms inclusions in primary motor neurons; 
ubiquitin positive aggregates detected in Cos7cells 
expressing mutant TUBa4a. 
Elden et al., 2010, Smith et al., 
2014; Rademakers & Blitterswijk, 
2014 
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DAO 
D-amino acid oxidase 
Oxidative deamination of neutral and polar 
amino acids (D-isomers) Increases ubiquitinated aggregates Mitchell et al., 2010; Pollegeioni 
CCNF 
Cyclin F An E3 Ubiquitin ligase Aggregate formation, UPS dysfunction Williams et al., 2016 
NEFH 
Neurofilament, heavy 
200kDa, heavy chain 
Neuronal cytoskeletal filament protein  Neurofilamentous swellings  Figlewicz et al., 1994;  lees et al. 
1988 
PRPH 
Peripherin 
Neuronal intermediate filament protein in cells 
connected to the periphery Ubiquitinated skein-like inclusions Leung et al. 2004 
SQSTM1 
Sequestosome 1 A ubiquitin-binding protein, activates NF- κB Included in ubiquitin positive inclusions, increases 
aggregate formation. 
Fecto et al. 2011; Moscat 2006; 
Mizuno et al. 2006 
GLE1 
GLE1 
Transcription control, and nuclear RNA export 
as a nuclear pore factor. 
Cytoplasmic aggregates in overexpression cellular 
systems.  
Kaneb et al. 2015; Kutay & Panse, 
2008, Aditi et al., 2016 
hnRNPA2B1/A1 
Heterogeneous nuclear 
ribonucleoproteins 
A2/B1 
RNA binding protein. Forms heterogeneous 
nuclear RNA complex. 
Prone to self-aggregation.  Reduced hnRNPA2B1 
has been detected in conjunction with TDP-43 
aggregates in ALS patient spinal cords.  
Calini et al., 2013; Honda et al., 
2015, Kim et al., 2013 
NEK1 
NIMA related kinase 1 
Phosphorylation of an E3 ubiquitin ligase Von 
Hippel-Lindau protein, and voltage dependent 
anion channel 1  (VDAC1) 
No cellular ALS studies have been performed to 
date following the recent identification of mutation. 
Known to associate with ALS associated proteins 
at endogenous levels including VAPB, VAPA, 
Alsin, C21orf2. 
Kenna et al. 2016; Patil et al., 
2013; Chen et al., 2009 
TBK1 
TANK-binding kinase 1 
Mediates degradation by UPS and 
inflammatory response; Complexes to mediate 
NF- ΚB activation,  
TDP-43, and p62 positive inclusion detected in 
patients.  
Pomerantz & Baltimore 1999; 
Freischmidt et al., 2015 
MATR3 
Matrin-3 RNA/DNA binding protein 
Aggregates with TDP-43 and MATR3 detected in 
tissue of ALS patients. MATR3 aggregates 
detected in C9ORF72 patients. 
Johnson et al., 2014; Zeitz et al., 
2009 
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1.5.3 Proteostasis dysfunction evident in sporadic ALS 
Understanding the dysfunction caused by the mutations to the UPS system is 
essential in treatment of ALS in patients who have proteostasis dysfunction. A 
proteostasis dysfunction phenotype is common not only amongst FALS, but is also 
described in SALS post mortem investigations. Transcriptome analysis of 148 post 
mortem cortex samples, the majority of which were SALS patients, has recently 
indicated that 61% exhibited an oxidative and proteotoxic phenotype, as clustered by 
an unsupervised machine learning algorithm (Tam et al., 2019).  Both Lewy-bodies 
and Bunina bodies are reported in SALS post mortem tissue (Kato et al., 1989; 
Okamoto et al., 2008). In a study of 102 SALS patient post mortem tissue, 86% were 
positive for Bunina aggregate structures (Piao et al., 2006).  The majority of SAL 
studies describe TDP-43 post mortem pathology, including cytoplasmic and nuclear 
inclusions (as described in the following section) (Van Deerlin et al., 2008; Webster 
et al., 2017). In some cases, all three - Lewy-bodies, Bunina bodies, and TDP-43 
inclusions have been detected in the same tissue (Miki et al., 2018). Given that the 
majority of ALS is SALS, identifying commonalities between SALS and FALS is an 
important step in therapeutic development.  The presence of these common 
aggregates, a result of proteostasis dysfunction, clearly indicates proteostasis as a 
critical target in ALS therapeutics (Webster et al., 2017). 
 
1.5.4 TDP-43 pathology implicates proteostasis dysfunction 
ALS is widely regarded as a TDP-43 proteinopathy, due to the detectable TDP-43 
positive aggregate phenotype common to post mortem investigations. TDP-43 
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positive inclusions are reported in over 90% of ALS pathology, representing the most 
prevalent hallmark of ALS pathology (Scotter et al., 2015).  Pathological TDP-43 has 
been detected in many altered forms, including ubiquitinated, hyper-phosphorylated, 
and cleaved (C-terminal fragment) (Mackenzie et al., 2010).  Why this protein is so 
widely included in aggregates in ALS is not clear. Normally, soluble TDP-43 is 
degraded by the UPS, and under conditions of aggregation, TDP-43 will be degraded 
by autophagy (Scotter et al., 2014). Disturbance to these proteostasis systems would 
therefore yield a retention of TDP-43, as seen in ALS pathology (Mackenzie et al., 
2010).  
 
Despite the presence of TDP-43 in a wide range of neurodegenerative disease 
pathology, the functional roles of this protein are still yet to be fully understood. 
TDP-43 has been detected to have both cytosolic and nuclear functions (Ederle and 
Dormann, 2017). Cytosolic localisation of TDP-43 is widely regarded as an ALS 
phenotype, alongside the presence of TDP-43 in aggregate/inclusion structures.  This 
mislocalisation prevents proper function of TDP-43 in mRNA splicing, as well as 
transcription, gene regulation and non-coding RNA processing (Ederle and 
Dormann, 2017). Ubiquitously expressed, TDP-43 is also essential in embryonic 
development (Sephton et al., 2010). Fortunately, this early expression of TDP-43 
facilitates the examination of the role of this protein in models such as patient 
derived stem cell and as well as stem cell derived motor neuron models which are 
increasingly commonly engaged for ALS research (Lee and Huang, 2017).  
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1.6 Mutations in CCNF can cause ALS 
 
Recent identification of a novel ALS associated gene has reiterated the links between 
the UPS and ALS.  Mutations in CCNF, a gene encoding cyclin F, an E3 ubiquitin 
ligase were implicated in a genetic study using genome-wide linkage analysis 
coupled with next generation sequencing (Williams et al., 2016). Genetic analysis of 
two patients revealed the mutation CCNFS621G was shared in the cyclin F gene.  
Genetic analysis revealed a further nine novel FTD/ALS causing mutations in the 
CCNF gene in families from Australia, Italy, Spain, Canada, Japan, the United States 
of America, and the United Kingdom.  Since this initial population study, the 
prevalence of cyclin F mutation in ALS and FTD in mainland China has been 
detected at 0.6% (Pan et al., 2017) in one cohort study, and 2.56% in FALS patients 
and 1.03% in SALS in another cohort (Tian et al., 2018).  One patient with a 
mutation in a 207 ALS patient cohort was identified in Taiwan (Y.-C. Lee et al., 
2017). 
 
1.6.1 The role of cyclin F must differ between mitotic and non-mitotic cells 
Prior to this identification of cyclin F as an ALS associated protein, the focus of 
cyclin F investigation was in cancer research. Accordingly, the function of the 
protein has been predominantly investigated in mitotic cells (Table 1.2).  Cyclin F is 
one of the eight conserved cyclin proteins that regulate the cell cycle (D’Angiolella 
et al., 2013).  First identified in 1994, cyclin F shares the common features of a 
cyclin - cyclin F levels fluctuate throughout the cell cycle, and crucially, changes in 
concentrations of cyclin F affect the cell cycle (Kraus et al., 1994). Control of the 
cell cycle is believed to be through degradation of cyclin F substrates. The conserved 
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sequence rich in proline, glutamic acid, serine, and threonine (PEST) determines 
ubiquitin dependent degradation, as is the mechanism for many cyclins (Bai et al., 
1994). The effect of cyclin F on the cell cycle has been demonstrated by increased 
expression of cyclin F in C33A cells.  Increased expression significantly increased 
the proportion of cells that expressed CD20, indicating the cells were in G2/M phase 
as measured by flow cytometry (Bai et al., 1994).  Cyclin F oscillates through the 
cell cycle in a pattern similar to cyclins A and B, though it peaks in G2 (Bai et al., 
1994; Murray, 2004).  
 
Cyclin F, also known as the F Box Only Protein 1, contains two motifs fundamental 
to its function in the UPS as an E3 ubiquitin ligase.  The PEST region is found in 
many cyclins; unlike other cyclins, cyclin F is the only cyclin that is kinase 
independent, thereby earning it the name  ‘The Orphan Protein’ (Bai et al., 1994). 
Cyclin F was the first identified member of the F box protein family; these proteins 
contain an F box motif, which is an approximately 55 amino acid sequence that 
mediates protein-protein interactions (Bai et al., 1996; Kraus et al., 1994). The F box 
motif is crucial to the activity of cyclin F as this motif binds to S-phase kinase-
associated protein 1 (SKP1) (Craig and Tyers, 1999); the binding of these two 
protein subunits allows cullin 1 (CUL1) to bind and form the SKP1-CUL1-F-box 
protein, an E3 ubiquitin ligase complex (Xie et al., 2013).   
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Table 1.2 Summary of cyclin F research  
Author Year Findings 
Kraus et al  1994 First Identification of cyclin F  - described as a cyclin  
Bai et al  1994 
Sequencing of CCNF indicated presence of conserved proline 
glutamic acid serine threonine rich (PEST) sequence that 
determines ubiquitin dependent degradation of other cyclins  
Bai et al 1996 
Skp1 identified as interactors with cyclin F, proposed as a 
component of an E3 ubiquitin ligase complex 
Movsesyan et 
al 
1996 
Nerve growth factor and fibroblasts growth factor reduced cyclin 
F expression in PC12EY cells  
Ng et al  1998 
Indicates Skp1 interact with Skp1 binding of Skp2 and cyclin F 
similar (noted as unpublished)  
Kong et al  2000 
Nuclear localisation signals of cyclin F are functional and 
independent; thought to co-localise with cyclin B to transport to 
nucleus (as cyclin B has no NLS) 
Fung et al 2002 
Cyclin F is degraded when the spindle-assembly checkpoint. 
Accumulates upon DNA damage checkpoint activation 
Tetzlaff et al 2004 
Heterozygous CCNF KO no obvious effects in mice; CCNF KO 
or non-functional cyclin f had developmental anomalies - lethal 
by day E10.5. Cyclin F deletion yields no obvious phenotypes in 
certain tissues (gut, bone, bladder, cornea, lens) fibroblast cell 
cycle progression affected 
D’Angiolella et 
al 
2010 
Cyclin F (as the substrate recognition unit) ubiquitinates 
centrosome duplication protein CP110; suggests cyclin F 
expression influences γ-tubulin and centrin 2 expression; 
Proposes cyclin F has the opposite role to cyclin E (limiting 
centrosome duplication via degradation of CP110) 
Emanuele et al 2011 
NUSAP1 is a cyclin F substrate; cyclin F substrates may also 
be acted on by other ligases (as would be expected)  
Buganim et al  2012 
Cyclin F expressed in mouse iPSCs during reprogramming 
(referenced as a cell cycle regulator marker) 
D’Angiolella et 
al 
2012 
Cyclin F ubiquitinates RRM2 for degradation when accumulated 
in the nucleus.  Binding of RRM2 different to binding of CP110. 
Cyclin F downregulation required for efficient DNA repair. 
Cyclin F keeps dNTPs in balance 
Klein et al  2015 
Cyclin F active in G2 DNA damage checkpoint checkpoint 
control via B-Myb  (and cyclin A pathway) suppression 
Elia et al  2015 
Nuclease EXO1 ubiquitinated  (and subsequently degraded) by 
cyclin F following UV radiation 
Choudhury et 
al  
2016 
There is a reciprocal feedback loop between SCF
cyclin F
 and 
anaphase promoting complex/cyclosome (APC/C
Cdh1 
) resulting 
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in the degradation of cyclin F signalled by APC/C
Cdh1 
in G1 
phase and the reverse in S phase  
Walter et al 2016 
Cell division cycle 6 (CDC6) is a cyclin F substrate; degradation 
of CDC6 following ubiquitination via cyclin F is required to 
prevent more than one DNA replications occurring  
Choudhury et 
al 
2017 
Cyclin F phosphorylated by protein kinase B (AKT), stablising 
cyclin F and increasing formation of SCF
cyclinF
 
Williams et al  2016 
First study identifying mutations in the CCNF gene causes ALS. 
Nine mutations identified globally. Phenotype included 
increased abundance of ubiquitinated TDP-43 ,ubiquitinated 
RRM2 and ubiquitin proteasome system dysfunction 
Hogan et al  2017 
Examined effects of CCNF
S621G
 in zebrafish - found reduced 
response to light stimulus, and reduced response distance in 
positive responders.  Examined expression of CCNF
S621G
 in 
Neuro-2a cells resulted in upregulation of caspase 3 activity 
compared to WT 
Lee et al  2017 
Identified 7 phosphorylation sites on Cyclin F 
transfected/expressed in HEK293 cells - 5 novel including 
Ser621. Mutation at S621G prevents phosphorylation, 
increasing ubiquitination activity. Phosphorylation decreases 
activity of cyclin F 
Pan et al  
  
2017 
The prevalence of CCNF mutation in ALS and FTD patients in 
mainland China was detected at 0.6% 
Lee et al  2017 
One patient in a 207 ALS patient cohort was identified in 
Taiwanese population study  
Lee et al 2018 
Expression of CCNF
S621G
 increased Lys48-specific 
(proteasomal) ubiquitination in transfected in Neuro-2A and SH-
SY5Y cells. Immunoprecipitation pull down of Lys48 
ubiquitinated proteins in CCNF
S621G
 found these proteins to be 
involved in autophagy, heat shock, chaperonin and 
sequestesome-1 
Tian et al 2018 
Identified 8 likely pathogenic variants of CCNF, and prevalence 
in the examined population was 2.56% in FALS and 1.03% in 
SALS 
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Figure 1.3 Structure of cyclin F protein 
Cyclin F structure includes two nuclear localization signals (NLS), an F Box motif 
(region binds to Skp1 and core components of E3 ligase), cyclin box (100 amino acid 
region conserved in cyclins) and PEST (proline, glutamic acid, serine and threonine) 
enriched region for ubiquitin dependent degradation (Adapted from Kong et al 
2000). 
 
These previous studies have indicated varying cyclin F localisation in different cell 
types, though has been predominantly detected to localise in the nucleus, and 
contains two nuclear localisation signals (Xie et al., 2013).  Perinuclear cyclin F was 
detected via immunofluorescence in COS-1 cells transfected with a CCNF encoding 
plasmid, which was used to detect cyclin F localization due to the naturally low 
expression of cyclin F in these cells.  Between 10 – 30 % of cells exhibited 
perinuclear staining positive for cyclin F.  This change in localization could indicate 
that: 1. Cyclin F localization changes throughout the cell cycle, reflecting another 
role in the cell (Bai et al., 1994). Alternate roles of cyclin F beyond DNA 
maintenance was described by Kong et al (2000) who found cyclin F acted to shuttle 
cyclin B to the nucleus. Similarly, D’Angiolella noted cyclin F co-localized with 
centrosomal protein 110 (CP110) at the centrosome as indicated by 
immunocytochemical analysis of synchronized U2OS osteosarcoma cells (2013); 2. 
Subcellular localisation is altered by forced overexpression of cyclin F; and/or 3. 
That the protein can mislocalise under cellular stress.  
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A small number of substrates have been identified to interact with cyclin F, 
predominantly in regulating DNA maintenance roles in mitotic cells. These 
substrates of cyclin F include: nucleolar spindle associated protein (NuSAP) which is 
associated with spindle formation of microtubules (Emanuele et al., 2011; 
Raemaekers et al., 2003); the aforementioned CP110, which regulates centrosome 
production during S phase (Chen et al., 2002; D’Angiolella et al., 2013).  
Ribonucleotide reductase family member 2, (RRM2) which catalyses ribonucleotide 
conversion to dNTPs - during G2, SKP1-CUL1-F-box-1 is the only ubiquitin ligase 
that controls the degradation of RRM2, making its activity crucial for maintaining 
DNA synthesis and repair (D’Angiolella et al., 2012); Myb-related protein B (B-
MyB), which is a transcription factor  - found to be suppressed by cyclin F binding 
(which inhibited phosphorylation) following UV damage; and exonuclease-1 EXO1 
which is a 5’-3’ exonuclease  (Elia et al., 2015; Klein et al., 2015). 
 
The functional role of cyclin F is not yet fully understood in the context of ALS.  To 
date, seven studies have been published concerning CCNF mutations in ALS; no 
studies have yet examined cyclin F in viable patient derived motor neurons.  
Preliminary cellular mechanistic studies by Williams and colleagues (2016), have 
indicated that mutant cyclin F may cause ALS through UPS dysfunction, and finding 
an increase in ubiquitinated TDP-43, indicating it as a likely substrate.   The cellular 
role of cyclin F as a cell cycle regulator/DNA maintenance protein would logically 
differ in a post-mitotic motor neuron.  As cyclin F is an ubiquitin ligase, Williams et 
al (2016)  examined the potential role of cyclin F in the UPS.  To determine protein 
clearance, a protein clearance assay was performed. The group found that Neuro2As 
had an increased propensity to retain proteins following the over -expression of eight 
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of the different mutant cyclin F forms, compared to wild type cyclin F. Investigation 
into the proteasome activity indicated mutant cyclin F had no effect on proteasomal 
activity, implicating the ubiquitin system of the UPS.  Immunoblotting of co-
immunoprecipitated ubiquitin in Neuro2A cells with overexpressed wild type, or 
mutant CCNFS621G, indicated an increase in ubiquitinated TDP-43, as well as a cyclin 
F substrate, RRM2.  Together these findings indicate that these forms of mutant 
cyclin F can cause ubiquitin system dysfunction (Williams et al., 2016). 
 
The disease mechanism of CCNFS621G has since been followed up by members of this 
same group: expression of human CCNFS621G in zebrafish was found to elicit more 
aberrant neurite branching and reduce photomotor responses (response to light 
stimulus as a nervous system activity indicator) compared to the WT (Kokel and 
Peterson, 2011). Measurement of the positive responders also indicated a decreased 
response in the CCNFS621G in zebrafish compared to the WT (Hogan et al., 2017). 
Cyclin F expressed in HEK293 cells indicated seven phosphorylation sites in cyclin 
F including at S621, which had previously been suggested by Kong et al., (2000).  
This study indicated that the mutation S621G prevented phosphorylation, thereby 
leading to an increase in ubiquitination activity. Examination of the expression of 
CCNFS621G in Neuro2As and SH-SY5Y cells indicated increase in degradation 
signaling ubiquitination (Lys48); further examination of the proteins that were K48 
ubiquitin tagged following CCNFS621G expression indicated an increased 
ubiquitination of proteins associated with autophagy and the heat shock response 
(Lee et al., 2018). 
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To date, studies into CCNFS621G have relied on the overexpression of proteins. More 
studies are required, however, to ascertain the function of the protein at endogenous 
level; this will be important to determine if there is only one mechanism affected by 
ALS causing mutations, or if multiple mechanisms may contribute to 
neurodegeneration.  It is clear is that cyclin F is an important protein in the cell cycle 
and is central to proteostasis. Further understanding of the effects of mutations in 
CCNF will be critical for elucidating potential therapeutics to provide reprieve. For 
ALS research, furthering our understanding of the role of this cyclin F could provide 
significant insight into ALS pathogenesis, particularly regarding the ubiquitin 
system. Identifying why cyclin F mutations cause ALS is therefore a crucial task. 
 
1.7 Induced pluripotent stem cells in ALS research 
 
1.7.1 Pluripotent stem cells provide access to previously inaccessible cells 
In 2006, Takahashi and Yamanaka successfully reprogrammed murine fibroblasts 
into a pluripotent state, creating the first induced pluripotent stem cells (iPSC) 
(Takahashi and Yamanaka, 2006). These iPSCs have a high rate of proliferation, are 
immortal, and most importantly, can differentiate into any cell types (Takahashi and 
Yamanaka, 2013).  The upregulation of four key pluripotency factors (Oct3/4, Sox2, 
Klf4 and c‐Myc also known as OSKM factors) via lentiviral transduction altered 
cellular phenotype via genome insertion, directing the cells into a state of 
pluripotency(Takahashi et al., 2007).  Nine years later this general principle is still 
applied, though reprogramming is often carried out without the use of lenti viruses or 
sendai viruses. Instead, techniques such as multiple synthetic mRNA transfections of 
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the OSKM factors are used to generate pluripotent stem cells (Warren et al., 2010; 
Yakubov et al., 2010) free from viral contaminants.  For neurodegenerative research 
these cells provide the tools to recapitulate neurodegenerative diseases such as ALS 
‘in a dish’ (Takahashi and Yamanaka, 2013). 
 
The ability to generate stem cells from a non-embryonic source eliminated the ethical 
controversy that had previously plagued embryonic stem cell research.  The concept 
of iPSCs generated opportunities for patient specific medicines, and excited the 
possibility for genetically identical models (Ooi et al., 2013).  Today, iPSC research 
divides into four fundamental areas: 1. Cellular replacement therapies research, 
wherein cells are generated with the aim to be placed back into the in vivo 
environment (including as entire organs); 2. Drug development research; 3. Cellular 
modelling for mechanistic studies, to better understand disease; 4. Stem cell research, 
which focuses on development and improvement of the generation of iPSCs through 
reprogramming (Ebert et al., 2012). 
 
1.7.2 Patient derived neurons are drastically changing ALS research 
Patient derived iPSCs are a compelling research tool for investigating ALS.  Indeed 
ALS was the first neurodegenerative disease to be modelled using iPSCs.  In 2008, 
Dimos et al. successfully differentiated motor neurons from an ALS patient using the 
cells to generate embryoid bodies, then generated spinal motor neurons and glial 
cells. The group demonstrated the generation of neurons that expressed the motor 
neuron specific markers homeobox protein 9 (HB9), and islet 1 and 2 (ISL1 and 
ISL2).  While this group did not demonstrate whether the neuron electrophysiology 
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was similar to in vivo motor neurons, nor examine disease phenotype, this research 
introduced the idea of iPSC modelling into ALS research (Dimos et al., 2008). 
 
1.7.3 Disease phenotypes are displayed in ALS iPSC derived neurons 
Proteostasis dysfunction has been identified repeatedly in independent ALS iPSC 
research.  Almost every iPSC derived motor neuron study of TDP-43 has observed 
an increase in TDP-43 levels compared to controls (Bilican et al., 2012; Burkhardt et 
al., 2013; Egawa et al., 2012; Nishimura et al., 2014; Serio et al., 2013; Zhang et al., 
2013).  Many have reported TDP-43 mislocalisation (Burkhardt et al., 2013; Serio et 
al., 2013; Zhang et al., 2013), decreased neuronal survival, (Bilican et al., 2012; 
Serio et al., 2013) and increases in TDP-43 associated with aggregates (Egawa et al., 
2012), matching post mortem findings.  Interestingly, Burkhardt et al. (2013) saw 
TDP-43 inclusions in SALS patient iPSC derived motor neurons, which matched the 
same patient post mortem, pathology.  The only study that has reported no difference 
in TDP-43 concentration and aggregate formation in ALS derived cells compared to 
controls was by Liu-Yesucevitz et al. (2014) The group compared an iPSC line 
derived from a patient with a TDP-43G298S mutation to a healthy control line, finding 
no significant difference in TDP-43 concentrations or aggregates as measured by 
western blot quantification and immunocytochemistry respectively (Liu-Yesucevitz 
et al., 2014).  These findings are contrary to previous reports, though could be due to 
alternate differentiation protocols, and incomplete characterisation: The group failed 
to characterise the type of neuron examined, determining only that the cells 
expressed neuronal markers βIII tubulin (βIII TUB), microtubule associated protein 2 
(MAP2) and choline acetyltransferase (ChAT), omitting motor neuron specific 
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markers HB9, ISL1, and ISL2. This omission is disappointing considering the 
fundamental involvement of motor neurons in ALS, particularly in early stage 
disease.  The authors’ suggestion that TDP-43 aggregation could increase with 
culture time in these neurons is inconsequential for identifying early stage events that 
translate to clinical ALS if they remain unwilling to determine the neuronal subtype 
of their cells.  Overall, the TDP-43 models have shown agreement between patient 
derived samples analysed by different groups, a positive step towards confirming the 
use of iPSC derived motor neuron models and suggests that iPSC derived neurons 
are an excellent model for investigating proteostasis in ALS (Lee and Huang, 2017).   
 
Patient iPSC derived neuron models have been used to examine early stage events in 
ALS pathogenesis (Kiskinis et al., 2014; Wainger et al., 2014).  Throughout the 
differentiation and maturation of iPSCs into motor neurons, it has been possible to 
examine disease progression, modelling disease mechanisms that can occur in vivo 
(Han et al., 2011).  This is perhaps the most potent feature of the iPSC derived 
neurons, as it is possible to monitor patient specific changes in cellular metabolism 
prior to the clinical presentation stage of the disease (Ooi et al., 2013).  Already, this 
ability to examine early stage events by iPSC derived motor neurons has yielded 
important findings in ALS research.  In early 2014, neurofilament aggregates were 
found to form in early stage disease in iPSC–derived motor neurons (Chen et al., 
2014).  The formation of neurofilament aggregates in motor neurons differentiated 
from SOD1D90A patient iPSCs was investigated; the concentration of the aggregates 
formed in the cells were similar to those seen in patients and significantly, the 
formation of neurofilament aggregates preceded neurite swelling and degeneration.  
Devlin et al. (2015) recently used iPSC derived motor neurons to address the changes 
 67 
 
in electrophysiology that occur in early stage ALS (Devlin et al., 2015).  Previous 
reports on electrophysiological properties of motor neurons had been conflicting in 
the field; Wainger et al. (2014) had reported that SODA4V patient iPSC derived motor 
neurons had exhibited hyperexcitability following 28 days of culture.  Seemingly 
contradictorily, Sareen et al. (2013) had previously reported that C9orf72 repeat 
expansion patient derived motor neurons exhibited a reduced action potential output 
(hypoexcitability) following 56 days of culture (Sareen et al., 2013).  Devlin et al. 
(2015) suggested that in fact, these cellular phenotypes could be sequential events in 
disease progression; in a longitudinal electrophysiology study of TDP-43 and 
C9orf72 repeat expansion patient derived motor neurons, the group found that both 
ALS affected cell lines had initial repetitive firing in the first six weeks of culture, 
corroborating with the Wainger et al. (2014) findings. This hyperexcitability then 
significantly decreased in the following four weeks of culture, as cells exhibited a 
progressive decrease in action potential output when measured at a similar culture 
time to Sareen et al. (2013), highlighting the impact of differences in differentiation 
protocols - particularly time. This phenotype change from hyperexcitability to 
hypoexcitabilty reflects that seen in patients, reiterating the strength of these models 
(Devlin 2017).  Importantly, these cells provide the opportunity to examine early 
stage events in ALS patient derived model. 
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1.8 Summary and directions of this study 
Using iPSC-technology it is possible to investigate the role of the UPS, not only in 
the context of ALS, but in the development of motor neurons - from the implications 
of the system in reprogramming fibroblasts to iPSCs, in maintaining these stem cells, 
and in the differentiation of the cells to the final motor neuron models.  Here, in this 
study iPSCs have been successfully generated from both healthy donor and from 
CCNFS621G patient (pre-symptomatic and symptomatic for ALS) fibroblasts.  A 
robust protocol to generate motor neurons was established for the first time in the 
Ooi laboratory, yielding neuronal cells positive for motor neuron markers at a high 
purity. ALS patient iPSC derived motor neurons exhibited distinct phenotypes from 
those derived from the healthy controls; In some cases these ALS motor neurons 
were different from previously established sporadic Alzheimer’s disease patient iPSC 
derived motor neurons (Balez et al., 2016).  This study highlights the strength of 
these models in expressing a disease relevant phenotype, as detectable via both bias 
and unbiased approaches, in a patient derived model. These studies move towards 
establishing potential screening models for diagnostic biomarkers, which is crucial 
for effective therapeutic intervention. Moreover, these cells represent an important 
addition to the therapeutic development pipeline; these cells will likely prove an 
important tool in validating the effects of novel drugs on a human neuronal model 
unhindered by protein overexpression, and broadly serve to improve our 
understanding of the UPS. 
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1.9 Hypotheses of this study 
1. Fibroblasts derived from symptomatic and pre-symptomatic CCNFS621G 
patients, as well as healthy donor derived fibroblasts can be reprogrammed to 
iPSCs, and differentiated to iPSC derived motor neurons. 
 
2. Disease relevant phenotypes can be modelled using iPSC derived motor 
neurons from CCNFS621G and SOD1E101G ALS patients. 
 
3. The ubiquitomes of iPSC derived motor neurons are different from derivative 
cell types (fibroblasts and pluripotent stem cells), and within individuals in 
motor neurons. 
 
1.10 Aims of this study 
1. Generate motor neurons using iPSCs from fibroblasts derived from patients 
with ALS, and healthy donors, including CCNFS621G ALS patients. 
 
2. Quantify ALS-relevant proteins TDP-43 and Cyclin F, and UPS dysfunction 
in iPSC derived motor neurons from ALS patients compared to healthy donor 
derived cell lines. 
 
3. Compare the ubiquitomes of iPSC derived motor neurons to derivative cell 
types (fibroblasts and pluripotent stem cells) and between different cell lines 
in motor neurons. 
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2 . METHODS AND MATERIALS 
 
Experiments in this study were carried out as described in this methods section (2.1 
Methods). All equipment and reagents referred to in the Methods section are 
described in detail in the Materials section  (2.2 Materials).  Experiments were 
carried out using cell lines described in Table 2.1, using media and solution 
compositions described in Table 2.2, with reagents described in Table 2.3, and 
equipment described in Table 2.4. Software used in these experiments are described 
in Table 2.5. Plasmids, primers and antibodies utilised in this study are described in 
Table 2.6, 2.7, and 2.8 respectively. Consumables used are described in 
Supplementary Table 7.1. 
 
2.1 Methods 
 
2.1.1 General cell culture 
The range of different cell lines and cell types of this study  (Table 2.1) were used in 
accordance with Human Research Ethics application  (HE13/272), in conjunction 
with a Materials Transfer Agreement (MTA; Ethics HREC/11/CRGH/179).  Patient 
and healthy donor derived fibroblasts, generously donated to the Macquarie 
University Motor Neuron Disease Centre, were supplied by A/Prof Ian Blair, and 
prepared by Dr Shu Yang (Macquarie University, Australia).  The fibroblasts were 
attained by skin punch from low UV exposed tissue, to minimise the potential 
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collection of cells with genetic abnormalities caused by UV damaged.  NSC34 cells 
were kindly donated by Neil Cashman (University of Toronto, Canada) and a stock 
was prepared by Natalie Farrawell (University of Wollongong), HEPG2 cells were 
previously cultured by Natalie Farrawell, and were kindly supplied by the Prof Mark 
Wilson (University of Wollongong) from stocks. C2C12 cell stocks, prepared by Dr 
Rodrigo Lozano (University of Wollongong), were kindly gifted by the Dr Elise 
Stewart (University of Wollongong).  Snuff cells were purchased from StemGent.  
The iPSC lines SAD (derived from a sporadic Alzheimer’s disease patient), and HC2 
(derived from an age- and sex-matched healthy donor) were kindly gifted from the 
laboratory of A/Prof Kuldip Sidhu (University of New South Wales, Australia) 
(Chung et al., 2012).  Fibroblasts from the SOD1 cell line (derived from ALS patient 
MQ130054 with SOD1E101G mutation) were provided under the MTA by the 
Macquarie University Motor Neuron Disease Centre; these fibroblasts were 
reprogrammed using mRNA reprogramming by Rachelle Balez. 
 
Cells were cultured at 37°C in 5% CO2, and maintained as described in General cell 
culture, unless otherwise stated. All cells centrifugation was carried out in a 15 mL 
centrifuge tube at 300 x g for 5 minutes unless otherwise stated. Cell passage 
number, as well as general morphology was monitored to ensure cells did not reach a 
high passage (relative to each cell type). Routine mycoplasma testing of cell lines 
was carried via supernatant samples of each cell line provided to technical officers 
(at the Illawarra Health and Medical Research Institute).  Short tandem repeat (STR) 
analysis was performed as described in this chapter.  
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Cells were cultured in tissue culture flasks in General Culture Media, which was 
changed three times a week.  Cells were passaged upon reaching 80% confluency; 
Cells were washed with phosphate buffered saline (PBS) treated with 0.05% Trypsin/ 
ethylenediaminetetraacetic acid (EDTA) for 2 mins to detach cells.  Cells were 
dislodged by tapping the flask, and trypsin was inactivated by the addition of serum 
containing General Culture Media. Cells were collected and centrifuged at 800 x g, 
for 5 mins.  The supernatant was aspirated and the cells were resuspended in General 
Culture Media. Cells were seeded at a density of 1.25 x 103 cell/cm2.  For long-term 
storage, cell stocks were generated. Cells were detached and pelleted as per 
passaging method.  The cell pellet was resuspended in General Culture Media 
containing 10% dimethyl sulfoxide (DMSO).  Resuspended cells were stored in 
cryovials and cooled to -80oC in a Mr Frosty freezing container overnight.  Cells 
were moved to long-term storage in liquid nitrogen vapour cryotank. Cells were 
thawed as required; Cells were quickly reheated to 37oC in a water bath.  Once the 
cells had defrosted, cells were aspirated and placed into 5 mL of warm General 
Culture Media in a 15 mL centrifuge tube. The cryovial was then washed with 5 mL 
of pre-warmed Dulbecco’s modified eagle medium with F12 supplement 
(DMEM/F12) to ensure all cells were collected, and the media was gently added to 
the cells.  Cells were pelleted via centrifugation, the supernatant was removed and 
cells were gently resuspended in General Culture media, and plated in a tissue 
culture flask.  
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2.1.2 Reprogramming fibroblasts to iPSCs 
Three fibroblast cell lines were reprogrammed for the purpose of this study. Cell 
lines from a healthy female, a pre-symptomatic CCNFS21G female (who became 
symptomatic during the course of this study), and a symptomatic CCNFS21G male 
were reprogrammed using a microRNA enhanced mRNA reprogramming kit. The 
reprogramming was carried out as per the manufacturer’s recommendations; Prior to 
reprogramming, pluriton media was conditioned using NuFF cells as described by 
the StemGent Generating NuFF-Conditioned Pluriton Medium Protocol; NuFF cells 
were thawed and cells were seeded at a density of 26.6 x 103 cells/cm2 in a T75 flask.  
NuFF cells were incubated overnight.  Cells were washed with PBS to remove the 
General Culture Media, and the cells were cultured in 20 mL pluriton media 
supplemented with basic fibroblast growth factor (bFGF; 4 ng/mL) overnight.  The 
conditioned media was collected and replaced daily for 10 days. The conditioned 
pluriton was filtered and frozen until required. Conditioned pluriton was 
supplemented with recombinant protein B18R and pluriton supplement immediately 
prior use in culture.   
 
Fibroblasts were plated in Matrigel coated 6 well plates at a density of 5 x 103 
cells/cm2, 1 x 104 cells/cm2 and 2.5 x 104 cells/cm2 as described in General cell 
culture.  On day 0 of the reprogramming protocol, fibroblasts were washed with PBS 
to remove the fibroblast media, and cultured in pre-warmed conditioned pluriton 
media for 2 h.  A microRNA transfection complex solution was prepared in a low 
binding microtube by adding Stemfect Buffer (64.5 µL) to a prepared microRNA 
cocktail (10.5 µL) and mixing gently.  In a separate low binding microtube, RNA 
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transfection reagent (12 µL) and Stemfect Buffer (63 µL) was also gently mixed and 
left to incubate for 5 min at room temperature. The transfection reagent-buffer 
solution was gently mixed with the microRNA solution, and left to incubate at room 
temperature for 15 minutes. The microRNA transfection complex (50 µL) was added 
dropwise to the 3 reprogramming, without piercing the surface of the media by 
holding the plate at a 45 degree angle. The plate was rocked in an X and Y plane, to 
minimise the adherence of the transfection complex to the plate.  Cells were 
incubated overnight.  On day 1, the transfection complex containing media was 
removed and replaced with fresh pre-warmed conditioned pluriton as per day 0.  A 
mRNA transfection complex solution was prepared in a low binding microtube by 
adding Stemfect Buffer (45 µL) to a prepared mRNA cocktail (30 µL; mRNA molar 
stoichiometry 3:1:1:1:1:1 Oct4:Sox2:Klf4:c-Myc:Lin28:nGFP) and mixed gently.  In 
a separate low binding microtube, RNA transfection reagent (12 µL) and Stemfect 
Buffer (63 µL) was also gently mixed and left to incubate for 5 min at room 
temperature. The transfection reagent-buffer solution was gently mixed with the 
mRNA solution, and left to incubate at room temperature for 15 minutes.  The 
mRNA transfection complex (50 µL) was added dropwise to the 3 reprogramming 
wells, as per the microRNA transfection complex.  Cells were incubated overnight.  
The mRNA transfection was repeated on day 2, 3, 5 - 11 of reprogramming. On day 
4, cells were co-transfected with both the microRNA and the mRNA transfection 
complexes. 
 
On day 12 of reprogramming, the transfection complex containing media was 
removed. Cells were cultured in conditioned pluriton media for 4 days, with daily 
media changes as iPSC colonies formed. These colonies were gently collected using 
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a 1000 µL pipette, and replated into a 24 well Matrigel coated tissue culture plate.  
Each colony was plated and cultured separately as different clones.  These clones 
were expanded upon reaching 80% confluency, or when the colonies appeared to be 
growing densely in the middle of the colony.  Clones were passaged and expanded to 
larger plates until enough cells were present to plate onto a 60 mm tissue culture 
plate.   
 
2.1.3 Culturing iPSCs 
All iPSC lines used in this study were cultured as follows unless otherwise stated. 
The iPSCs were cultured in TeSR E8 supplemented with 10,000 U/mL penicillin and 
10 mg/mL streptomycin on 60 mm tissue culture plates coated with Matrigel, diluted 
in DMEM/F12. Spontaneously differentiating cells were removed using a 20 µL 
pipette tip, prior to the daily media changes.  Cells were passaged upon reaching 
80% confluence.  The iPSC cultures were incubated with 1 mg/mL dispase for 3 min 
at 37oC. Dispase was aspirated and cultures washed three times with DMEM/F12.  
Colonies were gently detached into DMEM/F12 using a cell scraper, and centrifuged.  
Supernatant was aspirated and the cells resuspended in TeSR E8, triturating cells into 
even sized cell clumps.  A cell clump count was performed and cells were evenly 
distributed on a Matrigel coated 60 mm tissue culture plate at 1000 cell clumps per 
plate.  
 
In addition to these three reprogrammed lines, a further three lines were utilised for 
experiments. The iPSC lines 10.13 (derived from a sporadic Alzheimer’s disease 
patient), and 1.4 (derived from an age- and sex-matched healthy donor) were kindly 
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gifted from the laboratory of A/Prof Kuldip Sidhu (University of New South Wales, 
Australia) (Chung et al., 2012).  The iPSC line MQ54.2 (derived from ALS patient 
MQ54, who had a mutation at SOD1E101G) was also reprogrammed using mRNA 
reprogramming by R. Balez. 
 
For long-term storage iPSC cells stocks were generated.  Stem cells cultured for 5-6 
days were passaged as aforementioned; the cell pellet was gently resuspended in cool 
mFreSR to ensure larger colonies were maintained. Cells were then gently 
transferred to a cryovial, and slowly cooled to -80oC in a Mr Frosty freezing 
container overnight.  Cells were then moved to the -190oC cryotank for long-term 
storage.  To recommence cell culture, the cryovials were retrieved from cryogenic 
storage and quickly thawed in a water bath at 37oC. Cells were gently aspirated to 
minimise colony disruption, and placed in a 15 mL centrifuge tube. The cryovial was 
then washed with 5 mL of pre-warmed DMEM/F12 and the media was gently added 
to the cells.  Cells were centrifuged, and the cell pellet was resuspended in TeSR E8 
with Rho-associated protein kinase (ROCK) inhibitor (10 µM), and plated onto 60 
mm Matrigel coated plates.   
 
2.1.4 Characterising and selecting appropriate iPSC clones 
Stem cells clones were selected based on morphology, gene expression and protein 
expression.  The first stage of pluripotency assessment was based on observations of 
morphology.  Cells were examined daily for stem cell like morphology; Stem cells 
exhibit a round simple morphology, with a large dark nucleus observable under 4X 
magnification; iPSCs grow in colonies and are capable of self-renew with quick 
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proliferation. Clones that exhibited this morphology were selected for further 
examination as a potential clone. Gene expression was determined by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR; see Relative gene 
expression), and by the PluriTest.  Protein expression was determined by 
immunocytochemistry (see Protein expression).  Selected clones were verified by 
genome analysis, karyotype analysis and by the ability to differentiate into the three 
germ layer tissues (endoderm, mesoderm and ectoderm). Cells of each germ layer 
tissues were characterised by morphology, relative gene expression and protein 
expression (see Relative protein expression and Protein expression). 
 
2.1.5 PluriTest 
An iPSC clone from each of the three cell lines was further verified for pluripotency 
expression via the PluriTest.  RNA samples were purified and concentrations were 
calculated as described in Relative Gene Expression. RNA samples (500 ng) were 
submitted to Genea  (Sydney, NSW, Australia) for testing.  The microarray assay 
was performed on an Illumina HT12 Chip according to (Müller et al., 2011) as sub-
contracted by Genea Biotech. Scores including the non-negative matrix factorization 
generated novelty score, and logistic regression model pluripotency scores were 
generated using microarray data. These scores are determined by comparison of gene 
expression to previously characterised stem cell gene expression profiles as well as 
the gene expression profiles of other cell types.  
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2.1.6 Genomic analysis 
2.1.6.1 Short tandem repeat analysis 
In order to confirm the cell lines were not subjected to any detectable genetic 
abnormalities following reprogramming, ensure cell lines were not misidentified, and 
verify that no cross-contamination had occurred, the STR loci of the reprogrammed 
iPSC genomes were compared to the fibroblasts from which they originated.  Cells 
from the respective cell stages were cultured and passaged for collection as 
previously described. Once cells were pelleted by centrifugation, the respective pellet 
was washed in PBS and transferred to a microtube. The cells were again centrifuged, 
and the PBS was removed from the pellet. The cell pellet was stored at -80°C. 
Samples were delivered to the Garvan Institute for STR analysis of microsatellite 
profiles. Loci of tetra and pentanucleotide repeats from 18 established loci were 
amplified via PCR (from DNA extracted from the cell pellets).  Resulting STR 
profiles were compared to one another, and to the American Type Culture Collection 
database, the Deutsche Sammlung von Mikroorganismen und Zellkulturen database 
and internal institute database. 
2.1.6.2 Gene specific analysis 
2.1.6.2.1 Genomic DNA Purification for CCNF Sequencing 
To confirm the genotype of the cell lines were as previously reported, a gene specific 
analysis was performed via PCR.  Genomic DNA was purified using the Invitrogen 
PureLink Genomic DNA kit as per manufacturer’s recommendations.  Anterior 
neural precursor (aNPC) cells were washed twice with PBS, scraped using a cell 
scraper and collected in a 15 microfuge tube.  Cells were centrifuged at 800 x g for 5 
mins to pellet and PBS was removed.  Cells were further separated via trypsin 
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incubation for 5 min at room temperature. An equal part trypsin inhibitor was added 
to inactivate the trypsin. Cells were transferred to a microtube, centrifuged at 300 x g 
for 5 minutes at room temperature; the supernatant was removed.  Cell pellet was 
resuspended in PBS (200 µL), proteinase K (20 µL) and RNase A (20µL) and 
incubated at room temperature for 2 min. Cells were digested by incubating in 
PureLinkR Genomic Lysis/binding buffer (200 µL) at 55oC for 10 min.  Ethanol 
(200µL; 100%) was added to lysate.  Unwanted cellular material was removed by 
adding the lysate solution to the PureLinkR Spin Column and centrifuging at 10,000 
x g at room temperature for 1 min.  DNA was washed by adding PureLink Genomic 
Wash Buffer 1 (500 µL) to the column and centrifuging at 10,000 x g at room 
temperature for 1 minute, followed by the addition of PureLink Genomic Wash 
Buffer 2 (500 µL) to the column and centrifuging at 10,000 x g at room temperature 
for 3 minutes. DNA was eluted by incubating PurelinkR genomic elution buffer (80 
µL) in the column at room temperature for 1 min, and spinning at 3000 x g at room 
temperature for 1 min. This step was repeated to increase DNA yield. The 
concentration and purity (A260/A280 ratio) of the eluted DNA was measured on the 
nanodrop.   
2.1.6.2.1 Amplifying CCNF 
The Cyclin F genotype was verified with CCNF primers CCNF E16F and CCNF- 
E16R designed by Dr Tracey Berg for the mutated region (bp 621) using Snapgene 
software.  To amplify the region of interest in the genomic DNA, PCR was 
performed using Primestar reagents.  Primestar buffer (diluted in solution to 1X), 
dNTPs (2.5 mM), sense and antisense primers CCNF-E16F (2 µM) and CCNF-E16R 
(2 µM), polymerase and water were added to the purified genomic DNA.  The PCR 
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solution was heated to 98oC for 30 s followed by 30 rounds of heating to 98oC for 
10s, 58oC for 10 s, 58oC for 10s, 72oC for 10. Samples were cooled to 72oC for 10s 
then cooled to 4oC.  Sequencing was performed at the University of Wollongong, 
School of Biology by Research Technical Officer Margaret Phillips.  
 
2.1.6.2.2 Gene Expression Analysis 
PCR product was verified by gel electrophoresis by Dr Tracey Berg.  The PCR 
product (3µL) was added to bromophenol blue loading dye (1.5 µL) and loaded into 
an agarose gel (1%), along with a 100 bp ladder (3 µL; diluted 1:1 in loading buffer). 
An 85V current was applied to the gel for 40 min. The gel was stained and imaged. 
Bands present in the sample lanes were compared with the 100 bp ladder. 
 
2.1.6.3 Karyotype analysis 
To ensure reprogramming had no effect on the chromosomal integrity of the cell 
lines, a karyotype analysis was performed.  Induced pluripotent stem cells were 
cultured in a T25 flask until 25% confluent.  Cells were then transported to Stem 
Core (University of Queensland, Australia) to be analysed for any chromosomal 
anomalies.  Cells were arrested at metaphase and chromosomes were G-banded. 15- 
30 cells were assessed at a resolution of 400 bphs. 
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2.1.7 Differentiation to three tissue types 
2.1.7.1 Endodermal cell type differentiation 
Endodermal progenitors were differentiated using an endodermal progenitor 
differentiation protocol from Stem Cell Technologies.  Five days following 
passaging, iPSC colonies were dissociated using a 5 min accutase (1X) treatment.  
Accutase was inhibited with trypsin inhibitor (1 mg/mL), and cells were collected in 
DMEM/F12 and centrifuged.  Cells were resuspended in TeSR E8 supplemented 
with ROCK inhibitor (10 µM), and plated at 2.1 x 105 cells/cm2 on Matrigel coated 
plates.  On day 1, the media was aspirated and cells were washed with DMEM/F12. 
Cells were cultured overnight in STEMdiff definitive endoderm basal media 
supplemented with STEMdiff Definitive Endoderm Supplement B (1% v/v) and 
STEMdiff Definitive Endoderm Supplement A (1% v/v).  On day 2, a full media 
change was performed, and cells were cultured in STEMdiff definitive endoderm 
basal media supplemented with STEMdiff Definitive Endoderm Supplement B (1% 
v/v) for four days, with daily media changes to generate endodermal progenitors.  On 
day 5 the endodermal progenitors were harvested for characterisation.  
2.1.7.2 Mesodermal cell type differentiation 
Myoblasts, originating from mesodermal cells, were differentiated using a protocol 
adapted from Caron et al., 2014.  On day 0, cells were dissociated into single cells by 
treating with accutase for 5 minutes.  Accutase was inactivated via the addition of 
trypsin inhibitor (1 mg/mL), added 1:1 with accutase. 5 mL of DMEM/F12 was then 
added, and the cells were pelleted via centrifugation.  The cells were resuspended in 
skeletal muscle induction media (stage 1) and plated in collagen I coated plates 
(coated overnight) at 2,500 cell/cm2.  Cells were incubated in hypoxic conditions 
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(5% CO2, 5% O2), at 37
oC, with three partial media changes a week for 10 days.  On 
day 11, cells were again passaged with accutase as described for day 0, though were 
resuspended in skeletal muscle media (stage 2).  Cells were maintained for 1 week. 
On day 18, the skeletal muscle media (stage 2) was aspirated, and replaced with 
skeletal muscle maturation media. Cells were then incubated in normoxic conditions 
for two weeks with three partial media a week.  Cell morphology was compared to 
C2C12 cell line morphology as a positive control. 
 
2.1.7.3 Ectodermal Cell Type Differentiation: Motor Neuron Differentiation 
Ectodermal derived cells were the primary cell type of interest in this study; iPSCs 
were differentiated into motor neurons using a protocol adapted for this study from 
Qu et al., 2014 and Bilican et al., 2014.  The iPSC colonies were washed with PBS 
and colonies were collected in neural induction media using a cell scraper (Table 
2.1).  Cells were plated in a non-tissue culture plate and incubated for three days. A 
partial media change was performed on day 2.  The floating embryoid bodies formed 
by day 4 were collected and plated on a pre-coated laminin (20 µg/mL) tissue culture 
plate.  Partial media changes were performed three times a week for two weeks, 
during which time neural rosettes formed.  These rosettes were manually isolated and 
plated on 60 mm tissue culture dishes which were pre-coated overnight with collagen 
I (10 µg/mL), washed with PBS and coated for 1 h with laminin (10 µg/mL), 
fibronectin (10 µg/mL) and collagen in aNPC Media prior to use.  Cells were 
maintained in aNPC Media with partial media changes 3 times a week until plates 
were 80% confluent. 
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To prepare cells for the final differentiation phase, aNPCs were accutase treated and 
seeded at 3.125 x 103 cells/cm2 and cultured for seven days.  Cells were caudalised 
by the addition of increasing retinoic acid over three days (0.3 µM). Cells were 
cultured in motor neuron precursor media for seven days with a partial media change 
three times a week.  Media was gradually changed to Motor Neuron Media through 
half media changes, which were performed three times a week.  Cells were matured 
for six weeks.  
 
2.1.8 Relative gene expression 
To evaluate relative gene expression in different cell types, qRT PCR was 
performed.  Respective cells were thoroughly washed in PBS, then collected in TRI 
reagent (800 µL) using a cell scraper in ensure all cells were collected.  RNA was 
purified using TRI reagent; at this stage samples were stored at -80oC for a maximum 
of two months before continuing purification. All mRNA samples were kept on ice at 
all times, unless stated to ensure minimal sample degradation.   TRI reagent samples 
were incubated with chloroform (200 µL; 5 min). RNA was collected from the top 
aqueous phase after the solution was centrifuged (5 min; 12,000 x g).  Nucleic acids 
were precipitated using an incubation with ice-cold isopropanol (500 µL; -20oC for 
30 minutes). A nucleic acid pellet was collected via centrifugation at 4oC for 10 min 
at 12,000 x g.  The pellet was washed in 70% ethanol (v/v) and centrifuged for 5 min 
at 12,000 x g. The supernatant was aspirated, and the pellet air-dried before 
resuspension in 40 µL tris EDTA pH 8.0.  Nucleic acid concentrations and sample 
purity concentrations were then calculated using a UV-vis spectrophotometer 
(Nanodrop 2000C).  The nucleic acid was treated with Ambion TURBO DNA-free 
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as per manufacturer’s instructions to remove genomic DNA contamination.  Nucleic 
acid samples were diluted in nuclease-free water to a concentration of 200 µg/mL, in 
a final volume of 50 µL, and mixed with 1X TURBO DNase buffer with 1 µL 
TURBO DNase.  The DNase solution was incubated for 1 h at 37oC before the 
addition of DNase inactivation reagent.  Following incubation (5 min) at room 
temperature, the solution was centrifuged at 12,000 x g for 90 s and the supernatant 
containing the purified RNA was collected.  The RNA concentration was measured 
again. To reverse transcribe RNA to complimentary DNA (cDNA), 1 µg total RNA 
was annealed with 0.5 g oligo(dT) and 0.5 g random primers at 65oC for 4 mins, 
then incubated on ice for 1 min.  The RNA reaction was performed with 1X buffer, 2 
mM dNTPs, 200U MM-LV RTase, 40U RNasin (per sample) at 37oC for 2 h.  To 
quantitate cDNA levels, the Express SYBR GreenER qPCR Supermix Universal kit 
was used according to the manufacturer’s instructions. Each sample of template 
cDNA (2 µL) was reacted with a master mix containing 200 nM of both sense and 
antisense primers, with 10 µL EXPRESS SYBR GreenER qPCR supermix made up 
to 20 µL with nuclease free water.   Primers designed for coding regions of genes 
listed in Table 2.7 were utilised.  To quantitate gene expression levels, cDNA was 
analysed with the quantitative real time PCR Instrument. Reactions were heated to 
95oC for 5 min annealing at manufacturer indicated primer temperature denaturing 
for 40 cycles at 95°C for 10 s, annealing at specific primer Tm for 10 s and extension 
at 72°C for 10 s.  A melt curve was obtained by ramping the temperature from 37oC 
to 95oC at a rate of 2oC/min. A final cooling phase of 37oC for 5 min was performed. 
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2.1.9 Plasmid amplification 
2.1.9.1 Plasmid transformation 
In order to carry out plasmid-based assays, the mCherry empty vector and the degron 
(µGFP) plasmids were amplified via bacterial amplification.   Chemically competent 
bacteria (JM109 strain of Escherichia coli) were defrosted on ice. Two aliquots of 
bacteria (50 µL) were treated with β-mercaptoethanol (2 µL) and incubated for 10 
minutes. The solution was gently mixed by swirling every two minutes during this 
incubation. The plasmid (between 10-50 ng) was added to the bacteria in one aliquot. 
No plasmid was added to the negative control aliquot.  The bacteria cells were then 
heat pulsed by incubating at 42oC for 30 s, followed by incubation on ice for 2 min.  
Lysogeny broth (LB; 900 µL; 15% agar, 10% NaCl, 10% tryptone, 5% yeast extract 
in MilliQ H2O), once heated to 42
oC was added to the cells, which were incubated 
for 1 h at 37oC on a shaker at 250 rpm.  Cells were streaked onto freshly prepared 
kanamycin (50 µg/mL) LB agar plates with a cell spreader.   Cells were also plated 
onto a positive control plate, containing no antibiotic and a negative control plate 
containing ampicillin (100 µg/mL; no ampicillin resistance gene was present in the 
plasmids amplified).  Plates were incubated upside-down for 16 h at 37oC. If no 
colonies were growing on the negative control, the plates were placed upside-down 
at 4oC for 8 hours.   A colony from the kanamycin plate was collected with an 
inoculation loop. The colony was streaked out (16 streak) on agar plates. The plates 
were incubated upside-down for 16 h at 37oC.  A single colony was then selected 
with an inoculation loop and incubated in pre-warmed LB broth (37oC) containing 
kanamycin (25 µg/ml) and ampicillin (50 µg/ml) for 4 hours. This bacterial solution 
was then further diluted five fold in the antibiotic-containing LB broth and incubated 
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at 37oC for 16 hours on the shaker (180 rpm). The bacteria were pelleted via 
centrifugation at 4000 x g for 10 min. Supernatant was discarded at cell pellet was 
frozen at 20oC. 
 
2.1.9.2 Plasmid purification 
Plasmids were purified following bacterial amplification using Qiagen Maxiprep kit 
as per the manufacturer’s recommendations.  The cells were lysed by incubating the 
cell pellet in RNase A containing P1 lysis buffer (10 mL), and the P2 buffer (10 mL) 
for 5 minutes at room temperature. LyseBlue solution was used to a homogenous 
mixing of the solutions.  To remove the bacterial genomic DNA and the bacterial 
debris, the P3 buffer was vigorously mixed to the lysis solution and incubated on ice 
for 20 min; the plasmid was collected from the supernatant following centrifugation 
at 20,000 x g at 4oC for 30 min, and again for 15 minutes.  The plasmid containing 
supernatant was run through an equilibrated QIAGEN-tip column by gravity flow. 
To remove any contaminants the column was washed with the QC buffer (60 mL).  
The plasmid DNA was eluted from the column with the elution buffer (15 mL). DNA 
was precipitated with isopropanol (10.5 mL) and centrifuged at 15,000 x g at 4oC for 
30 min.  The DNA pellet was washed with the 70% ethanol and centrifuged at 
15,000 x g at room temperature for 10 min. The pellet was air drier for 10 mins and 
redissolved in TE buffer.  The purity was assessed via nanodrop as previously 
described (see 1.1.6.2.1 Genomic DNA purification for CCNF sequencing) 
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2.1.9.3 Plasmid verification via PCR 
To ensure the correct plasmid was amplified, the DNA sequence was verified via 
PCR.  The plasmids were amplified via PCR using the BigDye Terminator v3.1 
Cycle Sequencing Kit.  Each PCR amplification solution containing the plasmid of 
interest (500 ng), BigDye reaction mix (1 uL), BigDye sequencing buffer (5X) and 
CMV forward primer (1 uL, 1.6 uM), made up to a total volume of 10 uL with 
nuclease free water was amplified using a thermocycler preheated to 96oC. The 
amplification was performed over 35 cycles of 10s at 96oC, 5s at 55oC and 4 min at 
60oC.  
 
The sequencing PCR product was purified. The PCR sequencing product was diluted 
two fold in nuclease free water, and precipitated with 50 uL ethanol (50 uL), 2 uL 
EDTA pH 8 (125 mM), 2 uL sodium acetate at room pH 5.2 (3M) temperature 
overnight.  The DNA was then pelleted via centrifugation at 14,000 rpm for 30 mins 
at 4oC. The supernatant was discarded. The DNA pellet was washed with 70% ice-
cold ethanol and centrifuged 14,000 rpm for 30 mins at 4oC.  The pellet was air-
dried.  Sequencing was performed at the University of Wollongong, School of 
Biology by Research Technical Officer Margaret Phillips.  Snap Gene software was 
utilised to analyse the resulting sequence. The resulting sequence was compared to 
the known sequence, acquired from the Addgene online plasmid repository.   
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2.2 Protein quantification 
 
2.2.1 Relative whole cell protein expression 
To determine the expression of specific proteins in different cell types, 
immunocytochemical staining was performed.  Incubations were carried out at room 
temperature unless otherwise stated. Once cells reached the optimal confluence, 
media was aspirated and cells were gently washed three times with PBS (pH 7.4).  
Cells were fixed with paraformaldehyde (4% w/v).  Paraformaldehyde was aspirated 
and three PBST washes (5 min) were performed.  Fixed cells were permeablised with 
TritonX-100 in PBS (0.5% v/v) for 15 min and blocked. Cells were incubated in the 
appropriate primary antibody as described in Table 2.8. Cells were washed three 
times in tris buffered saline with tween 20 (0.05% v/v; TBST) and were incubated in 
an appropriate secondary antibody for 1 h.  Cells were incubated in a secondary 
antibody conjugated with a fluorescent (488) molecule for the corresponding species 
of which the primary antibody was raised (anti-rabbit or anti-mouse), diluted in PBS 
(1:1000).  Cells were gently washed three times with PBS with tween (PBST).  
Coverslips were mounted onto glass slides with 5 µL slowfade reagent with DAPI 
and sealed with nail varnish.  For nuclear staining at high magnification, RedDot2 
staining was performed prior to mounting the slide.  Cells were washed three times in 
PBST, and incubated in RedDot2 (1:200) in PBST. Cells were washed three times in 
PBST prior to mounting.   
 
Imaging was performed on a fluorescent microscope for iPSCs, on a live cell imager 
for endodermal cells, and on a confocal microscope for all other cell types, including 
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motor neurons.  Where appropriate protein expression was compared to positive 
controls, the iPSC clones were compared to other established iPSC lines, endodermal 
cells were compared to HEPG2 cells. All secondary antibodies were tested for cross-
reactivity and non-specific immunoreactivity using the appropriate immunoglobulin 
G negative control of the relevant species.  
 
Quantification of motor neuron markers was performed using FIJI Is Just Image J 
(FIJI) software. Cells lines from six different donors were differentiated in triplicate. 
Six -ten images were taken for each of the technical replicates.  Analysis was carried 
out using PRISM software; following confirmation that the data was normally 
distributed, one-way ANOVA, with Tukey’s multiple comparisons post hoc analysis 
was performed.  Quantification of Cyclin F and TDP-43 was carried out using Cell 
Profiler Software (as per Table 2.11).  
2.2.2 Protein collection and quantification 
To determine the abundance of total protein present in a sample for western blot and 
ubiqutinomics analysis, protein samples, once harvested, were quantified by 
detergent compatible (DC) protein assay, comparing against a BSA standard curve.  
Cells (fibroblasts, iPSCs, aNPCs, and motor neurons) were washed twice in PBS and 
lysed in radioimmunoprecipitation assay buffer (RIPA; (50mM Tris-HCl (pH7.4), 
1% sodium deoxycholate, 150mM NaCl, 1mM EDTA, 1%TritonX-100, 0.1% SDS 
with 1 mM sodium orthovanadate, 10 mM N-Ethylmaleimide (omitted for negative 
DUB inhibitor assay), 1X Phosphate Inhibitor cocktail 2)) lysis and extraction buffer. 
To ensure a large yield, a cell scraper was used to detach any non-lysed cells, and the 
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collected cell lysate solution was vortexed vigorously and stored on ice. The lysate 
was centrifuged at maximum speed for 5 minutes at 4oC. For insoluble fraction 
examination, the lysate was collected and the insoluble pellet was resuspended in 
RIPA buffer 2% sodium dodecyl sulfate (SDS).  The lysate solution was vortexed 
and centrifuged as per the RIPA soluble lysate. This was the SDS soluble fraction. 
The lysate was collected and the insoluble pellet was resuspended in RIPA buffer 8M 
Urea.  This was the Urea soluble fraction.  The lysate solution was vortexed and 
centrifuged as per the RIPA soluble lysate    
 
Protein concentration was quantified via a detergent compatible DC protein assay 
according to manufacturer’s specifications.  A standard curve was produced using 
BSA standards at 1000, 500, 250, 125, 62.5, 20.83, 6.94 and 0 µg/mL, in the buffer 
the samples were collected in.  Standards or samples were plated in triplicate in a 96 
well plate (5 µL).  Surfactant reagent S was combined with copper tartrate containing 
reagent A in a 2:100 ratio; this solution was added to each well (25 µL) and gently 
mixed.  Folin reagent containing Reagent A was then added to each well (200 uL). 
The plate was gently mixed on an orbital plate shaker and incubated for 15 minutes 
at room temperature.  The absorbance values were detected at 750 nm using a plate 
reader.  The protein sample concentrations were interpolated from the BSA standard 
curve.  Samples were stored at -80oC. 
 
To determine the relative abundance of proteins including cyclin F, TDP-43 and 
phosphorylated TDP-43, western blot assays were performed.  Two techniques were 
used to quantify proteins: 1. Quantification with 10% acrylamide gels, normalising to 
neuronal marker NSE; 2. Quantification with total protein.  In both methods, 
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statistical significance was determined using PRISM software, using a one-way 
ANOVA, with Tukey’s post hoc.   
 
2.2.3 Protein quantification via western blot 
To separate the proteins by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS PAGE), 10% acrylamide (v/v) resolving hydrogels and 5% 
(v/v) acrylamide stacking hydrogels were prepared using the Mini-PROTEAN® 
Tetra Handcast System (Bio-Rad) using the 10 well gels (see Table 2.2 Media and 
solution compositions) and assembled prior to placement in the gel electrophoresis 
tank in SDS-PAGE buffer to ensure no leaking occurred.  To minimize protein 
degradation, samples were slowly defrosted on ice.  XT sample buffer and 25 mM 
dithiothreitol (DTT) were added to the defrosted lysate samples (10 µg), and made 
up to a total volume of 10 µL with excess RIPA lysis and extraction buffer. Samples 
were incubated at 95°C for 5 minutes to denature proteins and stored on ice prior to 
loading. Sample (10 µL), pre-stained precision plus protein ladder (6 µL) and a 
pooled sample of the six cell lines (10 µL) were loaded in the stacking hydrogel. 
Samples were separated at 100 V (constant voltage) for 100 mins.  The hydrogels 
were then equilibrated in ice-cold transfer buffer for 20 minutes. Gels were 
transferred onto a polyvinylidene fluoride (PVDF) membrane using a transfer tank at 
100 V (constant voltage) in stirred ice-cold transfer buffer for 42 min.  Membranes 
were vigorously washed three times in tris buffered saline with TBST for seven 
minutes. Membranes were blocked overnight in 5% BSA in TBST (w/v). Membranes 
were incubated in TPD-43 antibody raised in mouse (1:1000), or phosphorylated 
TDP-43 raised in rabbit (1:1000), or cyclin F antibody raised in rabbit (1:2000) 
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diluted in 3% BSA in TBST (w/v) overnight.  Membranes washed again in triplicate, 
and incubated with the appropriate secondary antibody (anti-mouse-horseradish 
peroxide 1:10000 or anti-rabbit-horseradish peroxidase (1:10000) diluted in 3% BSA 
in TBST (w/v) for 1 h.  Membranes were washed again in triplicate.  Membranes 
were incubated in chemiluminescent substrate (ECL) for 30 s and sandwiched 
between two clear plastic films, ensuring neither bubbles nor debris were present. 
The membrane was exposed to film in a dark room.  The film was developed using a 
film processor and assessed for any saturation by eye. The membrane was washed in 
triplicate. The film was scanned with a densitometer, and the density of the bands 
was assessed for saturation using Quantity One software.  If saturated bands were 
present, the ECL was reapplied and the membrane was re-imaged. The non-saturated 
developed film image was exported, and the band density was quantified using Licor 
software; Bands corresponding to the proteins of interest were identified by 
comparison to the known weights of the protein ladder, and from descriptions in the 
literature.  To normalised to neuron specific enolase (NSE), membranes were 
incubated with the NSE antibody from a different species; Neurons were incubated 
in NSE antibody 1:10000 antibody raised in mouse or NSE antibody 1:5000 antibody 
raised rabbit) for diluted in 3% BSA in TBST (w/v) for 1 h. Membranes washed 
again in triplicate, and incubated with the appropriate secondary antibody (anti-
mouse or anti-rabbit-horseradish peroxide diluted in 3% BSA in TBST (w/v) for 1 h.  
Membranes were washed in triplicate and imaged as described above.  The density of 
the proteins of interest were normalised to the pooled sample within the respective 
gel, and normalised to the normalising protein density. 
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2.2.3.1 Protein quantification via western blot, normalised to total protein 
Separation of proteins was carried out using a 4 – 20% precast Criterion gels (Bio 
Rad). Prior to transfer of the protein to PVDF membrane, the gradient gel was 
equilibrated in water to reduce any movement of the gel, and imaged in a gel 
imaging system. The Criterion gel was then equilibrated in transfer buffer and 
proteins were transferred as aforementioned. Prior to incubation in blocking buffer, 
the PDVF membrane was imaged again for total protein. The PDVF membrane was 
divided according to the protein ladder (following initial investigation into band 
sizes), and the respective membranes were incubated as described in the previous 
section.  Blots were imaged with a gel imager using ECL as previously described.  
Exposure time was optimised for each membrane, and normalised to the pooled 
control. Protein bands were quantified as previously described using Licor software, 
and were normalised to total protein.  
2.3 Increasing UPS stress 
 
Two inhibitor compounds were engaged in this study to increase ubiquitin 
proteasomal stress.  The Z-Leu-Leu-leu-Al peptide, commonly known as MG132, 
was used as a proteasomal inhibitor.  PYR41, an inhibitor of apex E1 ubiquitin 
activating enzyme UBA1 was used to partially inhibit the ubiquitin system.  Both 
inhibitors were solubilised in DMSO, therefore a vehicle (DMSO) control was 
included in each experiment, in which DMSO was added in equal concentration. 
Final concentrations used in these assays were as follows: concentration curve assay 
concentrations were 0 (DMSO control), 1, 2.5, 10, 100 and 250 μM MG132 and 0 
μM (DMSO control) 1 μM, 2.5 μM, 5 μM, and 10 μM PYR41; proceeding MG132 
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assays were 10 μM MG132, and PYR41 assays were 1 μM, and 10 μM PYR41.  For 
cells requiring a partial media change, media was removed from the well, returning 
an exact half volume, and adding a second half volume of fresh inhibitor 
supplemented media.  Cells were treated with MG132 for 16 h, PYR41 for 24 h (or 
refreshed every 48 h in the longitudinal study) at the indicated concentration (using 
either a concentration curve, or single concentration, as described). Neurite analysis 
was performed using the Incucyte Zoom software using the NeuroTrack package. 
Cell-body cluster parameters were set for brightness for segementation mode, with 
0.9 Segmetnation adjustment. Minimum cell width was set at 10.000 for cleanup. 
cell-body cluster filters were set to minimum 200.00 μm2, maximum 1000.0. Neurite 
paramters were set to filter: best, neurite sensitivity: 0.6, width: 1. 
 
2.4 Assessing cellular viability  
 
Resazurin based viability assay was performed to indicate cellular health.  Cells 
(fibroblasts (at 70% confluence), iPSCs (at 40% confluence) and motor neurons (on 
day 54 of differentiation)) were treated with proteasomal inhibitor or UBA1 
inhibitor, as per 2.1.1.1.  The total media was aspirated and replaced with PrestoBlue 
reagent diluted 10X in DMEM/F12.  Cells were incubated for 2 hours, and the 
PrestoBlue solution was transferred to a black 96 well plate.  Fluorescence was 
measured at 560 nm excitation/590 nm emission. Background fluorescence was 
subtracted, and where indicated, florescence was normalised to no treatmeatment 
(vehicle) controls. A minimum of three replicates were performed, as indicated.  
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2.5 Assessing the efficacy of the UPS: Degron assay 
 
To assess the efficacy of the ubiquitin proteasome system a degron assay was 
performed in motor neuron precursors. Once cells had reached an appropriate 
confluence or stage of differentiation, cells were transfected with Lipofectamine 
LTX according to the manufacturer’s protocol.  All reagents were incubated at room 
temperature for 20 min. The pEGFP-C1-GFPµ, and mCherry plasmids were diluted 
to 0.5 μg/µL in Opti-MEM. To ensure cells that had taken up the pEGFP-C1-GFPµ 
also took up the mCherry plasmid, these were added in a 2:1 ratio, to a total of 100 
ng of DNA per 96 well plate well.  The LTX PLUS reagent was added to the DNA; 
LTX reagent (0.4 µL per 100 ng plasmid) was added to the DNA solution. The LTX-
plasmid solution was incubated for 25 min at room temperature to allow the 
liposomes to form. The LTX-plasmid complexes (100 μL) were added dropwise to 
the centre of the well, and gently rocked in an X-Y plane. Cells were imaged 
following 16 h of incubation, using the in-incubator microscope (Incucyte Zoom). 
Analysis was performed using the Incucyte Zoom Software. The standard analysis 
package was used; Green channel images, indicating degron signal retention as an 
indicator of proteasomal function were analysed using Top-Hat Parameters with 
radius 80.000 μm, 1.3000 GCU threshold no edge split applied. Cells were filtered 
for red fluorescence, as an indicator of mCherry expression, indicative of a 
transfection success, using Top-Hat Parameters, radius 100.000 μm, 1.0000 RCU 
threshold, no edge split applied, minimum area filtered to 20.000 μm2, and minimum 
eccentricity of 0.1500. 
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2.6 Ubiquitinomic analysis of fibroblasts, iPSCs and motor neurons 
 
2.6.1 Lysate collection 
Cells were harvested as per protein quantification, by manually scraping in lysate 
buffer containing protease inhibitors and a deubiquitinating enzyme inhibitor. 
Samples were quantified by DC Assay, as previously described and delivered dry ice 
to the University of New South Wales for ubiquitinomic sample processing by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) by Jess McKenna, 
Research Assistant (Saunder’s Laboratory) as described in 2.1.1.4 Ubiquitin 
immunoprecipitation and LC-MS/MS. 
 
2.6.2 Ubiquitin immunoprecipitation and LC-MS/MS 
The following protocol was used by Jess McKenna for purification and subsequent 
LC-MS/MS analysis: Mono- and poly-ubiquitinated proteins were immunopurified 
using specialized ubiquitin matrix (VIVAbind Ubiquitin Kit, VIVA Bioscience).  
After significant washing to remove residual detergent, beads were digested for 30 
min at 27°C, then reduced with 1mM DTT and left to digest overnight at room 
temperature with sequencing-grade trypsin (5 μg/mL, Promega), as described 
previously (Turriziani et al., 2014). Samples were alkylated with iodoacetamide (5 
mg/mL), and protease digestion terminated with trifluoroacetic acid (TFA). The 
trypsin-treated eluents were collected following brief centrifugation. Eluant was 
purified and desalted using self-packed stage tips with 6 layers of C18 Empore disks 
(Pacific Laboratory Products), and dried in a SpeedVac. Samples were resuspended 
in a formic acid (5%), acetonitrile (2%) solution (12 μL).  The purified eluate was 
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stored at -80°C prior to mass spectrometry analysis.  The digested peptide sample (5 
μL) was separated along a self-made C18 column and introduced by nanoelectrospray 
into the LTQ Orbitrap Velos Pro coupled to an Easy-nLC HPLC.  Tandem mass 
spectrometry data was collected for the top 10 most abundant ions per scan over a 
140-minute time gradient. The MS/MS raw files were analysed using MaxQuant 
(v1.2.7.4) against the Uniprot human database, and exported as a ‘proteinGroups.txt’ 
from MaxQuant. The file generated by MaxQuant was used for all subsequent 
analyses carried out in this study by Monique Bax. 
 
2.6.3 Filtration of LC-MS/MS output 
Data filtration and analysis was performed using RStudio (v1.1.423) unless 
otherwise specified.  The raw MaxQuant output was imported into R Studio where 
the data were filtered for contaminants, reverse hits, proteins only identified by site 
and number of unique peptides (≥ 2), and all further analysis was performed using 
these filtered data. The identified proteins were filtered for contaminants, a label-free 
quantitation (LFQ) intensity score > 0 in at least three of the four replicates of each 
cell stage.  
 
2.6.4 Verification of data and analysis of change to ubiquitome 
To validate these data, a comparison of the samples was carried out. Multiscatter 
plots of the data, a heatmap of the Pearson’s Correlation calculated values and a 
Principal Component Analysis were used to visualise the comparisons of the 
different replicates, within and between cell lines.  Venn analysis using InteractiVenn 
software was employed to compare the proteins present in each combination of the 
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two cell stages.  The resulting filtered list used to qualify protein-protein interactions 
using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; v10.5; 
Szklarczyk et al., 2017). The KEGG enriched protein interactions list was exported, 
and a heatmap of these KEGG grouped proteins generated in PRISM v7, ordered by 
the most KEGG pathways with highest number of protein interactions.  
 
To quantify and compare the changes of the ubiquitomes at the different cellular 
stags, the Pegasus method was utilised to scale and statistically analyse the 
differences in LFQ intensity between cellular stages. Briefly, the Perseus 
methodology was adjusted with concepts from Benjamini and Hochberg (1995), Cox 
et al., (2012), and Hogl et al., (2013); LFQ intensities were transformed to logarithm 
(log2) and post-transformation missing values were assigned random numerical 
values within the lowest quartile of the resulting normal distribution of each 
replicate. To compare two cell stages, the mean of one cell stage was subtracted from 
each replicate of the opposite cell stage, and vice versa, scaling these LFQ 
intensities.  A two-sided, unequal variance Student’s T-test with a Benjamini-
Hochberg test to reduce Type I errors was performed. The mean abundance from the 
scaled LFQ intensity, and a significance threshold was set at an abundance ≥ 2 and 
Q-value < 0.01.  Significantly different proteins were analysed for significant protein 
interactions using the STRING and Cytoscape.  Proteins were analysed for 
significantly higher than expected interactions based on the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG), Functional and Cellular Component enriched 
grouping.   
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To determine if these changes were consistently occurring in different cell lines this 
analysis was repeated for three other cell lines. Filtering was completed as 
aforementioned. Venn analysis using InteractiVenn to was implemented compare the 
changes common to all four cell lines at each change of cellular stage, following 
export of the STRING enriched protein interactions, following filtering as 
aforementioned (Heberle et al., 2015).  
 
To compare the ubiquitomes of the cell lines, data was filtered and normalised as 
aforementioned. A principal component analysis was performed comparing 1. The 
different cellular stage from the different cell lines; 2. The cell lines at each cellular 
stage.  The transformed relative abundances of in the motor neurons were analysed 
for significant differences via one-way ANOVA, filtering for false discoveries using 
BH, using PRISM. The proteins that were significantly different were filtered by 
patterns of significance.  The resulting list of significant proteins was analysed for 
protein interactions in STRING. Protein interactions pathways that were significant 
were exported.  Ubiquitinated proteins were also compared to known proteins 
associated with ALS as available on the ALSoD website (Abel et al., 2013). 
 
2.7 Assessing cellular nitrite as an indicator of nitrosative stress 
 
To assess nitrosative stress in the ALS affected cell lines compared to controls, a 
Griess assay was performed as per Balez et al., 2016.  Supernatant samples were 
collected from cell cultures prior to harvesting for protein.  Supernatant was 
measured using the microplate assay. A nitrite standard was prepared with sodium 
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nitrate 100 µM, 50 µM, 25 µM, 12.5 µM and 0 µM diluted in MN Media.  Griess 
reagent (20 µL; N-(1-naphthyl)ethylenediamine 0.1% (w/v)  Sulfanic acid 1% (w/v) 
in 5% phosphoric acid (v/v)), supernatant or nitrite standard (150 µL) and milliQ 
water (130 µL) was added to a black well clear bottom 96 well plate under low light 
conditions and incubated at room temperature in darkness for 30 min.  Absorbance 
was detected at 548 nm using a plate reader.  A standard curve was generated from 
the linear standard absorbance measurements, and the supernatant samples were 
calculated from the line of best fit.  Analysis was performed using PRISM software, 
via one-way ANOVA with Bonferroni post hoc analysis.  
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2.8 Materials 
Table 2.1 Cell lines utilised in this study 
Cell line Description Species Sex Age  
Commonly used cell culture lines 
NuFF 
Newborn human foreskin fibroblasts used 
to condition media. 
Human M 0 
NSC34 
A motor neuron-like cell line from mouse 
neuroblastoma x spinal cord hybrid. 
Mouse NA* NA* 
Hep G2 Liver cancer cell line.  Human M 15 
C2C12 Skeletal myoblast from C3H mouse Mouse F 2 months 
HEK293T  Human Embryonic Kidney 293 cells Human F 0 
ALS Patient and Control Lines 
CCNF1 
Fibroblasts from skin punch sibling of 
CCNF2 with CCNFS621G, pre-symptomatic 
at time of collection.  APOE ε3/3 
Human F 62 
CCNF2 
Fibroblasts from skin punch of patient 
with CCNFS216G mutation. APOE ε3/4 
Human M 59 
UBQLN2 
Control 
Healthy donor sibling of an ALS patient 
with UBQLN2 mutation.  APOE ε3/4 
Human F Unknown 
MQ130054 
Fibroblasts from skin punch from an ALS 
patient with SOD1E101G mutation. APOE 
ε2/3 
Human M Unknown 
HDF1 
Control donor 1; age and sex matched for 
SAD patient 
Human M 57 
HDF10 
Sporadic Alzheimer’s disease patient 
number 10 
Human M 65 
Reprogrammed ALS Patient and Control iPSC lines 
CCNF1; 
MB1-10 
iPSC line generated from CCNF1 
fibroblasts; mRNA reprogrammed in this 
study 
Human F 62 
CCNF2; 
MB2-1 
iPSC line generated from CCNF2 
fibroblasts; mRNA reprogrammed in this 
study 
Human M 59 
HC1; 
MB3-10 
iPSC line generated from UBQLN2 
Control fibroblasts; mRNA reprogrammed 
in this study 
Human F Unknown 
SOD1;  
MQ54-2 
iPSC line generated from MQ130054, the 
SOD1E101G mutation fibroblasts; mRNA 
reprogrammed for this study by Rachelle 
Balez 
Human M Unknown 
HC2;  
1-4 
HC2 iPSC line; Healthy control donor 2; 
age and sex matched to SAD patient; 
previously virally reprogrammed 
Human M 57 
SAD; 
10-13 
SAD iPSC line; previously virally 
reprogrammed 
Human M 65 
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*NSC34 cells, are a hybrid cell line with abnormal chromosomes, XX and XY 
chromosomes, as reported by Neil Cashman.  
Table 2.2 Media and solutions composition 
Media Volume 
General Culture Media 500 mL Total Volume: 
DMEM/F12 440 mL 
Foetal Bovine Serum 50 mL 
Glutamine 5 mL 
Penicillin-Streptomycin (10,000 U/mL) 5 mL 
Pluriton Media 500 mL Total Volume: 
Pluriton Base Media 494.8 
Penicillin-Streptomycin (10,000 U/mL) 5 mL 
Pluriton Supplement (2500X) 200 µL 
Recombinant B18R 300ng/mL 
bFGF 4 ng/mL 
TeSR E8 500 mL Total Volume: 
TeSR E8 Basal media 474 mL 
TeSR E8 20X supplement  25 mL 
TeSR E8 500X supplement  1 mL 
Neural Induction Media 50 mL Total Volume: 
DMEM/F12 47.8 mL 
Penicillin-Streptomycin (10,000 U/mL) 500 µL 
Glutamax 500 µL 
MEM non-essential amino acids 500 µL 
N2 Supplement 500 µL 
B-27 Supplement 200 µL 
Anterior Neural Precursor Media 50 mL Total Volume: 
DMEM/F12 47.75 mL 
Penicillin-Streptomycin (10,000 U/mL) 500 µL 
Glutamax 500 µL 
MEM non-essential amino acids 500 µL 
B-27 Supplement 250 µL 
N2 Supplement 500 µL 
bFGF 500 ng 
Motor Neuron Precursor Caudalising 
Media 
50 mL Total Volume: 
Neurobasal media 48 mL 
Penicillin-Streptomycin (10,000 U/mL) 500 µL 
Glutamax 500 µL 
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MEM non-essential amino acids 500 µL 
N2 Supplement 500 µL 
bFGF 250 ng 
Retanoic acid 0.3 µM 
Motor Neuron Precursor Media 50 mL Total Volume: 
Neurobasal media 48 mL 
Penicillin-Streptomycin (10,000 U/mL) 500 µL 
Glutamax 500 µL 
MEM non-essential amino acids 500 µL 
N2 Supplement 500 µL 
bFGF 250 ng 
Retanoic acid 0.1 µM 
Purmorphamine 2 µM 
Motor Neuron Media 50 mL Total Volume: 
Neurobasal media 48.15 mL  
Penicillin-Streptomycin (10,000 U/mL) 500 µL 
Glutamax 500 µL 
MEM non-essential amino acids 500 µL 
B-27 Supplement 100 µL 
N2 Supplement 250 µL 
BDNF 500 ng 
GDNF 500 ng 
IGF 500 ng 
cAMP 500 ng 
Polyacrylamide Resolving Gel (10%) 40 mL Total Volume: 
Water   (MilliQ) 19.87 mL 
Acrylamide  (40%) 10 mL 
Tris-HCl 1.5M pH 8.8. 10.13 mL 
SDS (10%) 400 µL 
Ammonium persulfate (10%) 400 µL 
Tetramethylethylenediamine 32 µL 
Polyacrylamide Stacking Gel  12 mL Total Volume 
Water (MilliQ) 9 mL 
Acrylamide (40%) 1.5 mL 
Tris-HCl 1.5M pH 6.8. 1.5 mL 
SDS (10%) 120 µL 
Ammonium persulfate (10%) 120 µL 
Tetramethylethylenediamine 12 µL 
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Table 2.3 Reagents used 
 
Material/Compound Company 
Concentration 
Used  
(unless stated) 
Catalogue 
Number 
Accutase 
Stemcell 
Technologies 
1X 07920 
Acetonitrile Sigma Aldrich 2% 271004 
Acrylamide/Bis Solution Bio Rad (40% v/v) 161-0148 
Agar 
Thermo Fisher 
Scientific 
1.5%  BD 244510 
All-Trans Retanoic Acid 
Stemcell 
Technologies 
0.3 µM 
0.1 µM 
72262 
Ambion Turbo DNA-free Invitrogen As Described AM1907 
Ammonium Persulfate Bio Rad 10% 161-0700 
Ampicillin 
Thermo Fisher 
Scientific 
1:1000 11593027 
B-27 Supplement 
Life 
Technologies 
100X 17504-044 
BigDye Terminator v3.1 Cycle 
Sequencing Kit 
Thermo Fisher 
Scientific 
As Described 4337455 
Bovine Serum Albumin Sigma Aldrich 10% 
A7906-
100G 
C18 Empore Disks 
Pacific 
Laboratory 
Products 
1X 
34-7054-
5218-2 
Chemiluminescent Substrate Thermo Fisher 1X 32106 
Chloroform Sigma Aldrich 100% 
C2532-
500ML 
Collagen I 
Life 
Technologies 
10 µg/mL A1048301 
Corning Matrigel hESC-
Qualified Matrix, LDEV-Free 
In Vitro 
Technologies 
 354277 
Criterion 4-20% TGX Stain-
Free Precast Gel 
Bio Rad 1X 567-8095 
Detergent Compatible Assay 
(Reagents A, B, S) 
Bio Rad 1X S36942 
Dibutyryl Cyclic Adenosine 
Monophosphate 
Millipore 10 ng/mL 28745 
Dimethyl Sulfoxide Sigma Aldrich 10% 
472301-
100ML 
Dispase 
Stemcell 
Technologies 
1X 7913 
Dithiothreitol Sigma Aldrich 4X 101977770
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01 
DMEM/F12 Invitrogen 1X 12500-096 
Ethanol VWR  100% AJA214-2 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma Aldrich 1 mM 
E9884-
100G 
Express SYBR GreenER 
qPCR Supermix Universal Kit 
Life 
Technologies 
As Described 11784-01K 
Fibroblast Growth Factor 
Basic (bFGF) 
Miltenyi Biotec 5 ng/m 
130-104-
923 
Fibronectin Human Protein 
Plasma 
Life 
Technologies 
10 µg/mL 33016015 
Foetal calf Serum (FCS) 
Bovogen 
Biological 
10% SFBS-F 
Formic Acid Sigma Aldrich 5% 106526 
Glutamax 
Life 
Technologies 
1:100 35050061 
Glycerol (Molecular Biology 
Grade) 
Sigma Aldrich 1:1 G5516-1L 
Griess Reagent 
Molecular 
Probes 
1:14 F-7921 
Insulin-Like Growth Factor 1 
(IGF) 
Miltenyi Biotec 10 ng/mL 
130-093-
887 
iPS Brew Miltenyi Biotec 1X 130104258 
Isopropanol Sigma Aldrich 100%   
Kanamycin 
Thermo Fisher 
Scientific 
1:1000 11815024 
L-Glutamine 
Life 
Technologies 
100X 25030 
Laminin Mouse Protein, 
Natural 
Life 
Technologies 
2.0 mg/mL 23017-015 
Lipofectamine LTX 
Thermo Fisher 
Scientific 
As Described 15338-100 
MEM Non-Essential Amino 
Acids 
Life 
Technologies 
0.1 mM 11140050 
mFreSR 
Stem Cell 
Technologies 
1X 5854 
MM-LV RTase Promega 200 U M1708 
MMdNTP Promega 200 U U1511 
mRNA Reprogramming Kit Stemgent As Described 00-0071 
N2 Supplement 
Life 
Technologies 
1:50 17502-048 
N-Ethylmaleimide  Sigma Aldrich 10 mM E3876-5g 
Neurobasal Media 
Life 
Technologies 
1X 21103-049 
Nuclease-Free Water Promega 1X 7732-18-5 
Oligo(dT) 15 Primers Promega 0.5 μg C1101 
OptiMEM Thermo Fisher 1X 31985-070 
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Paraformaldehyde Sigma Aldrich 4% 
158127-
100G 
Penicillin Streptomycin Sigma Aldrich 
10,000 U/mL & 
10 mg/mL 
P4333-
100ML 
Phenol-Chloroform-Isoamyl 
Alchohol Mixture 
Sigma Aldrich 1X 
77617-
500ML 
Phosphate Inhibitor Cocktail Roche 1X   
Pluriton Medium Stemgent 1X 00-0070 
Pluriton Supplement  Stemgent 2500X 01-0016 
Polyvinylidene Fluoride 
(PVDF) 
Merck Millipore 1X IPVH00010 
Precision Plus Protein Dual 
Color Standards 
Bio Rad 1X 1610374 
PrestoBlue 
Thermo Fisher 
Scientific 
1:100 A13261 
Protease Inhibitor Cocktail II 
Astral 
Scientific 
1 x tablet P-1511 
Proteinase K   20 mg/mL   
PureLinkR Genomic Mini Kit 
Life 
Technologies 
1X K1820-00 
Purmorphamine 
Stem Cell 
Technologies 
2 µM 72204 
PYR41 Sigma Aldrich Conc Gradient N2915 
Qiagen Maxiprep Kit Qiagen  12162 
Random Primers Promega 0.5 μg C1181 
Recombinant Human Brain-
Derived Neurotrophic Factor 
(BDNF) 
Miltenyi Biotec 10 ng/mL 
130-103-
435 
Recombinant Human Glial 
Cell-Derived Neurotrophic 
Factor (GDNF) 
Miltenyi Biotec 10 ng/mL 
130-098-
449 
Recombinant RNasin 
Ribonuclease Inhibitor 
Promega 40U N2515 
Rnase A   20 mg/mL  
ROCK Inhibitor Sigma Aldrich 10 μM SCM075 
Slowfade Gold Antifade 
Mountant with DAPI 
Invitrogen 1X S36942 
Sodium Acetate Sigma Aldrich 7.5 M  S2889 
Sodium Chloride (NaCl) Sigma Aldrich 150 mM  S5886 
Sodium Deoxycholate Sigma Aldrich 1% D6750-25G 
Sodium Dodecyl Sulfate 
Solution (In H2O; SDS) 
Sigma Aldrich 10% 
71736-
500ML 
Sodium Nitrate Sigma Aldrich As Described  221341 
Sodium Orthovanadate Sigma Aldrich 1 mM S6508-10G 
STEMdiff Definitive Endoderm 
Kit TeSR E8 Optimised 
Stemcell 
Technologies 
As Described 5115 
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TeS-E8 20X, 500X 
Supplement and Basal 
Medium 
Stemcell 
Technologies 
1X 
5940, 5942, 
5943 
Tetramethylethylenediamine Bio Rad 1X 161-0800 
Trifluoroacetic Acid (TFA) Sigma Aldrich 1X T62200 
Trireagent 
Molecular 
Research 
Centre 
1X TR 118 
Tris-EDTA Sigma Aldrich 1.5 M 93302 
Tris-HCl Sigma Aldrich 50 mM   
Triton X-100 Sigma Aldrich 1X 
T8787-
250ML 
Trypsin (Sequencing Grade; 5 
μg/mL) 
Promega 5 μg/mL 25300054 
Trypsin Inhibitor Sigma Aldrich 1 mg/mL 
T9128-
500MG 
Trypsin/EDTA 
Life 
Technologies 
0.05% 25300054 
Tryptone (bacto) BD Bioscience 1.0% BD211705 
Turbo Dnase 
Life 
Technologies 
As Described AM1907 
UltraPureTM Distilled Water 
(DNAse, RNAse free) 
GIBCO 1X 10977 
Urea Sigma Aldrich 8 M 
U4883-
6X25ML 
VIVAbind Ubiquitin Kit 
Viva 
Bioscience 
As Described  VB2950 
XT Sample Buffer Bio Rad 1X 1610791 
Y-27632 (ROCK inhibitor) Millipore 10 μM 688000 
Yeast Extract  Sigma Alrich 0.5%  92144 
Z-Leu-Leu-Leu-al (HPLC 
grade; MG132) 
Sigma Aldrich As Described 
C2211-
5MG 
β-Mercaptoethanol Sigma Aldrich 1X 60-24-2  
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Table 2.4 Equipment utilised 
Equipment Model Source 
Autoclave HS 5510EC1 Getinge 
Western blot imager Amersham Imager 600 GE 
Benchtop centrifuge 5415R Eppendorf 
Biosafety cabinet S@femate 1.2 ABC NATA LAF technologies 
Cell freeze down vessel Mr Frosty ThermoFisher Scientific 
Centrifuge Multifuge 1XR  ThermoFisher Scientific 
Centrifuge  (primary) 
Heraeus Labofuge 
400R  
ThermoFisher Scientific 
Confocal microscope DMI6000  Leica 
Densitometer GS-800  Biorad 
Electric pipette Pipette Pal controller Wheaton 
Film processor CP1000  AGFA 
Fluorescence plate 
reader 
FLUOstar OPTIMA BMG LabTech 
Fridge/freezer Westinghouse Westinghouse 
Fumehood Conditionaire Safe-Tee Conditionaire International 
Gel imager Amersham Imager 600 GE Healthcare Life Sciences 
Haemocytometer 
Weber 
Haemocytometer 
Weber 
Heat block MD-02N-220 Major Science 
Hypoxic incubator 
HERA Cell 150i CO2 
Incubator 
ThermoFisher Scientific 
In-incubator imager IncuCyte ZOOM Essen Bioscience 
Mass spectrometer 
LTQ Orbitrap Velos Pro 
with Easy-nLC HPLC 
ThermoFisher 
Microplate reader SpectraMax Molecular Devices 
Microscope (cell 
culture) 
Eclipse T5100 Nikon 
Microwave Timesaver Samsung 
Normoxic incubator Autoflow IR direct CO2  Nuaire 
Orbital shaker Bioline Orbital Shaker 
Edwards Instrument 
Company 
PCR Thermocycler Master Cycler Pro Eppendorf 
Pipettes 
Eppendorf Research 
Plus 
Eppendorf 
Platform shaker STR6 Stuart Scientific 
qRT-PCR  Light Cycler 480 II Roche 
Spectrophotometer Nanodrop 2000C ThermoFisher Scientific 
Ultra low freezer (-
80°C) 
TSU series ThermoFisher Scientific 
Vortex 250VM  
HWAShin mixer technology 
company 
Waterbath SWBD Stuart- Bibby Scientific 
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Table 2.5 Software packages utilised 
Software Source Version 
Amersham Software. GE 1.2.0 
CellProfiler BSD 3-clause 2.1.1 
Cytoscape The Cytoscape Consoritum 3.5.1 
Excel Microsoft, USA 2010 
FIJI 
W. Rasband, National Institutes 
of Health 
1.50a 
FLUOstar Optima and 
Data Analysis BMG 
LABTECH 
MARS Data 2.30R3 
Image Studio LI-COR Biosciences 4.0.21 
Incucyte Zoom Essen Bioscience 2015A 
Inkscape Free Software Foundation 0.91 
Leica Application Suite 
AF 
Leica Microsystems 2.6.0 
Leica Application Suite 
X 
Leica Microsystems 
1.9.0.1374
7 
LI-COR LI-COR Biosciences 5.2 
Light Cycler 480 Roche 1.5.0.39 
Nanodrop 2000/2000C Thermo Fisher Scientific 1.4.2 
SoftMax pro Molecular Devices 7.0 
Prism  GraphPad Software 5.01 & 7.0c 
Quantity One Biorad 4.3.0 
R Studio 
Foundation for Open Access 
Statistics 
1.1.423 
STRING Creative Commons BY 4.0 10.5 
InteractiVenn GPLv3 (InteractiVenn @ GitHub) 1.0 
ALSoD Abel O. 6.0 
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Table 2.6 Plasmids utilised 
Plasmid Description 
pEGFP-C1-GFPµ  Degron 
mCherry mCherry Vector 
eGFP GFP Vector 
pHB9-mCMV-GFP HB9 Vector 
pMD2.G Lentivirus VSV-G envelope 
pRSV-Rev Lentivirus REV packaging 
pMDLg/gRRE Lentivirus REV Gag and Pol packaging 
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Table 2.7 Primers employed in this study 
Primer 
Sense (S)/ 
Antisense (A) 
Protein 
Target 
Primer Sequence 5’-3’ 
CCNF  (E16F)  S 
Cyclin F GGCTCTCTCCACCTTGC 
CCNF (E16R)  A 
Cyclin F GATGTCCCTTCTGGTGCAC  
CMV S 
CMV Promoter CGCAAATGGGGCGGTAGGCGTG 
CMV A 
CMV Promoter CAGGATTCTTACTTGTACAGCTC 
NANOG S 
NANOG TGGTGGTAGGAAGAGTAAAG 
NANOG A 
NANOG CCAGAACCAGAGAATGAAATC  
POU5F1 S 
Oct4 GCTTTGCATATCTCCTGAAG  
POU5F1 A 
Oct4 GATCACCCTGGGATATACAC  
U6 S 
RNU6B CTCGCTTCGGCAGCACA  
U6 A 
RNU6B AACGCTTCACGAATTTGCGT  
HPRT1 S 
HGPRT  ATAAGCCAGACTTTGTTGG  
HPRT1 A 
HGPRT  ATAGGACTCCAGATGTTTCC  
GDF3 S 
GDF3 CCAAGGTTTCTTTCTTTACCC  
GDF3 A 
GDF3 AATGTCAACTGTTCCCTTTC  
PAX3 S 
PAX3 ATCAACTGATGGCTTTCAAC  
PAX3 A 
PAX3 CAGCTTGTGGAATAGATGTG  
PAX7 S 
PAX7 AGGAGTACAAGAGGGAAAAC  
PAX7 A 
PAX7 TAATCGAACTCACTGAGGG  
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Table 2.8 Antibodies and parameters optimised and utilised for immunocytochemistry  
Antibody Species Supplier Product Code Dilution 
Time to 
Fix/Permeabilise 
time (min) 
Block 
Primary Antibodies 
OCT4 Mouse Stemcell T 01550 1:500 8/15 1h Gt Ser 
SSEA4 Mouse Abcam ab16287 1:200 8/15 1h Gt Ser 
TRA-1-60 Mouse Stemcell T AB_2686905 1:200 8/15 1h Gt Ser 
FOXA2 Mouse Abcam Ab60721 1:200 10/15 2h 5% BSA 
SMI32 Rabbit Abcam Ab7795 1:800 10/15 1h Gt Ser 
Islet 1 Mouse Abcam ab20670 1:600 10/15 1h Gt Ser 
HB9 Mouse DSHB 81.5C10 1:50 10/15 1h Gt Ser 
CCNF2 Rabbit Santa Cruz santsc-952 1:1000 10/15 1h Gt Ser 
Phos-TDP-43 
(409/410) 
Rabbit 
PT 22309-1-AP 1:200 
10/15 1h Gt Ser 
TDP-43 Mouse Abnova H00023435-M01 1:600 10/15 1h Gt Ser 
IgG Control Mouse Thermo Fisher 10400C APP APP 1h Gt Ser 
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IgG Control Rabbit Sigma Aldrich I5006-10MG APP APP 1h Gt Ser 
NSE Mouse Abcam ab16808 1:10,000 - 1h Gt Ser 
NSE Rabbit Abcam ab53025 1:5,000 - 1h Gt Ser 
Secondary Antibodies 
Alexa Fluor 
488 Anti-
Rabbit 
Goat 
Thermo FS A11001 
1:1000 
- 
1h Gt Ser 
Alexa Fluor 
488 Anti-
Mouse 
Goat 
Thermo FS A11008 
1:1000 
- 
1h Gt Ser 
Alexa Fluor 
633 Anti-
Rabbit 
Goat Thermo FS A21050 1:1000 - 1h Gt Ser 
Mouse HRP Goat Merck M AP308P 1:10,000 - 1h BSA 
Rabbit HRP Goat Merck M AP307P 1:10,000 - 1h BSA 
APP: As per primary; DSHB: Developmental Studies hybridoma bank; Gt Ser: Goat Serum; Merck M: Merck Millipore; Stemcell T: 
Stemcell Technologies; Thermo FS:Thermo Fisher Scientific; PT: Proteintech 
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Table 2.9 Cell profiler settings 
Primary Object 
Identification  Nuclei 
Dead 
Cells/Debris 
Nuclear 
Speckles 
Diameter of nucleus (pixel units) 
Minimum 30 5 2 
Maximum 100 30 35 
Border 
Exclusion On On On 
Threshold 
Strategy Global Automatic Per Object 
Masking - - Nuclei 
Smoothing 
Threshold 
Scale 
5 - - 
Threshold 
Minimum 0.0001 - 0 
Maximum 1 - 1 
Declumping 
Method Shape, 
propagate - Intensity 
Size of 
smoothing 
filter 
Automatic 
detection - Intensity,2 
Distance 
between 
maxima 
Automatic 
detection - Size filter,2 
Fill hold after 
thresholding 
and 
declumping 
On Off  On 
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3 GENERATION OF PATIENT INDUCED PLURIPOTENT STEM CELL 
DERIVED MOTOR NEURON MODELS  
 
3.1 Introduction 
 
3.1.1 iPSCs in neurodegenerative research 
The central premise of developmental biology is that differentiation relies on 
epigenetic changes to stem cells to differentiate mature somatic cells.  In 2006, 
Takahashi and Yamanaka took advantage of this concept, reversing this process in 
murine cells to generate the first murine induced pluripotent stem cells (iPSCs). 
These adult-cell derived stem cells were immortal, self-renewing and had the 
potential to differentiate into any cell type.  Following this success, the technique 
was quickly applied to human patient cells offering the opportunity to investigate and 
model disease in a patient specific context.  
 
3.1.2 mRNA reprogramming overcomes concerns for genetic interference  
Initially, reprogrammed iPSCs were reported to have high levels of genetic mutations 
and chromosomal deformities, particularly due to lentiviral involvement (Hayden, 
2011). The initial method of human fibroblast-to-iPSC reprogramming relied on the 
upregulation of four pluripotency factors, Oct4, Klf4, Sox2, and c-Myc, (OKSM 
factors) by retroviral transductions.  These transductions caused an increased 
expression of the OKSM proteins, which act to upregulate a range of downstream 
pluripotent factors, causing the adult somatic cells to revert back to a state of 
pluripotency.   
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As with all cell culture systems, genetic mutations are an area of concern in cellular 
reprogramming; for early iPSC research, viral integration was an obvious issue.  
Though very effective, the inclusion of viral genetics in the cell lines impinged on 
potential future applications.  New reprogramming methods have since been 
developed that ensure the donor genome is not altered by viral integration (Bellin et 
al., 2012).  Reprogramming via regular mRNA transfections eliminated the need for 
viral involvement in the reprogramming process, thus paving the way for disease 
modelling, and the potential for cellular replacement therapies.  This mRNA 
reprogramming method is thought to reduce cellular mutations (Miyoshi et al., 
2011). Recorded aneuploidy events in mRNA reprogramming have been detected at 
rates of 2.3% using mRNA reprogramming products, compared to other non-
integrating systems which are as high as 11.5% (Schlaeger et al., 2015; Warren et al., 
2010).  Donated fibroblasts may contain mutations, so it is difficult to determine if 
mRNA reprogramming does induce a higher mutation rate than other cellular 
experiments (Gore et al., 2011). Nonetheless, methods are available to identify if 
genetic mutations have been induced by cellular reprograming; karyotyping and 
genome sequencing are widely regarded as essential steps in selecting stem cell lines 
for future use (Müller et al., 2008) .  
 
3.1.3 Reprogramming efficiency improved using mRNA transfections 
Though mRNA reprogramming overcame the major shortfalls of early iPSCs 
reprogramming, the initial efficacy of non-integrating systems still proved to be low 
(Bellin et al., 2012; Schlaeger et al., 2015).  Integrating retroviral reprogramming, 
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had an initial success rate of 0.01% for reprogramming fibroblasts. By the time 
mRNA reprogramming was published in 2012, this had increased to 0.04% (Bellin et 
al., 2012; Hayden, 2011; Warren et al., 2012).  Given this low success rate, there has 
been a concerted effort in the field to increase the reprogramming rates.  Initially, as 
a novel technique, little was understood of the reprogramming process. It is now 
evident that cellular reprogramming occurs in what are usually described as three 
phases: an early, intermediate, and late stage (Milagre et al., 2017; Wen and Tang, 
2015; Zunder et al., 2015).  Partial reprogramming is therefore possible, as cells may 
not necessarily complete the entire reprogramming process. The selection of the 
individual colonies that arise in cultures following successful reprogramming is 
therefore an important process.  Previous studies have focussed on improving the 
reprogramming process, including changing the compounds used to reprogram.  In 
2007, Yu et al., found that c-Myc could be replaced with Lin-28 to reduce cellular 
death and differentiation found to be induced by c-Myc expression in hESC (Yu et 
al., 2007).  Supplementation of c-Myc with Lin-28 has since been found to assist the 
process, and is thus included in mRNA reprogramming cocktails (Feng et al., 2009). 
 
Additional compounds have been found to increase reprogramming rates.  The 
introduction of B18R, a Type I interferon vaccinia virus neutralising receptor, saw 
significant reduction of cellular death through reprogramming (Mandal and Rossi, 
2013). Inclusion of this interferon inhibitor allowed cells to be dosed with a larger 
amount of mRNA without causing cellular death, which resulted in a larger final 
reprogramming yield (Warren et al., 2012).   MicroRNA (miRNA), small non-coding 
RNA molecules, were also identified to directly contribute to reprogramming 
efficiency, following the known necessity of miRNAs in embryonic stem cell 
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maintenance. The addition of miRNAs to reprogramming cocktails has been found to 
increase efficiency by up to 14-40 fold (Mallanna and Rizzino, 2010). Together, 
these improvements to mRNA reprogramming methods have steadily increased the 
success rate mRNA reprogramming up to 0.6-4.4% successful reprogramming – a 36 
fold improvement in initial efficacies (Rao and Malik, 2012; Schlaeger et al., 2015; 
Warren et al., 2010). 
 
3.1.4 Selection of iPSC clones and pluripotency maintenance is essential 
Establishing the pluripotency of the reprogrammed iPSC lines is crucial to ensure a 
cell line is a viable tool for any application in stem cell research. Upon successful 
reprogramming multiple colonies of stem cells normally arise in the culture (Mandal 
and Rossi, 2013).  Characterisation of these colonies is crucial to select cell lines that 
have fully reprogrammed, and ensure no genetic abnormalities have arisen through 
reprogramming.  A series of steps should be carried out for optimal characterisation 
(Figure 3.1) (Müller, 2014).  Initial observations of proliferation, overall colony 
shape and cellular morphology provide crude but crucial criteria for early stage 
colony characterisation.  Prior to the final step of screening for maintained genetic 
stability, for example by way of karyogram, determining gene and protein expression 
of pluripotency factors via qRT-PCR, and immunocytochemistry, respectively, 
serves to narrow iPSC colony choice without the need to generate large sample sizes.  
 
Comparative tools such as the PluriTest are useful in assessing global cellular 
profiles compared to already established pluripotent cell lines. Developed in 2012, 
the PluriTest was designed as a less expensive, faster, and more ethical alternative to 
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the traditional teratoma assay. The PluriTest is a bioinformatics assay used to 
determine the pluripotency of a cell line.  RNA samples from the reprogrammed cell 
lines are submitted to a microarray assay, which detects the global genomic profile of 
the cells. The profiles are compared to known profiles of both pluripotent and 
somatic cell lines in a standardised non-bias approach.  Two scores are produced 
from the PluriTest analysis: the pluripotency score and the novelty score. The 
pluripotency score is a determined through analysis of metagenes identified by 
Mϋller et al. (2011). The data for the pluripotency score is scored using a logistic 
regression model which gives a choice between the two classifications (pluripotent 
and non-pluripotent). A high pluripotency score indicates the microarray data has a 
signature similar to that of known pluripotency signatures.  The novelty score is 
generated using non-negative matrix factorization, modelling to compare the 
microarray data to known pluripotency data in a stem cell model matrix. This score is 
used to assess the purity of the pluripotency.  A low novelty score indicates that the 
microarray data can be reconstructed based on the stem cell model matrix.  Non-
pluripotent cells such as somatic cells and even abnormal cells would yield a high 
novelty score. 
 
 
Figure 3.1 Experimental workflow of iPSC generation and characterization.  
A series of characterisation steps ensure optimal iPSC clone selection, adapted from 
Müller et al. 2012. Following reprogramming, and upscaling isolated colonies, stem 
cell phenotypes are assessed via morphology, gene and protein expression to shortlist 
iPSC clones. Likely clonal candidates should be further investigated via a gene 
expression panel assessment, comparing other known stem cell expression profiles 
(such as the Pluritest), and be tested for genetic stability. 
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3.1.5 Generating motor neurons from iPSCs to model motor neurone diseases 
Like all neurodegenerative conditions ALS is a difficult disease to study.  Limited 
access to the affected cells of the central nervous system make models a necessity 
when trying to understand the events that cause the death of motor neurons.  For 
ALS, animal models and cellular models are available to study living tissue affected 
with disease symptoms.  Previously, cellular models were not able to account for the 
unique genetics of ALS patients. When Takahashi and Yamanaka first described the 
reprogramming of somatic human cells into induced pluripotent stem cells, the 
possibility to create patient specific models for neurodegenerative disease was made 
a reality.   
 
Since the commencement of the first motor neuron differentiation study by Dimos et 
al., many advances have been made in motor neuron differentiation protocols.  
Claims of motor neuron culture purities have increased from 18% to up to 70% 
(Dimos et al., 2008; Qu et al., 2014).  These significant increases in purity can be 
credited to an improved understanding of motor neuron development, quality, and 
affordability of compounds.  The improvement of morphogen consistency through 
higher quality control from suppliers, inclusion of small molecule inhibitors and 
improved extra cellular matrices are notable features of the many protocols since the 
first iPSC derived motor neuron differentiation protocol was published.  
 
To mimic the in vivo environment, a number of steps are common in all motor 
neuron protocols. Generation of neural rosettes, to replicate the neural tube 
development stage, and embryoid bodies are common steps (See Table 3.1). 
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Caudalisation of the neural precursors is increasingly used, meaning that most motor 
neuron protocols would likely generate spinal motor-neuron like cells, though little 
has been done in the field to verify motor neuron subtypes in iPSC derived motor 
neuron cultures. 
 
Morphogens including basic fibroblast growth factor (bFGF), retinoic acid (RA), and 
brain derived neurotrophic factor (BDNF), and glial derived neurotrophic factor 
(GDNF) are motor neuron differentiation staples. The addition of growth factors 
such as insulin-like growth factor (IGF) and cyclic adenosine monophosphate 
(cAMP), as well as the use of small molecule purmorphamine are more recent 
additions to protocols. Collectively, these advancements in both fibroblast-to-iPSC 
reprogramming, and motor neuron differentiation provide viable methods to generate 
novel models to study the mechanisms of motor neurone diseases (Figure 3.2) 
 
 
 
Figure 3.2 Overview of patient iPSC derived motor neurons generation 
Workflow of reprogramming fibroblasts to iPSCs, and the use of these cells to 
differentiate motor neurons. Characterisation at each step is essential to ensure 
success of the previous step and establish population. 
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Table 3.1 Motor neuron differentiaiton protocols published prior to the commencement of this study 
Reference Major findings 
Repro
gram 
metho
d 
iPSC 
lines: 
patients 
Mutation of 
concern in 
iPSC lines 
Cell 
type 
MN 
markers 
Electro 
physiology 
Maturation 
from EB 
formation 
ECM 
Maturatio
n time 
from EB 
Other 
Dimos et 
al., 2008 
First patient iPSC derived 
model. 
RV 2 (1 ALS 
line): 
2 
SOD1
 L144F
 MN HB9, 
BIIITUB, 
ISL1, ISL2 
ChAT 
Olig2 Pax6 
- RA,AA,SHH 
agonist, GDNF, 
BDNF CTNF 
Laminin, 
and/or 
primary 
murine glia 
monolayer 
7-15 days 
 
Boulting et 
al., 2011 
 No indication of differences in 
phenotype of ALS-iPSC MNs 
compared to healthy iPSC 
motor neurons during 
differentiation. Implied 
differences at maturation, 
although no significance 
noted. 
RV 11: 
7 
SOD1
G85S
 
SOD1
L744F
 
MN HB9, 
BIIITUB, 
ChAT, 
CHT1, ISL 
(1/2) 
Whole cell 
patch clamp 
& calcium 
imaging 
RA, AA, SHH, 
agonist, β-merc, 
LDN193189, 
SmoA, 
SB431542, 
GDNF, BDNF, 
CTNF 
 
11 days 
 
Mitne-Neto 
et al., 2011 
Decrease level of VABP in 
ALS-iPSC motor neurons.  
 First VABP iPSC derived 
motor neuron model 
RV 7 (4 
ALS):7 
VAPB
P56S
 MN HB9, Chat, 
MAP2, 
ISL1, α-
bungarotox
in 
- bFGF, Dorso, 
RA, AA, SHH, 
BDNF, GDNF* 
cAMP  
Laminin 
poly-
ornithine 
 21 - 56 
days 
  
Co-
cultured 
with 
C2C12 
Egawa et 
al., 2012 
Reduced neurite length, 
increase in TDP-43 mRNA 
expression and increased 
TDP-43 levels in aggregates in 
ALS iPSC- derived motor 
neurons. 
RV 
EV 
16 (3 
ALS): 
8 
TDP-43
Q343R
 
TDP-43
M337V
  
TDP-43
G298S
 
Spina
l MN 
HB9, 
ChAT, 
SMI-32, 
ISL (1), 
MAP2, 
GFAP 
   Dors, bFGF, 
SB431542, 
BDNF, GDNF, 
NT3, RA, SHH 
Matrigel 35 days 
  
 
Bilican et 
al., 2012 
Decrease in neuronal survival 
in TDP
337V
 patient iPSC motor 
neurons. Increase in TDP-43 
protein (soluble and detergent 
resistant) expression in the 
motor neurons. 
RV 4 (1ALS): 
3 
TDP-43
M337V
 MN HB9, 
BIIITUB, 
ChAT, 
SMI32 
Whole patch 
clamp, 
current 
clamp, 
voltage 
clamp 
SB431542, 
Dorsomorphin, 
N-
acetylcysteine, 
RA, 
Puramorphine, 
Bfgf', Bdnf, 
Gdnf, Forskolin, 
EGF, DAPT  
Laminin 
Fibronectin 
Matrigel 
21 - 42 
days  
  
 
 125 
 
Yao et al., 
2013 
Decreased neurite length in 
murine ALS-iPSC motor 
neurons.. 
RV 6 (3 
mouse 
ALS): 
6 
SOD1
G93A
 MN HB9, 
BIIITUB, 
ChAT,  
Whole-cell 
patch clamp 
SHH, RA, 
GDBF, BDNF, 
IGF, CNTF,  
Laminin SNS 
 
Sareen et 
al., 2013 
Decreased ability to 
continuously fire action 
potentials in iPSC C9ORF72 
RE patient derived neurons  
EV 8 (4 ALS): 
8 
C9ORF72 RE Spina
l MN 
HB9, 
BIIITUB 
ChAT, 
SMI-32, 
GFAP 
Patch clamp  RA, Pur, cAMP, 
AA, BDNF, 
GDNF 
Poly-
ornithine, 
laminin 
14 – 49 
days 
 
Zhang et 
al. 2013 
Higher levels of TDP-43 
localized in cytoplasm in TDP-
43
A90V
 mutation lines.  
Decreased levels of 
microRNA-9 in the motor 
neurons.  
RV 5 (2 ALS): 
4 
TDP-43
M337V
 
TDP-43
A90V 
 
Neuro
ns 
BIIITUB,  Whole cell 
perforated 
patch clamp 
bFGF, BDNF, 
GDNF 
PL-ornithine 
laminin 
Matrigel 
  
8 or 14 
days 
 
Serio et al. 
2013 
Increased levels of mutant 
TDP-43, and mislocalisation in 
iPSC astrocytes.  Decrease in 
neuronal survival in iPSC 
astrocytes. TDP-43 not non-
cell autonomous.  
LV 4 (2 ALS): 
3 
TDP-43
M337V
 MN 
and 
astroc
ytes 
GFAP Calcium 
imaging 
RA, BDNF, 
GDNF, CNTF 
Matrigel SNS Co-
cultured 
with 
murine 
primary 
astrocyte
s and MN  
Burkhardt 
et al. 2013 
Majority of sporadic ALS lines 
had TDP-43 pathology 
including TDP-43 
mislocalisation, 
hyperphosphorylation, TDP-43 
positive aggregates, and 
Ubiquitin aggregates.  . 
Cellular models corresponded 
to post mortem findings in 
same patient. Only sporadic 
ALS models published to date. 
RV 34 (24 
ALS): 
34 
Sporadic 
SOD1
N139K
 
SOD1
A4V
 
TDP-43 
A315T
 
FUS
G1566A
 
FUS not 
specified 
MN – 
Upper 
and 
lower 
MN-
like, 
and 
CN. 
HB9, ISL1, 
L1CAM 
MAP, 
SMI31  
Whole cell 
patch clamp 
& calcium 
imaging 
Dihydrochloride, 
FGF, AA, CNTF, 
BDNF, GDNF, 
SmoA, DAPT 
PL-Lysine 
Laminin 
14 – 86 
days 
  
Co-
cultured 
with 
primary 
human 
astrocyte
s and MN  
Popescu et 
al., 2013 
Human-iPSC derived neural 
progenitors can be 
differentiated to motor neuron-
like cells when transplanted in 
SOD1
G93A
 murine models. 
RV 1:1 - Neuro
ns – 
MN 
like 
MAP2 - - Collagen 14 days 
In vivo 
 
Donnelly et 
al., 2013 
 Neurons derived from patients 
iPSCs with a repeat expansion 
in C9ORF72 express toxic 
RV 13 (8 
ALS): 
13 
C9ORF72 RE 
SOD1
D90A
 
MN HB9, 
BIIITUB 
- BDNF, GDNF, 
CTNF NT3 
Poly-D-
Lysine  and 
laminin,or 
33 – 38 
days 
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GGGGCC RNA foci,  SOD1
A4V
 
SOD1
D91A
 
laminin or 
collagen. 
Liu-
Yesucevitz 
et al, 2014 
Presence of TDP-43 positive 
aggregates increased with 
culture time. 
LV 4 (1 ALS): 
2 
TDP-43
G298S
 MN BIIITUB, 
MAP, 
CHaT 
- SNS - two 
methods 
referenced. 
  
Laminin 
Fibronectin 
Matrigel 
Poly-L-
Lysine 
>21 – 28 
days, SNS 
  
 
Kiskinis et 
al. 2014 
The SOD1
A4V
 exhibited 
oxidative and ER stress, 
reduced mitochondrial 
function, subcellular transport 
and proteostasis. Correction of 
SOD1
A4V
 alleviated 
dysfunctions. Cell lines with 
the C9ORF72 RE share some 
transcriptional changes with 
the SOD
1A4V
 iPSC-ALS MN 
lines.  MN can integrate with 
chick embryo spinal cord. 
RV 10 (4 ALS) 
9 
SOD1
A4V
 
C9ORF72 RE  
Spina
l MN 
HB9, ISL1 
BIIITUB, 
MAP 
Whole cell 
voltage and 
current 
clamp 
BDNF, GDNF 
CNTF, AA  
Laminin 
lysine 
3-30 days Correctio
n of 
SOD1 
mutation 
via Zinc 
finger 
nuclease  
and Co-
culutred 
with 
murine 
glia, 
chick 
embryo 
spinal 
cord  
Chen et al. 
2014 
Insertion of the SOD1
D90A
 
expression in ESC can cause 
cells to exhibit disease 
phenotype.  Correction of the 
SOD1
D90A
 alleviates 
neurofibillary aggregation and 
cellular degeneration. 
Neurofibrillary aggregate 
formation is an early ALS 
event. 
RV 
and 
SV 
5 (2 ALS): 
3 
SOD1
A4V
 
SOD1
D90A
 
Spina
l MN 
BIIITUB, 
HB9, 
CHaT 
- SB431542, 
LDN193189, 
CHIR99021, RA, 
Pur   
Laminin 
  
11 days  Used 
TALEN 
and Co-
cultured 
with 
C2C12 
myocytes 
and MN  
Wainger et 
al. 2014 
Gene correction for SOD1 
mutation rescinded 
hyperexcitability. Retigabine 
increased survival of ALS-
IPSC motor neurons.  
RV 13 (8 
ALS): 
13 
SOD
A4V
 
FUS
H517Q
 
FUS
M511Nfs*6
 
C9orf72 RE 
Motor 
Neuro
ns 
HB9 Whole-cell-
patch, multi 
electrode  
BDNF, GDNF 
CNTF, AA  
Poly-D-
lysine 
Laminin 
Primary 
cortical 
murine glia 
Monolayer  
15-30 
days 
Used the 
Correcte
d cells 
from 
Kiskinis 
et al. 
2014  
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Chestkov 
et al., 2014 
Possible to develop an ALS-
iPSC motor neuron model 
from a SOD1-assocated 
patient line. 
SV 
and 
LV 
2: 
2 
SOD1-SNS MN HB9, 
BIIITUB, 
CHaT, 
GFAP 
- SB431542, 
RA,SHH, bFGF, 
BDNF, GDNF,   
Matrigel 
Gelatin 
  
  
14 days  Co-
cultured 
with 
iPSC  
derived 
Astrocyte
s  
Nishimura 
et al. 2014 
RNAi has potential as a 
selective target for a TDP-43
 
M337V
 to reduce disease 
phenotypes. 
RV 2 (1 ALS): 
2 
TDP-43
M33V7
 MN BIIITUB - 32 32 24 days 
 
Devlin et 
al., 2015 
Motor neurons with C9ORF72 
RE and TDP-43
M337V
 exhibit 
hyperexcitability prior to 
reduction of action potential 
output. 
SV 
and 
RV 
8 (4 ALS): 
6 
TDP-43
M337V
 
C9ORF72 RE 
MN BIIITUB, 
GFAP 
SMI32 
Whole patch 
clamp, 
current 
clamp, 
voltage 
clamp 
N-acetyl 
cysteine, bFGF, 
RA, Pur, BDNF, 
GDNF, CTNF, 
SmoA, CTNF, 
Forskolin 
Poly-
ornithine, 
Laminin, 
Fibronectin, 
Matrigel 
80 -150 
days 
 
Ascorbic acid, AA; β-III tubulin, BIIITUB, β- mercaptoethanol; β-merc;  Brain –derived neurotrophic factor, BDNF; cortical neurons, CN; cyclic adenosine 
monophosphate; dorsomorphin, DORS; extracellular matrix, ECM; endoplasmic reticulum, ER;  episomal vector system, EV; glial derived neurotrophic 
factor, GDNF; Glial fibrillary acidic protein, GFAP; induced pluripotent stem cell, iPSC; islet 1, ISL1; lentiviral, LV; microtubule associated protein 2, 
MAP2; poly-L, PL; purmorphamine, Pur; retinoic acid, RA; repeat expansion, RE; retroviral, RV; neurofilament H, SMI32; smoothened agonist, SmoA; 
sonic hedgehog, SHH; specifics not specified, SNS; sendai virus, SV; Transcription activator-like effector nuclease system, TALEN; *Listed as growth 
derived-neurotrophic factor. 
.
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3.2 Hypotheses 
 
1. Fibroblasts derived from ALS patients with a cyclin F mutation (CCNFS621G) can 
be reprogrammed to induced pluripotent stem cells.  
 
2. Induced pluripotent stem cells reprogrammed from fibroblasts from ALS patients 
and control lines can be differentiated to motor neurons. 
 
3.3 Aims 
 
1. To reprogram, fibroblasts derived from ALS patients with a cyclin F mutation 
(CCNFS621G), as well as an additional healthy donor to iPSC and complete 
subsequent characterisation.  
 
2. To differentiate motor neurons from ALS patient derived iPSCs, and healthy 
donor derived iPSCs, and complete subsequent characterisation.  
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3.4 Successful reprogramming of patient derived fibroblasts to 
iPSCs. 
 
3.4.1  Fibroblasts from motor neurone disease patients and control lines are 
capable of reprogramming to iPSCs. 
To generate iPSCs, fibroblasts were reprogrammed using daily transfections of 
pluripotency mRNA transcripts for 12 days; GFP mRNA transcripts were also 
included in the transfection to monitor successful transfection (efficiency was not 
calculated).  By day 6, fibroblasts from a healthy donor and two CCNFS621G patients 
exhibited fluorescence indicating transfection was occurring (Figure 3.3). Following 
four days of culture, upon the completion of reprogramming, (day 16) stem cell-like 
colonies appeared in culture, amongst cells that had retained fibroblast morphology 
(Table 3.2). Colonies exhibited a round morphology of densely packed cells. High 
magnification indicated cells with large nuclei and round morphology growing in 
very close proximity (Figure 3.4).  Following collection and separation of the 
individual colonies, single colonies were expanded and monitored for growth, and 
for any changes to morphology.  Colonies with difficulties attaching following 
passage, and cells with slow rates of proliferation were discarded; clones that were 
successfully expanded to a 60 mm dish were catalogued and cryogenically stored.  
Each independent reprogramming experiment generated a minimum of eight clones 
that were likely candidates for future use.  
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Table 3.2 Successful isolation and expansion of iPSC clones following 
reprogramming  
Cell line Cell line abbreviation Number of 
clones 
HC1 HC1- (Clone number) 15 
CCNF1 CCNF1- (clone number) 10 
CCNF2 CCNF2- (clone number) 8 
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Figure 3.3 Representative images of fibroblast to iPSC reprogramming by transient 
mRNA transfections 
Images are representation of cells through the stage of reprogramming including 
fibroblasts prior to reprogramming, cells positive for GFP due to the internalisation 
and translation of GFP mRNA, as part of the mRNA reprogramming cocktail during 
reprogramming, and the colonies arising from reprogramming. Images were taken 
during reprogramming of three cell lines derived from a healthy female donor (HC1), 
a female ALS patient with CCNFS621G mutation (CCNF1), and a male ALS patient 
with CCNFS621G mutation (CCNF2). Brightfield images of fibroblasts were taken one 
day following passage, prior to transient mRNA reprogramming (day -2). Scale bar = 
200 µm. Fluorescent images of GFP expression were taken on day 10 of 
reprogramming. Scale bars = 100 µm. Brightfield images of induced pluripotent stem 
cell colonies on day 16 amongst fibroblast-like cells that were not fully 
reprogrammed. Scale bars = 100 µm. 
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3.5 Cells reprogrammed from ALS patient and healthy donor 
fibroblasts have stem cell-like morphology. 
 
To narrow the selection of iPSC clones for use in further experiments, clones were 
first assessed for stem cell-like morphology.  Clones were short-listed based on stem 
cell-like qualities, including rounded cell shape, large nuclei, smooth colonies, self -
renewal ability and speed of proliferation.  Clones 2, 7 and 10  reprogrammed from 
fibroblasts from healthy female donor 1 (HC1; HC1-2, HC1-7, HC1-10), clones 2, 5, 
7, 8 and 10 from a female pre-symptomatic ALS patient with CCNFS621G mutation 
(CCNF1; CCNF1-2, CCNF1-5, CCNF1-7, CCNF1-8 and CCNF1-10), and clones 1, 
7 and 8 from a male symptomatic ALS patient with CCNFS621G mutation CCNF2 
(CCNF2-1, CCNF2-7 CCNF2-8) all displayed these stem cell-like qualities (Figure 
3.4). Cell morphology and proliferation in these clones was similar to previously 
characterised iPSC cell lines including the iPSC line derived from an ALS patient 
with a SOD1E101G mutation (SOD1), the iPSC line derived from a healthy donor 
(HC2), and iPSC line derived from a patient with sporadic Alzheimer’s disease 
(SAD), age- and sex-matched to the HC2 line.  
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Figure 3.4 Induced pluripotent stem cell morphology following transient mRNA 
reprogramming 
Brightfield images of iPSC colonies following passage from cell lines derived from a 
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS donor (CCNF1), a 
symptomatic CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G 
mutation (SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s 
disease patient (SAD) as a neurodegenerative control. Cells were grown in TeSR E8, 
and showed typical rounded cells, with rapidly expanding spiky colony borders 
typical of pluripotent stem cell culture in TeSR E8. Asterisk (*) indicates 
spontaneously differentiating cells that are routinely removed from cultures.  Image 
was taken at 10X magnification on an Incucyte imager; scale bars = 100 µm. 
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3.5.1 Reprogrammed clones had variable pluripotency gene expression.  
To select an appropriate stem cell clone for further experiments, relative gene 
expression was measured in the clones that exhibited stem cell-like qualities. RNA 
samples were measured for expression of the pluripotency factor Oct-4 encoded by 
POU5F1, and Nanog, encoded by NANOG in comparison with levels expressed in 
fibroblasts.  The relative mRNA expression of these pluripotency genes in the 
shortlisted clones was normalised to housekeeper genes U6 and HPRT. 
 
Clones reprogrammed from the healthy control female fibroblasts (HC1) exhibited a 
higher relative pluripotent gene expression compared to fibroblasts, with an over 
3,400 fold increase in NANOG in clone 10, and a near 27,000 fold in POU5F1. As 
expression of both mRNAs was highest in clone 10 (HC1-10), this clone was 
selected for further characterisation as the representative HC1 cell line (Figure 3.5).   
 
The clones reprogrammed from the pre-symptomatic CCNFS621G patient fibroblasts 
(CCNF1) were the first fibroblasts to be reprogrammed and characterised via qRT-
PCR for this study.   All the iPSC clones characterised, including CCNF1-3, CCNF1-
5, CCNF1-7, CCNF1-8 and CCNF1-10, showed significantly higher levels of both 
POU5F1 mRNA and NANOG mRNA compared to fibroblasts; this included an over 
3,000 fold increase in NANOG in clone 10 (F (5, 14) = 22.56. P<0.0001) and an over 
2,800 fold increase in POU5F1 in clone 10 (F (5, 24) = 775.5.  P<0.0001). Clone 10 
showed a higher expression of NANOG compared to clone 2, and had a higher 
expression of POU5F1 compared to three other clones. This clone 10 (CCNF1-10) 
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was therefore selected for further iPSC characterisation as the representative CCNF1 
cell line (Figure 3.6).    
 
Clones reprogrammed from symptomatic CCNFS621G patient (CCNF2) all expressed  
higher levels of POU5F1 compared to the fibroblasts (a 700 fold increase in NANOG 
in clone 1 compared to fibroblasts; and an over 9000 fold increase in POU5F1 in all 
clones. Clone 1 (CCNF2-1) showed higher POU5F1 expression than clone 7, and 
expression of NANOG was also higher in clone 1 compared to both other clones 
measured, as well as the fibroblasts sample.  Clone 1 (CCNF2-1) was consequently 
selected for further characterisation (Figure 3.7).    
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Figure 3.5 Relative gene expression of pluripotency factors in HC1 clones.  
Relative mRNA expression of pluripotency factor genes NANOG and POU5F1 in 
clones generated from mRNA reprogramming of fibroblasts from a healthy donor. 
Lysate was collected from cultures with ~80% confluency, five days following 
passage. Relative gene expression was determined by quantitative real time PCR, and 
normalised to two house keepers U6 and HPRT.  Expression of pluripotency factors 
was compared to fibroblasts collected prior to reprogramming. N=2 independent 
samples. 
B 
 
A 
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Figure 3.6 Relative gene expression of pluripotency factors in CCNF1 clones. 
Relative mRNA expression of pluripotency factor genes NANOG and POU5F1 in 
clones generated from mRNA reprogramming of fibroblasts from an ALS patient 
donor with a pre-symptomatic CCNFS621G mutation. Lysate was collected from 
cultures with ~80% confluency, five days following passage.  Relative gene 
expression was determined by qRT-PCR, and normalised to two housekeepers U6 
and HPRT.  Expression of pluripotency factors was compared to fibroblasts collected 
prior to reprogramming. N=3 independent samples. **P>0.01, ***P>0.001. 
B 
 
A 
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Figure 3.7 Relative gene expression of pluripotency factors in CCNF2 clones. 
Relative mRNA expression of pluripotency genes NANOG and POU5F1 in clones 
generated from mRNA reprogramming of fibroblasts from an ALS patient with a 
symptomatic CCNFS621G mutation. Lysate was collected from cultures with ~80% 
confluency, five days following passage.  Relative gene expression was determined 
by qRT- PCR, and normalised to two housekeepers U6 and HPRT.  Expression of 
pluripotency factors was compared to fibroblasts collected prior to reprogramming. 
N=2 independent samples.  
 
B 
 
A 
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3.5.1 Cells reprogrammed from ALS patients and healthy donor fibroblasts express 
pluripotency factors. 
To further validate that the reprogrammed cells were pluripotent, pluripotent protein 
expression was evaluated by immunocytochemistry.  Protein expression for 
pluripotency factors Oct-4 (Figure 3.8) were confirmed using fluorescent-labelled 
secondary antibodies. Expression levels were comparable to previously characterised 
iPSC cell lines in the Ooi lab, including the SOD1 iPSC line derived from an ALS 
patient with a SOD1E101G mutation, the HC2 iPSC line derived from a healthy donor, 
and the age- and sex-matched SAD iPSC line, derived from a patient with sporadic 
Alzheimer’s disease. 
 
Clone 10, clone 1, and clone 10 from the reprogrammed fibroblasts of a symptomatic 
CCNFS621G patient, the pre-symptomatic CCNFS621G donor and a healthy donor 
respectively, showed ubiquitous expression of the pluripotent protein Oct-4 in the 
iPSC colonies two days following passage. Pluripotent protein levels were 
comparable to other established pluripotent cell lines. 
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Figure 3.8 Reprogrammed cells from ALS patients and a healthy donor express 
pluripotency factor Oct4 
Representative fluorescent images of iPSCs on day two following passage, stained 
with an antibody for Oct4, with secondary Alexa Fluor 488, nuclear stain for DAPI, 
and corresponding overlay images. The iPSC clones were derived from cell lines 
derived from a healthy donor (HC1), a pre-symptomatic ALS patient with 
CCNFS621G mutation (CCNF1), a symptomatic ALS patient with CCNFS621G mutation 
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy 
donor (HC2) and a sporadic Alzheimer’s disease male patient (SAD) as a 
neurodegenerative control. N=2 independent samples. 
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3.5.1 All selected iPSC lines generated from mRNA reprogramming exhibited 
pluripotent bioinformatics profiles 
To further confirm pluripotency of the cells, the PluriTest was performed by Genea 
Biocells.  RNA samples from the three aforementioned clones (HC1-10, CCNF1-10 
and CCNF2-1) as well as the SOD1 cell line, derived from a male ALS patient donor 
with a SOD1E101G were analysed for a range of pluripotency markers using a 
microarray assay. Microarray data was analysed for pluripotency and novelty. 
Pluripotency scores, determined by Genea Biocells, ranged from 18.19 – 22.04 au. 
Novelty scores ranged from 1.53 – 1.68 au. All cell lines submitted for the PluriTest 
were deemed be normal pluripotent cells, and passed the PluriTest (Figure 3.9). 
These clones were therefore submitted to the final stages of characterisation.  
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Figure 3.9 PluriTest score output 
Non-negative matrix factorization generated novelty score and logistic regression 
model pluripotency scores were generated using microarray data by Genea Biotech 
from supplied RNA samples of clones from reprogrammed iPSC cultures from (A) a 
healthy donor (HC1; green), (B) a pre-symptomatic CCNFS21G ALS patient (CCNF1; 
pink), (C) a symptomatic ALS CCNFS621G patient (CCNF2; red), and (D) an ALS 
patient with a SOD1E101G mutation (SOD1; SOD1). N=1 independent sample. 
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3.5.1 Gene specific analyses verified genetic profile, including CCNF genotype, 
was unchanged by reprogramming  
Previous reports have indicated genetic mutations can arise during cellular 
reprogramming. To ensure no genetic mutations were induced by the reprogramming 
process, genomic analyses were performed. Genomic DNA from fibroblasts and the 
respective reprogrammed iPSCs from each cell line (HC1, CCNF1, CCNF2 and 
SOD1) was sequenced STR analysis by the Garvan Medical Research Institute. 
Sequences were then compared to fibroblasts of origins. No genetic variations were 
detected.   To verify specifically that the CCNF genotype was as originally reported 
upon collection, specific gene analysis was performed by Dr Tracey Berg.  
Genotypes for CCNF were as expected: CCNF1 and CCNF2 were heterozygous 
S621G/S621S (AGT/GGT); The HC1, SOD1, HC2 and SAD lines were all 
homozygous S621S (AGT) (Figure 3.10). 
 
3.5.2 Genomic analysis confirms no chromosomal abnormalities 
To confirm that no chromosomal abnormalities were induced by the reprogramming 
process, iPSC samples were submitted for karyotyping at StemCore.  The G-bands 
from 15-30 cells per cell line were assessed for copy number variations and 
translocations at a resolution of 400 bphs.  No chromosomal abnormalities were 
detected in any cell lines (Figure 3.11). 
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Figure 3.10 Genetic sequencing of CCNF gene 
Representative genotyping of the CCNF gene in iPSC derived neural precursor 
samples generated from (top) a pre-symptomatic ALS patient with CCNFS621G 
mutation (CCNF1), a symptomatic ALS patient CCNFS621G mutation (CCNF2) - 
heterozygous S621G/S621S (AGT/GGT) and (bottom) WT CCNF carriers 
originating from a healthy donor (HC1), an ALS patient with a SOD1E101G mutation 
(SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s disease 
patient (SAD)  - homozygous S621S (AGT). Nucleotides detection represented in 
colours - adenine (A; green), guanine (G; black), thymine (T; red); ALS associated 
mutation S621G is represented is denoted by ‘M’ (pink) wherein an overlay of both 
adensoine and guanine is present.  Samples were collected by Monique Bax, PCR 
run by Dr Tracey Berg. 
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Figure 3.11 Representative karyograms of the six induced pluripotent stem cell lines.  
Karyograms were generated by Stem Cells Limited at 400 bphs from the iPSCs 
originating from a healthy donor (HC1), a pre-symptomatic ALS patient with 
CCNFS621G mutation (CCNF1), a symptomatic ALS patient with CCNFS621G mutation 
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy 
donor (HC2) and a sporadic Alzheimer’s disease male patient (SAD) as a 
neurodegenerative control.  G-banding from 15-30 cells were investigated per cell 
line.  
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3.5.1 Stem cell clones differentiated into the three tissue types 
For the final confirmation of pluripotency, the clones from the three respective cell 
lines, as well as previously established pluripotent control cell lines were 
differentiated into cells originating from the three germ layer tissue types: the 
endoderm, mesoderm, and ectoderm. All cell lines were able to differentiate into 
cells expressing morphology and protein markers consistent with cells from all three 
germ layers; also verfiied via q-RT PCR as per Bax et al. (2019) (data not shown). 
 
3.5.1.1 Reprogrammed stem cells were able to differentiate into cells from each of 
the three germ layers 
To assess that the stem cell lines could differentiate towards an endodermal lineage, 
all six cell lines were differentiated using a definitive endoderm protocol. All cell 
lines displayed classic endodermal progenitor morphology following differentiation 
Cells formed tight clusters in a dense monolayer. Cells from the six cell lines that 
were differentiated to endodermal progenitors exhibited expression of FOXA2 via 
immunochemistry (Figure 3.13), indicative of definitive endodermal progenitors.  To 
assess the ability of the cells to differentiate down a mesodermal lineage, cells from 
all six cell lines were differentiated according to a myotube differentiation protocol.  
Cells from all six cell lines showed typical myoblast morphology: cells elongated 
and aligned, and in some cases began to fuse becoming multinuclear (Figure 3.14).  
To assess the cells capacity to differentiate to an ectodermal lineage, the cells from 
all six cell lines were differentiated to neuronal precursors using a motor neuron 
differentiation protocol. All cell lines showed morphology consistent with neural 
rosettes, neuronal progenitors and motor neurons (as described further).  
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Figure 3.13 Selected pluripotent stem cell lines differentiated into cells expressing 
endodermal marker FOXA2 
Immunocytochemical analysis of endodermal marker FOXA2 in the iPSC clone lines 
differentiated to endodermal progenitor show positive expression of the marker. The 
staining indicates the clustering morphology in all cell lines which included from a 
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a 
symptomatic CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G 
mutation (SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s 
disease patient (SAD). N=2 Independent differentiations per cell line. Scale bar = 
200 μm. Brightfield high magnification images as per Appendices Figure 8.0. 
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Figure 3.14 Selected pluripotent stem cell lines differentiated into cells with 
mesodermal morphology 
Myoblast-like morphology was displayed in cells differentiated in all cell lines which 
included from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS donor 
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), an ALS patient with a 
SOD1E101G mutation (SOD1), an additional healthy donor (HC2) and a sporadic 
Alzheimer’s disease patient (SAD). Scale bar = 50 μm. 
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3.5.2 Successful differentiation of motor neurons from iPSCs 
Once the selected reprogrammed clone lines were confirmed to be pluripotent, and 
capable of differentiation to an endodermal and mesodermal lineage, cells were 
differentiated through the ectodermal lineage to motor neurons.  Initial 
differentiations using the protocol of Dimos et al. (2008) generated low yields 
(observations only, data not quantified) and resulted in high cell death in neuronal 
development and maturation phases.  More recent protocols were trialled, generating 
a higher yield of cells with neuronal morphology (based on observations only).  The 
final protocol used for motor neuron differentiation was an amalgamation of these 
protocols, utilising aspects of the protocols by Bilican et al. (2015) and Qu et al. 
(2014).   
 
As per Bilican et al. (2015), cells were maintained in hypoxic conditions following 
the formation of neural rosettes. Following the differentiation of anterior neural 
precursors (aNPCs), the still mitotic cells were plated for the final maturation step. 
As per Qu et al. (2014), cultures were grown on laminin, fibronectin and collagen I. 
As per all motor neuron protocols that had been published at the time of this study, 
cells were caudalised with retinoic acid, and ventralised, to generate spinal motor 
neurons.  This study used purmorphamine, as a sonic hedgehog (ventralising 
morphogen) agonist, similar to the original Dimos et al. (2014) protocol.  For 
maturation, cells were treated with GDNF and BDNF as per previous motor neuron 
differentiation protocols, and with cAMP and IGF to increase cell survival as per Qu 
et al. (2014).  Unlike these published protocols, motor neurons were matured for six 
weeks to allow further maturation. Following this maturation period, the neuronal 
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cells were characterised based on morphology, protein expression and 
electrophysiological properties as measured by Dzung Do-Ha.  
 
3.5.3 Differentiated iPSCs formed neural rosettes followed by aNPCs 
Following removal of iPSC maintenance media (TeSR E8) Cells were left in 
suspension for three days, to form embryoid bodies. When plated down on laminin, 
these cells attached and dispersed into rosette structures, radiating from a centre point 
(Figure 3.15).  All six cell lines were able to successfully generate neural rosettes 
with no discernible difference in yield based on general observation. Following 
culture in hypoxic conditions, and treatment with bFGF, cells collected from neural 
rosettes formed aNPCs (Figure 3.16).  Cultures from all six cell lines could be 
maintained at this stage for five passages before changes in cellular proliferation.  
Cell lines had a varying propensity to change proliferation and eventually 
morphology at higher passages.  Below this number of passages there was no 
discernible difference in overall morphologies of cells in culture between the six cell 
lines. aNPCs from all six cell lines were capable of further differentiated towards a 
neuronal phenotype as required with no discernible difference in yield from general 
observation.  
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Figure 3.15 Neural rosette morphology following differentiation to ectodermal 
lineage  
Representative inverted microscopy images of neural rosettes formed in cultures 
differentiated from iPSC clones derived from a healthy female donor (HC1), a 
female ALS patient with CCNFS621G mutation (CCNF1), a male ALS patient with 
CCNFS621G mutation (CCNF2), a male ALS patient with a SOD1E101G mutation 
(SOD1), a healthy male donor (HC2) and a sporadic Alzheimer’s disease male 
patient (SAD). Scale bar =100 µm 
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Figure 3.16 Cells exhibited anterior neural precursor morphology following 
differentiation towards neural linage 
Representative Incucyte Zoom images of anterior neural precursor cells 
differentiated from neural rosettes as an intermediate stage of the motor neuron 
differentiation. Cells are derived from a healthy donor (HC1), a pre-symptomatic 
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an 
ALS patient with a SOD1E101G mutation (SOD1), an additional healthy donor (HC2) 
and a sporadic Alzheimer’s disease patient (SAD). Scale bar =100 µm. 
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3.5.1 aNPCs were matured to motor neurons 
Following caudalisation and ventralisation of aNPCs, cells developed neuronal 
morphology.  Cells exhibited outgrowth of neurite structures that appeared to form 
networks (Figure 3.17).   Differentiated iPSCs expressed motor neuron-specific 
protein markers; To assess the yield of motor neurons generated by the developed 
protocol, cells were probed for three neuronal markers, including motor neuron 
specific neuronal marker HB9, Islet 1 and neuronal marker neurofilament heavy 
(SMI32). The expression of these motor neuron markers were not significantly 
different between cell lines (discussed further in this chapter) indicating a similar 
propensity in these cells to generate motor neurons using this protocol. Negative 
immunocytochemistry controls showed low background fluorescence, and image 
settings were adjusted for this. 
 
All cell lines differentiation with this protocol successfully generated cells that 
expressed the motor neuron marker HB9 (Bax et al., 2019a).  Confocal images of the 
neuronal cultures indicated consistently high percentages (ranging from 73-92%) of 
this motor neuron marker regardless of the cell line differentiated (Figure 3.19). 
Manual cell counts of a minimum of 1,400 cells indicated an average of over 83.9 ± 
2.5% HB9 positive cells across the six cell lines (Table 3.3). ANOVA analysis with 
Tukey’s multiple comparison post hoc indicated no significant difference in yields 
between the different cell lines were detected (F(5,10)=0.99. P=0.47). 
 
All cell lines differentiated with this protocol generated cells that expressed Islet 1.  
Confocal images of the neuronal cultures indicated consistently high percentages of 
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this motor neuron marker regardless of the cell line differentiated (Figure 3.21.  
Manual cell counts using FIJI software indicated an average of over 88.0±1.4% Islet 
1 positive cells across the cell lines (Table 3.3). ANOVA analysis with Tukey’s 
multiple comparison post hoc indicated no significant difference in yields between 
the different cell lines were detected F(5,12)=1.81. P=0.19). 
 
All cell lines differentiation with this protocol generated cells that expressed SMI32.  
Confocal images of the neuronal cultures indicated consistently high percentages of 
this neuronal marker regardless of the cell line differentiated (Figure 3.22).  Manual 
cell counts via FIJI software indicated an average of over 90.5±1.4% SMI32 positive 
cells across the six cell lines (Table 3.3).  ANOVA analysis with Tukey’s multiple 
comparison post hoc indicated no significant difference in yields between the 
different cell lines were detected F(5,12)=1.81. P=0.19).  
 
Table 3.3.  Motor neuron markers detected by immunocytochemistry   
Percentage of cells positive for motor neuron markers as indicated by 
immunocytochemistry 
Cell line HB9 Islet 1 SMI32 
HC1 84.2 ± 2.7% (N=2) 81.4 ± 3.7% 94.3 ± 1.1% 
CCNF1 91.5 ± 2.4% 92.8 ± 1.9% 94.0 ± 0.7% 
CCNF2 80.7 ± 5.6% 90.2 ± 1.7% 87.5 ± 2.1% 
SOD1 84.5  ± 10.5% (N=2) 92.2 ± 1.0% 91.9%  (N=1) 
HC2 72.6 ± 1.9% 88.2 ± 5.2% 86.3 ± 06.1% 
SAD 85.7 ± 6.8% 88.1 ± 2.8% 89.5 ± 3.1% 
Average 83.9 ± 2.5% 88.8  ± 1.4% 90.5 ± 1.4% 
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Figure 3.17 Motor neuron differentiation produced cell with motor neuron 
morphology.   
Representative Incucyte Zoom images of motor neurons in culture, which exhibited 
long neurite structures and formed intricate networks following the six weeks 
maturation. Cells were differentiated from iPSC clones derived from a healthy donor 
(HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic 
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an 
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) 
Scale bar =100 µm  
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Figure 3.18 Motor neuron differentiation produced a high percentage of HB9 
positive cells in all cell lines 
Representative fluorescent images of motor neurons matured for six weeks, 
following staining with mouse anti-HB9 (Alexa Fluor 488), nuclear stain Reddot2. 
Overlay image demonstrates the typical nuclear localisation. Cells were 
differentiated from iPSC clones derived a healthy donor (HC1), a pre-symptomatic 
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an 
ALS patient with a SOD1E101G mutation (SOD1), an additional healthy donor (HC2) 
and a sporadic Alzheimer’s disease patient (SAD) (Bax, 2019a). Scale bar = 250 µm.  
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Figure 3.19 Quantification of HB9 positive cells in all cell lines   
Percentage per image of cells expressing green fluorescence indicative of HB9.An 
average of 93.41 cells were manually counted per image of motor neurons matured 
for six weeks were quantified using FIJI. Following staining of motor neurons with 
mouse anti-HB9 (Alexa Fluor 488) and nuclear stain Reddot2, a minimum of 10 
images per cell line were examined for cells with both red and green signal, and red 
signal only.   No significant difference in HB9 expression in cells differentiated iPSC 
clones derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS 
patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an ALS patient with a 
SOD1E101G mutation (SOD1), an additional healthy donor (HC2) and a sporadic 
Alzheimer’s disease patient (SAD) were detected through ordinary one-way 
ANOVA with Tukey’s multiple comparison test post hoc. Averages were determined 
from a minimum of two separate differentiations. 
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Figure 3.20 Motor neuron differentiation produced a high level of Islet 1 positive 
cells in all cell lines 
Representative overlay of fluorescent images of motor neurons matured for six 
weeks, following staining with Islet 1 (green) and Reddot2 nuclear stain (red). Cells 
were differentiated from iPSCs derived from iPSC clones derived from a healthy 
donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic 
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an 
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD). 
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Figure 3.21 Quantification of Islet 1 positive cells in all cell lines 
Fluorescent images of motor neurons matured for six weeks were quantified using 
FIJI. Following staining of motor neurons with mouse anti-Islet 1 (Alexa Fluor 488) 
and nuclear stain Reddot2, a minimum of 10 images per cell line were examined for 
cells with both red and green signal, and red signal only.   No significant difference 
in HB9 expression in cells differentiated iPSC clones derived from a healthy donor 
(HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic 
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an 
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) 
were detected through ordinary one-way ANOVA with Tukey’s multiple comparison 
test post hoc. Averages were determined from a minimum of two separate 
differentiations.  
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Figure 3.23 Quantification of SMI32 positive cells in all cell lines  
Fluorescent images of motor neurons matured for six weeks were quantified using 
FIJI. Following staining of motor neurons with mouse anti-SMI32 (Alexa Fluor 488) 
and nuclear stain Reddot2, a minimum of 10 images per cell line were examined for 
cells with both red and green signal, and red signal only.  No significant difference in 
HB9 expression in cells differentiated from iPSCs derived from a from a healthy 
female donor (HC1), a female ALS patient with CCNFS621G mutation (CCNF1), a 
male ALS patient with CCNFS621G mutation (CCNF2), a male ALS patient with a 
SOD1E101G mutation (SOD1), a healthy male donor (HC2) and a sporadic 
Alzheimer’s disease male patient (SAD) were detected through ANOVA with 
Tukey’s multiple comparison test post hoc. Averages were determined from a 
minimum of two separate differentiations. 
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Figure 3.24 Quantification of SMI32 positive cells in all cell lines  
Representative fluorescent images of motor neurons matured for six weeks, 
following staining with SMI32 (green) and DAPI nuclear stain (blue). Cells were 
differentiated from iPSCs derived from iPSC clones derived from a healthy donor 
(HC1). 
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3.6 Discussion 
3.6.1 Three fibroblast cell lines were reprogrammed to iPSCs 
In this study, three cell lines were successfully reprogrammed using repeated mRNA 
transfections of pluripotency factors (Mallanna and Rizzino, 2010; Mandal and 
Rossi, 2013). The reprogramming experiments successfully generated multiple 
clones, of which three iPSC lines (CCNF1, CCNF2 and HC1) were selected to 
represent stem cells derived from a pre-sympotmatic  female donor with  a 
CCNFS621G mutation, a male patient with a CCNFS621G mutation and a healthy donor, 
respectively. Clones from these reprogramming experiments displayed stem cell like 
qualities including a round cellular form, large nuclei, round colony formation, self-
renewal and quick proliferation (Takahashi and Yamanaka, 2013).  Clones CCNF1-
10 (CCNF1), CCNF2-1 (CCNF2) and HC1-10 (HC1) all exhibited high levels of 
gene expression of POU5F1 (Oct4) and NANOG relative to other clones and 
significantly higher than the fibroblasts from which they were derived; Further 
evaluation of these cell lines for pluripotency protein expression confirmed 
consistent expression of pluripotency factor OCT4, indicating a successful 
reprogramming of these fibroblasts to iPSCs (Müller, 2014). 
 
PluriTest scores typical of pluripotent cell lines with no previously known 
abnormalities were detected (Müller et al., 2011); karyotyping indicated 
chromosomal integrity was maintained; STR profiling, as well as specific PCR of the 
CCNF gene failed to reveal any mutations as a result of the reprogramming. 
Maintaining the genetic integrity of these cells (I.e. confirming the genetic 
background of the donors from which these cells derive matches) is of paramount 
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importance, given one of the strengths of engaging iPSCs is that these cells 
genetically reflect patients (Ooi et al., 2013).  Continuity of the genetic profile is also 
of importance for genetic editing which will be undoubtedly critical in future 
investigations into the effects of mutations and environmental in ALS (Musunuru, 
2013).  The final, and most important aspect of establishing pluripotent stem cells 
was the confirmation of the capacity to differentiate to the three germ layers 
(Takahashi and Yamanaka, 2006).  The reprogrammed cells were capable of 
differentiation into cells with characteristics consistent with those from the three 
germ layers, including mesodermal, endodermal and ectodermal cell types, as 
indicated by morphology and progenitor markers, thereby confirming the successful 
generation of iPSCs (Takahashi and Yamanaka, 2013). 
 
3.6.2 iPSC generation unaffected by S621G mutation 
The reprogramming of the cells derived from the two ALS patients indicated for the 
first time the S621G mutation in the CCNF gene did not inhibit reprogramming or 
pluripotency maintenance.  The ability to successfully reprogram these cells was not 
assured given the involvement of the UPS in stem cell generation and pluripotency 
maintenance, and what little was known of the role of cyclin F (Williams et al., 
2016).  Some lines of evidence suggest that cells from different donors exhibit 
different reprogramming capacity and that not all cell lines are capable of reversion 
to a stem cell state (Kyttälä et al., 2016; Liebau et al., 2013). The reprogramming of 
the two CCNFS621G cell lines indicated that this mutation did not significantly impact 
the ability of these cells to revert to the stem cell state.   
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3.6.3 Developed differentiation protocol robustly generated motor neurons 
The differentiation protocol developed in this study robustly generated cells with 
neuronal morphology, with a high yield of HB9, Islet 1 and HB9 positive cells.  This 
protocol was developed using features of previously published work, following a 
high cell death in cultures generated from the Dimos et al. protocol (data not shown). 
The introduction of a more comprehensive extracellular matrix (ECM) cocktail 
provided a more biologically relevant extra cellular environment, similar to that 
found in vivo.  Similar to the importance of the ECM in maintaining pluripotency in 
stem cell cultures (Hughes et al., 2010), recent studies indicated that the type of ECM 
proteins present directly affect differentiation (Qu et al., 2014).  An increased motor 
neuron yield is attributed in part to the introduction of collagen I and fibronectin to 
this protocol, which was not incorporated in early foundational studies such as that 
by Dimos et al. (2008; which used a laminin matrix). Qu et al (2014) found that the 
introduction of these two additional ECM proteins to the typically used laminin plate 
coating increased the motor neuron yield by over 50 fold. Given over 30 collagen 
types have been identified, it would be unsurprising that these ECM proteins would 
influence differentiation (Fox, 2008). Indeed, collagen XIII appears to be important 
in the formation of neuromuscular junctions (Härönen et al., 2017). Though cells will 
secrete their own extracellular proteins (Fox, 2008), further investigation into 
supplementing cultures with other collagen subtypes would be an important 
undertaking for development of the field.  
 
The introduction of a neural precursor stage in the protocol used by Bilican et al. 
(2015) provided a maintenance point within the differentiation. At the neural 
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precursor stage, cells maintained a relatively plastic state, still capable of 
proliferation and self-renewal for up to five passages, allowing time for expansion, if 
required. As per the Bilican et al. (2015) protocol, caudalisation of the neural 
precursors would begin the final stages of maturing the cells; these cells would 
eventually become post-mitotic and would begin to behave as adult somatic cells.  
 
3.6.4 Motor neuron differentiation unaffected by S621G mutation 
Characterisation and subsequent quantification of expression of motor neuron 
specific proteins HB9, and Islet 1, as well as neuronal marker SMI32 did not indicate 
any significant differences in the propensity of the six cell lines to differentiate to 
motor neurons. The S621G mutation of CCNF therefore also appeared to have no 
effect on the ability of the cells to differentiate into motor neurons, or other cell 
types.  Findings by Hogan et al. (2017) indicated that mutant cyclin F impacted 
neurodevelopment more than wild type cyclin F in zebrafish. It would therefore be 
pertinent to quantify the length of the neurite extensions throughout development in 
future studies to examine if these effects are temporal, occurring at a certain through 
development, or is perhaps only a phenotype exhibited in zebrafish transfected with 
human CCNF. 
 
Motor neuron differentiation protocol development is a fast moving field - at the 
commencement of this study the highest reported motor neuron yield was an 
impressive claim considering the highest previously reported purity was 50% (Rao 
and Malik, 2012). Early into the customisation and development of this protocol, Qu 
et al. reported an approximately 70% yield of motor neurons by using a combination 
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of compound C, retinoic acid, sonic hedgehog and other neurotrophic factors at new 
stages in the differentiation, including the introduction of compound C at day one, 
and retinoic acid as early as day three (Qu et al., 2014). The optimisation of the 
protocol here has thus yielded significant increases in the motor neuron 
differentiation efficiency.  Despite this, the protocol described in this study can still 
be improved upon. Since this study was completed, advances have been made in 
protocol developments.  Motor neuron differentiation protocols are subject to 
constant improvement - owing largely due to demand this cell type for motor neuron 
research. Development of new commercial reagents and increases in 
developmental/motor neuron differentiation knowledge are providing constant 
opportunities for protocol development.  This founding protocol is however, a very 
efficient stepping stone for further studies, and serves as an effective protocol to 
study the early stages of ALS.   
 
One of the current limitations in the development of these cells is the lack of mature 
motor neuron markers. HB9 and Islet 1 expression are currently accepted markers for 
motor neurons, however these cannot define the motor neuron subtype, or the 
maturity of the cells.  Work in the Ooi lab has recently generated motor neurons with 
an increased neuronal maturation and electrophysiological activity using 
commercially available products that were not available at the time of this study.  
This includes a new basal medium that is now commercially available, which more 
closely resemble physiological conditions of the central nervous system (Bardy et al., 
2015).  Small molecule inhibitors have become commercially available since the 
development of this protocol.  In addition to the small molecule purmorphamine 
engaged in this study, small molecules including DMH1, an inhibitor of bone 
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morphogenetic protein signalling, SB431542, inhibitor of activinnodal signalling and 
CHIR99021, a Wnt signal antagonist can be engaged to regulate motor neuron 
differentiation and maturation (Du et al., 2015; Huang et al., 2017).  
 
Advances in 3-dimensional (3D) culture systems are providing an additional 
approach for generating motor neurons. In order to mimic the in vivo environment, 
cells can be cultured in 3D systems.  These can range from polymer gels, solid 
porous scaffolds, fibrous scaffolds, and acellular scaffolds, to organoidal chip-based 
or even microfluidic- based systems (Bhatia and Ingber, 2014; Murphy et al., 2017). 
These 3D systems serve to increase the surface area available to the cells, allowing 
for greater cellular interactions both the ECM (including available nutrients/growth 
factors), and other cells in culture, increasing the potential direct interactions 
(Carletti et al., 2011).  Though 3D systems present many complex challenges to 
experimental designs (for example, how to image cells entrapped in a 3D structures), 
the field is increasingly engaging the use of these systems, and will no-doubt 
creatively problem solve (such as the use of post mortem techniques and reporter 
systems) to engage with these culture systems which better replicate in vivo systems 
(Ko and Frampton, 2016). 
 
Motor neuron differentiation research has not only expanded into the 3D, but is also 
focussing on the culture of specific cell types, both non-neuronal and motor neuron 
subtypes.  It has been long established that co-culturing motor neurons with 
myotubes increases cellular survival and maturation in chicks (O’Brien and 
Fischbach, 1986; Prives et al., 1976); Logically, the next step in developing human 
motor neuron differentiation protocols is to pair these neuronal cells with their 
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natural interactors including Schwann cells, astrocytes, and myotubes to generate a 
neuromuscular circuit. The field, including the Ooi laboratory, is working towards 
these co-culture systems (Bucchia et al., 2018; Sances et al., 2016). Excitingly, the 
use of iPSCs means these culture systems can be genetically matched - meaning all 
cell types will be of the same origin, replicating even closer the neuromuscular 
circuit of a patient. 
 
In additiona to examining the different cell types of the neuromuscular circuit, 
research into motor neurons is increasingly moving towards understanding 
differentiaitons to specific types of motor neurons.  An increased understanding of 
Hox genes, a subset of the fundamental development transcription factors, serves to 
hone our ability to differentiate motor neuron subtypes (Dasen and Jessell, 2009; 
Pearson et al., 2005). For example, the Hox controlled Ret and Gfrα genes have been 
identified as key regulators for the development of limbic motor neurons (Catela et 
al., 2016).  This is a particularly attractive motor neuron subtype to target, as these 
are the first motor neurons affected in the majority of ALS aetiology (Vucic et al., 
2007). Generally, motor neuron differentiation protocols have focused on generating 
lower (spinal cord) motor neurons, though the early work in upper (corticospinal) 
motor neurons will no-doubt serve to drive robust protocols to model these neurons 
(Sances et al., 2016). Understanding the differences, and subsequently allowing for 
the differentiation of the different motor neuron subtypes will undoubtedly serve to 
aid in therapeutic developments for motor neurone diseases (Brockington et al., 
2013). 
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3.7 Summary and future directions 
 
As we increasingly refine our ability to effectively and efficiently generate iPSC 
derived motor neuron through improvements to iPSC reprogramming, maintenance, 
and subsequent cellular differentiation, we increase the accuracy in which we will be 
able replicate disease ‘in a dish’. Improvements to iPSC culture protocols that 
promote upscaling (via increased reprogramming efficiencies, and reduced cost in 
maintenance, including labour required) allow for the potential to increase in sample 
size and number (including the number of cell lines employed).   The successful 
reprogramming of iPSCs performed here provides a canvas to create not only cell 
types relevant to the study of ALS but also the perfect control cell lines. 
Developments in genetic editing with CRISPR have meant that these reprogrammed 
cells can be corrected for these ALS causing mutations alone; these cells provide the 
exact same genetic background, removing the genetic ‘noise’ from influencing 
results. Since the completion of this study, these cells have been used to generate 
CRISPR clones. Together, the patient-iPSCs generated from this study, (following 
identification of disease phenotypes), and CRISPR clones, generated from these 
reprogrammed cells, are powerful tools for therapeutic development. Improved 
understanding of motor neuron generation furthers our ability to recapitulate ALS.  
Future studies which are able build from this protocol, engaging newly commercial 
available small molecules, basal media, 3D systems alongside new protocols to 
generate neuromuscular circuits promise the potential to produce in vitro systems to 
mimic those in vivo closer than ever before. Employing these holistic systems will 
undoubtedly aid furthering our understanding, not only of the effects of the CCNF 
mutations, but of ALS as a neurodegenerative disease. 
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Chapter Four:  
 
ALS Associated Protein 
Expression in Patient Induced 
Pluripotent Stem Cell Derived 
Motor Neurons 
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4 ALS ASSOCIATED PROTEIN EXPRESSION IN PATIENT INDUCED 
PLURIPOTENT STEM CELL DERIVED MOTOR NEURONS 
 
4.1 Introduction 
 
4.1.1 Patient iPSC derived motor neurons to model ALS  
One of the major strengths of engaging iPSCs in neurodegenerative research is the 
ability to examine the endogenous proteins in cell types of interest.  For ALS 
research this allows for the investigation of the endogenous cellular mechanisms 
affected by the disease, particularly proteostasis dysfunction, in motor neurons. One 
of the primary objectives in developing the iPSC derived motor neuron models in 
this study was to identify if, and if so, what ALS phenotypes are present, in order to 
understand these mechanisms, and to provide potential read-outs for early therapeutic 
trials (Faravelli et al., 2014). An invaluable advantage of using these iPSC derived 
motor neurons in ALS research, is that overexpression of ALS relevant proteins is 
potentially not necessary, as is the case for other motor-neuron model cell lines such 
as NSC34 cells (Cashman et al., 1992; Williams et al., 2016).  This is particularly 
important as the upregulation of proteins can generate artificial effects, which may be 
falsely interpreted as disease relevant phenotypes (Hjerpe et al., 2016). 
 
4.1.2 TDP-43 and cyclin F in iPSC derived motor neuron models 
As aforementioned, most cases ALS are considered a TDP-43 proteinopathy. TDP-
43 post-translational modifications are associated with ALS pathology (Mackenzie et 
al., 2010); Ubiquitinated and phosphorylated TDP-43 are both found in cellular 
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aggregates (Arai et al., 2010).  TDP-43 therefore represents a fundamental ALS 
protein to examine in ALS models (Ederle and Dormann, 2017).  Conversely, cyclin 
F represents a relatively novel protein associated with ALS, which will provide new 
and important insight into the mechanisms that underlie the disease. While there have 
been studies examining TDP-43 in ALS iPSC motor neuron models previously, this 
study represents the first to examine TDP-43 in a mutant CCNF model (Bilican et al., 
2012; Burkhardt et al., 2013; Egawa et al., 2012; Nishimura et al., 2014; Serio et al., 
2013; Zhang et al., 2013). To date, no study has examined the endogenous 
expression of cyclin F in a motor neuron model.  
 
4.1.3 ALS associated protein localisation and nuclear bodies 
Protein localisation is central to ALS aetiology; protein mislocalisation, particularly 
the mislocalisation of nuclear proteins to the cytosol is commonly observed in ALS 
associated proteins including TDP-43 (Barmada et al., 2010).  The inappropriate 
localisation of proteins in aggregates is a hallmark of ALS pathology. These protein 
bodies, which can be cytosolic and/or nuclear in localisation, can be classified to an 
extent by shape, size and number. Cytosolic bodies including JUxta Nuclear Quality 
control compartment (JUNQ), Insoluble Protein Deposit (IPOD), RNA interactor 
specific compartments/inclusions (RISCI), aggresome-like structures (ALIS), ER-
associated degradation-associated vesicles (ERADAV), are vital in modulating 
proteostasis in the cytosol.  A number of different functional nuclear protein bodies 
have been classified to date (Table 4.1; Scotter et al., 2015); the nuclear bodies may 
play important roles in mediating transcription and translation processes.  In the 
cytosol, there are three main types of protein bodies: aggresomes, processing bodies 
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(p-bodies) and stress granules. Aggresomes are single irregular bodies up to 10 μm in 
size; P bodies are small (0.1 - 1.0 μm large) round bodies that can be far more 
abundant reaching up to 30 bodies per cell.  P bodies also have overlapping common 
features with cytosolic stress granules, which are present in numbers between 5 - 30 
per cell, and can be 0.4- 5.0 μm in size. Unlike P bodies, however, stress granules are 
irregular in shape (Scotter et al., 2015; Spector, 2006).   
 
Table 4.1. Nuclear protein body (based on Cellular Bodies by Spector (2006)) 
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4.1.4 Ubiquitome proteasome dysfunction 
The presence of aggregates/protein bodies in motor neurons is a hallmark phenotype 
of ALS. As aforementioned, it is not clear which and/or to what extent these 
aggregate structures are detrimental to motor neurons (Webster et al., 2017). 
Nonetheless, the presence of these aggregates is linked to UPS function, and it is 
therefore important to investigate aggregation as a potential therapeutic target or 
biomarker for disease. Many methods are now available to examine the viability of 
the iPSC derived motor neurons, and the efficacy of the UPS. Traditional viability 
assays coupled with tools, such as the degron assay (Bett et al., 2009), provide a 
powerful platform to investigate cellular populations in bulk cell assays in an 
endogenous system.  The degron assay provides a functional readout of UPS activity 
via expression of florescent proteins. Proteins that are typically destined for 
proteasomal degradation are tagged with a degron, a degradation signal.  This assay 
takes advantage of this degron signalling via expression of a degron tagged GFP (via 
plasmid transfection); dysfunction in UPS activity results in an accumulation of GFP, 
thereby providing a functional readout.   
 
This study sought to assess abundance and localisation of the above mentioned 
proteins, as well as the UPS function in the iPSC derived motor neuron models 
generated.  To identify the cellular mechanisms affected by cyclin F, and 
subsequently, why mutations to this gene lead to motor neuron death, it is necessary 
to first identify the properties of cyclin F in motor neurons.  Cellular localisation, 
inclusion in aggregates and relative abundance will aid in understanding the role of 
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cyclin F in neurons.  The successful generation and characterisation of patient-iPSC 
derived motor neurons (as described in Chapter Three), including a healthy control, 
two CCNFS621G patients, and a SOD1E101G  derived cell lines provided dynamic 
cellular models with the potential to examine endogenous cyclin F. Together, using 
these cells along with two additional iPSC lines (an additional healthy control, and a 
sporadic Alzheimer’s disease patient derived cell line, which has been shown to 
exhibit a disease phenotype, to act as a neurodegenerative control (Balez et al., 
2016))  it is possible to examine the expression of ALS-relevant phenotypes.  Here, 
the presence, relative abundance and localisation of endogenous cyclin F and 
endogenous TDP-43, along with UPS function have been investigated in these 
patient derived motor neurons. 
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4.2 Hypotheses 
 
1. ALS patient iPSC derived motor neurons express endogenous cyclin F at 
abundances detectable by western blot. 
2. Endogenous cyclin F localises to the nucleus of ALS patient iPSC derived 
motor neurons. 
3. ALS patient iPSC derived motor neurons will express endogenous TDP-43 at 
abundances detectable by western blot, and these abundances will be reduced 
in the ALS patient lines. 
4. Endogenous TDP-43 localises in the nucleus of ALS patient iPSC derived 
motor neurons. 
5. Increasing ubiquitin proteasomal system stress will reduce the viability in 
ALS patient iPSC derived motor neurons compared to healthy control donor 
derived iPSC derived motor neuron. 
 
4.3 Aims 
 
1. To measure cyclin F expression in ALS patient-iPSC derived motor neurons, 
and compare to expression in control-iPSC derived motor neurons. 
 
2. To assess the cellular localisation of cyclin F in ALS patient iPSC derived 
motor neurons, and compare to control-iPSC derived motor neurons. 
 
3. To measure TDP-43 expression in ALS patient-iPSC derived motor neurons, 
and compare to expression in control-iPSC derived motor neurons. 
 
4. To assess the cellular localisation of TDP-43 in ALS patient iPSC derived 
motor neurons, and compare to control-iPSC derived motor neurons. 
 
5. To assess ubiquitin proteasome system dysfunction in ALS patient iPSC 
derived motor neurons compared to healthy donor derived iPSC derived 
motor neurons. 
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4.4 Endogenous cyclin F in motor neurons 
 
4.4.1 Expression of cyclin F decreased in CCNFS621G patient iPSC derived motor 
neurons  
Following the successful generation of CCNFS621G patient iPSC derived motor 
neurons, the next crucial task for establishing the iPSC derived motor neurons was to 
determine if ALS-associated proteins were detectable at endogenous levels in these 
models.  Cyclin F, the newly identified ALS-associated protein was first examined:  
Endogenous cyclin F was detectable via western blot.  Quantification of the protein 
in the different iPSC derived motor neuron models (normalising the quantities to 
NSE) identified a reduction in cyclin F in the Triton X soluble cell lysate in all three 
of the ALS-patient derived lines (Figure 4.1). These reductions were significantly 
lower (3.81 - 4.98 fold; F(5,12)=6.771. P=0.0032) compared to one of the two 
healthy control lines, though trended to be reduced compared to all other control cell 
lines.  
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Figure 4.1. Quantification of endogenous cyclin F  
Representative image, and dotplot quantification of cyclin F quantified by western 
blot analysis of triton X soluble cyclin F in whole cell lysate from iPSC derived 
motor neurons. Cell lines were derived from a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor 
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative 
control. N=3 independent differentiations; Significance determined via ANOVA, 
Tukey’s multiple comparison post hoc test**P>0.01 
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4.4.2 Endogenous cyclin F localises in the nucleus of motor neurons, as nuclear 
bodies. 
Confirming cyclin F was detectable at endogenous levels, it was next imperative to 
investigate the localisation of cyclin F in these cells. In order to further understand 
the role of cyclin F in motor neurons, confocal analysis of cyclin F immunolabelled 
motor neurons was performed. Confocal imaging revealed that cyclin F was 
expressed in the nucleus in puncta consistent with nuclear bodies across all six cell 
lines examined.  Imaging at increased magnification of the nuclear bodies indicated 
that at least four bodies, irregular in shape were present per nucleus, in all six cell 
lines (Figure 4.2). Image analysis via LAS AF software indicated that these nuclear 
bodies ranged up to 1.57 μm in diameter.  
 
 
 183 
 
 
 
Figure 4.2 Representative high magnification confocal images of nuclear cyclin F 
positive bodies in motor neurons.  
Representative images, of cyclin F in iPSC derived motor neurons Cell lines were 
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient 
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS 
patient (SOD1), and an additional healthy donor (HC2) and a sporadic Alzheimer’s 
disease patient (SAD) as a neurodegenerative control. N=3 differentiation repeats 
minimum per cell lines; differentiation batches imaged with same confocal settings. 
Scale bar = 10 μm. 
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Further image analysis was performed to compare the populations of these nuclear 
bodies in the different cell lines using Cell Profiler.  Comparison of the intensity of 
the nuclear bodies (N=3 independent differentiations, normalised to each 
differentiation batch) indicated no significant difference in the abundance of cyclin F 
present in the nuclear bodies in the different cell lines, as indicated by One-way 
ANOVA with Tukey’s post hoc test F (5, 10) = 0.9873. P=0.4715; Figure 4.4A.   
 
A count of the mean number of nuclear bodies per detectable nucleus was also found 
to have no significant difference between the cell lines (indicated by One-way 
ANOVA with Tukey’s post hoc test F (5, 10) = 0.7602. P=0.5982; Figure 4.4B).  
When all replicates were grouped by neurodegenerative motor neurons (cell lines 
CCNF1, CCNF2, SOD1 and SAD) or healthy controls (cell lines HC1 and HC2), an 
opposite correlation was evident when the average number per nucleus and intensity 
of the nuclear bodies were compared (Figure 4.5); Though these correlations were 
not significantly non-zero, healthy controls had a trend to have an increased number 
of high intensity nuclear bodies (R2= 0.08752. F(1,4)=0.2405. P=0.6496) compared 
to the neurodegenerative controls which had a decreasing number of high intensity 
nuclear bodies (R2= 0.05671. F(1,8)=0.7673. P=0.4066). 
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Figure 4.4 Quantification of cyclin F positive nuclear bodies from confocal images of 
iPSC derived motor neurons 
Dot plots of (A) intensity of nuclear body and (B) number of nuclear bodies per total 
number of nuclei from image quantification of cyclin F in iPSC derived motor 
neurons calculated using Cell Profiler analysis. Cell lines were derived from a 
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a 
symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS patient (SOD1), 
and an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient 
(SAD) as a neurodegenerative control. N=3 differentiation repeats; differentiation 
batches imaged with same confocal settings.  Significance determined via ANOVA, 
Tukey’s post hoc (P>0.05). 
 
A 
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Figure 4.5 Correlation of cyclin F positive nuclear body intensity and number per 
nuclei 
Analysis is from confocal images of motor neurons calculated using Cell Profiler 
analysis. Cell lines were derived from a healthy donor (HC1), a pre-symptomatic 
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), 
a SOD1E101G ALS patient (SOD1), and an additional healthy donor (HC2) and a 
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control. N=3 
differentiation repeats; differentiation batches imaged with same confocal settings.  
Significance determined via Linear Regression Analysis (P>0.05). 
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4.5 TDP-43 and phosphorylated TDP-43  
 
4.5.1 TDP-43 and phosphorylated TDP-43 expressed in motor neurons 
To determine if endogenous TDP-43 was expressed at detectable quantities in these 
iPSC derived motor neurons, western blot analysis was performed. Using the 
phosphorylated TDP-43 antibody (409/410), both protein bands at both 50 kDa, 
(corresponding to phosphorylated TDP-43), and 43 kDa, (the native weight of TDP-
43), were detectable in all cells lines at endogenous levels (based on previous 
antibody use (Foulds et al., 2009; Neumann et al., 2007) (Figure 4.6).  Interestingly, 
a third band (at approximately 45 kDa) between these two molecular weights was 
also detected in the CCNFS621G cell lines in two of the four replicates performed 
(lysates collected from independent differentiations). Previous reports of bands at 
this weight (45 kDa) have have been detected in ALS patient post mortem tissue 
(Sorarú et al., 2009). 
 
To assess if the endogenous TDP-43 was ubiquitinated, a deubiquitinating enzyme 
(DUB) inhibitor was either omitted or included at lysate collection.  Interestingly, the 
different lysates did generate protein bands at different molecular weights in the 
presence or absence of the DUB inhibitor, at roughly the same weight as the 
previously detected band present in the two CCNFS612G patient derived motor 
neurons. Though these changes did not exactly match the change in molecular weight 
of ubiquitin (8.5 kDa), the 43 kDa TDP-43 protein band was only present in the 
lysates with DUB inhibitor. In lysates without DUB inhibitor bands with higher 
molecular weight were detected (Figure 4.6). 
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NSE 
Figure 4.6. Expression of endogenous TDP-43  
Representative image, TDP-43 detected via western blot analysis of triton X soluble 
cyclin F in whole cell lysate from iPSC derived motor neurons. Cell lines were 
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient 
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS 
patient (SOD1), and an additional healthy donor (HC2) and a sporadic Alzheimer’s 
disease patient (SAD) as a neurodegenerative control.  N=4 (N=3 independent 
differentiations, and 1 additional replicate). Replicates not shown. 
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Figure 4.6. Endogenous TDP-43 in presence and absence of DUB inhibitor 
TDP-43 quantified by western blot analysis of triton X soluble cyclin F collected 
with DUB inhibitor (+) and wihtout DUB inhibitor (-) in whole cell lysate from iPSC 
derived motor neurons. Cell lines were derived from a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor 
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative 
control.  N=1 independent differentiation.  
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4.5.2 Endogenous TDP-43 localises in the nucleus of motor neurons consistent 
with nuclear bodies. 
Following detection of TDP-43 at endogenous levels, it was pertinent to investigate 
the localisation (and potential mislocalisation) of endogenous TDP-43 in these iPSC 
derived motor neurons.  Confocal analysis of TDP-43 immunolabelled motor 
neurons revealed that TDP-43 was expressed in the nucleus indicative of nuclear 
bodies consistently across all six cell lines examined (Figure 4.7). TDP-43 was also 
detected in the cytosol in the motor neurons.  Images taken at an increased 
magnification indicated diverse bodies of irregular in shape and size were present in 
the nucleus, in all six cell lines.  Unlike cyclin F, TDP-43 nuclear body analysis was 
not possible in the iPSC derived motor neurons due to the inability to discern 
individual bodies - being so densely populated in the nucleus. From a general 
observation, it appeared that different populations of nuclear bodies existed - some 
areas of the nucleus displayed areas of high intensity fluorescence. Further 
investigation, using nuclear body specific markers, or actin, is required to allow 
quantification to determine what these nuclear bodies are, and if differences are 
evident between the different cell lines.   
4.5.3 Endogenous TDP-43 can localise in the cytosol in a subset of cells 
In all six cell lines examined, TDP-43 was detected to be cytosolic as well as nuclear. 
This cytosolic localisation did not appear to be ALS patient derived cell line specific 
mislocalisation. The localisation of fluorescence observed is consistent to stress 
fibres, as long elongated spindles (Figure 4.8). 
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Figure 4.7 Representative high magnification confocal images of nuclear TDP-43 
positive bodies in motor neurons 
Representative images, of TDP-43 (Abnova, H00023435-M01) in iPSC derived 
motor neurons. Cell lines were derived from a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor 
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative 
control.  N=3 differentiations per cell line; differentiation batches imaged with same 
confocal settings. Scale bar = 25 μm. 
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Figure 4.8 Cytosolic TDP-43 in small population of iPSC derived motor neurons 
Representative images, of TDP-43 (Abnova, H00023435-M01) in iPSC derived 
motor neurons. Cell lines were derived from a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor 
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative 
control.  N=3 differentiation repeats; differentiation batches imaged with same 
confocal settings. Scale bar = 50 μm. 
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4.5.4 Endogenous TDP-43 is non significantly decreased in CCNF mutant iPSC 
derived motor neurons  
Given the propensity of TDP-43 to aggregate in motor neurons, and the presence of 
TDP-43 in nuclear bodies observed here, the solubility of the TDP-43 present was 
investigated.  The solubility of the endogenous TDP-43 was probed via a crude 
fractionation process, re-suspending proteins insoluble in RIPA buffer, with a 2% 
SDS RIPA solution, and any remaining insoluble proteins in 8M Urea to further 
solubilise the remaining TDP-43 (Figure 4.9).  Quantification of the protein 
abundance in the three fractions (normalised to the total protein of the triton X 
fraction), indicated that soluble TDP-43 at ~50 kDa was present in 2% SDS soluble 
fractions, (though less abundant) in the six cell lines examined. In some instances, 
there was also 50 kDa TDP-43 present in the least soluble 8M urea fraction (Figure 
4.10 A). There was no significant difference between the cell lines when examining 
each individual fraction (As indicated by Two-way ANOVA with a Bonferroni post 
hoc test; F (10, 30) = 0.7907 P=0.6378.  However, the sum of these three solubility 
fractions was calculated for the 50 kDa TDP-43 (Figure 4.10 B); in the two 
CCNFS621G cell lines (CCNF1 and CCNF2) and trended towards being less abundant 
when compared to the other cell lines (though was not significantly different; As 
indicated by One-way ANOVA with a Tukey’s post hoc test F (5, 12) = 0.5355.  
P=0.7460). 
 
Bands corresponding to the 43 kDa TDP-43 (i.e. TDP-43 with no post-translational 
modifications) were also present in all six lines (Figure 4.11 A). No significant 
difference was detected between the cell lines when examining each individual 
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fraction (As indicated by Two-way ANOVA with a Bonferroni post hoc test; F (10, 
36) = 0.4629. P=0.9027). The total abundance of the respective bands at these three 
solubilities was then calculated (Figure 4.11 B). There was no significant difference 
between the total abundance of 43 kDa TDP-43 between cell lines (as indicated by 
One-way ANOVA with a Tukey’s post hoc test (5, 12) = 0.5863. P=0.7107).  
 
 
 
 
Figure 4.9 TDP-43 abundance by solubility, normalised to total protein. 
Representative image of western blot of TDP-43 detected at three solubilities, (T) 
Triton X, (S) 2% SDS, and (U) Urea soluble in iPSC derived motor neurons. Cell 
lines were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS 
patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G 
ALS patient (SOD1), and an additional healthy donor (HC2) and a sporadic 
Alzheimer’s disease patient (SAD) as a neurodegenerative control. N=3 
differentiation replicates. 
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Figure 4.10 TDP-43 ~50kDa band abundance normalised to total protein.  
Quantification of TDP-43 50kDa protein in three solubilities detected by western blot 
in the (A) Triton X, 2% SDS, and Urea soluble fractions, and (B) sum total in motor 
neurons differentiated from the following cell lines: a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor 
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative 
control. Concentrations were normalised to the concentration of total protein. N= 3 
biological replicates. Significance determined via ANOVA, Tukey’s post hoc test 
(P>0.05). 
A 
B 
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Figure 4.11 TDP-43 ~43kDa band abundance normalised to total protein.  
Quantification of total TDP-43 43kDa protein detected by western blot in the (A) 
Triton X, 2% SDS, and Urea soluble fractions, and (B) total sum in motor neurons 
differentiated by following cell lines: a healthy donor (HC1), a pre-symptomatic 
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), 
a SOD1E101G ALS patient (SOD1), and an additional healthy donor (HC2) and a 
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control. 
Concentrations were normalised to the concentration of total protein. N= 3 biological 
replicates, N=2 technical replicates for 2 biological replicates. Significance 
determined via ANOVA, Tukey’s post hoc test (P>0.05).
A 
B 
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4.6 Proteasomal stress affects motor neuron viability 
4.6.1 Motor neuron viability decreases following increased proteasomal inhibition 
To understand the relationship between cyclin F, ubiquitin proteasome system, and 
cellular viability, a proteasomal inhibition assay was performed.  Motor neurons 
from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient (CCNF1), a 
symptomatic CCNFS621G patient (CCNF2), a SOD1E101G (SOD1) patient, an 
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) 
were treated with a range of concentrations of proteasomal inhibitor MG132 (ranging 
from 1-250 µM), a vehicle control (DMSO), and untreated. Cell viability was 
monitored at three time points (16 h, 48 h, and 72 h).  Treatment duration and 
MG312 concentrations were based on previously published cellular works (Mazroui 
et al., 2007).  At each of these three times points, cellular viability was measured 
using a PrestoBlue assay as an indication of cellular viability.  
 
Following 16 h of treatment of MG132, there were significant differences in cellular 
viability across the cell lines at concentrations between 1-100 µM (normalised to 
vehicle control) as indicated by Two-way ANOVA with Tukey’s post hoc test; F (20, 
149) = 2.249. P=0.0031 (Figure 4.12).  At the lowest concentration of MG132 (1 
µM), the SAD patient derived motor neurons exhibited a significantly lower viability 
(between 1.43 - 2.34 fold) than other cell lines including the healthy control (HC1; 
P=0.003), the CCNFS621G patient (CCNF2; P= 0.0123) and the SOD1E101G (SOD1; 
P=0.0011) patient derived motor neurons (Appendices Table 8.2).  There was no 
significant difference in the viability when comparing within each cell line as the 
concentration increased from 1 µM to 2.5 µM MG132, nor between 2.5 µM and 10 
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µM MG132 (Appendices Tables 8.3 and 8.4).  Following treatment at 100 µM 
MG132, viability in motor neurons was significantly lower in HC1 compared to the 1 
µM MG132 treated motor neurons and the 2.5 µM MG132, as well as in SOD1 
compared to the 1 µM MG132 treated cells  (all by approximately 2 fold; P = 0.0372, 
0.0006, 0.0026 respectively).  Following treatment at 100 µM MG132, motor 
neurons from one of the two CCNFS621G patient (CCNF1) did not exhibit the same 
reduction in viability as the other cell lines (Appendices Table 8.6). Treatment of 
motor neurons from this same cell line with 250 µM MG132 did not elicit the same 
response; this higher dose resulted in a decrease in viability as per the general trend 
across these treatments, that an increase in proteasomal inhibition inversely 
correlated to cellular viability. 
 
Following 48 h of treatment of MG132, a general decrease in viability was evident 
across all cell lines (as indicated by Two-way ANOVA with Tukey’s post hoc test F 
(20, 150) = 1.087. P=0.3686).  Little difference between cell stages was evident 
following this treatment. The only significant difference in viability was between a 
CCNFS621G patient (CCNF1) and SOD1E101G patient  (SOD1) derived motor neurons: 
The SOD1 motor neurons indicated significantly higher viability than the CCNF1 
(1.6 fold higher; P = 0.0444; Appendices Tables 8.8 - 8.11).  Viability of motor 
neurons at this timepoint were repeatedly decreased in inverse correlation with 
increased MG132 concentration in all six cell lines examined. Comparison of 
viability in motor neurons treated with the lowest concentration of MG132 (1 µM) to 
the highest concentration (250 µM) revealed a decrease of between 1.9 fold to 4.4 
fold decrease in viability in all cell lines (significance as indicated in Figure 4.13 A, 
determined via Two-way ANOVA with Tukey’s post hoc test).   
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Following 72 h of treatment of MG132, motor neuron viability was reduced again, 
compared to the other time points, and cells morphology (or lack of) indicated high 
levels of cell death. At lower concentrations (1- 10 µM) MG132, some differences 
were evident between cell lines as indicated by Two-way ANOVA with Tukey’s post 
hoc test; F (20, 139) = 2.901. P=0.0001 (Figure 4.13 B; Appendices Tables 8.12 - 
8.16). At higher concentrations, cell death was consistently observed.  
 
Figure 4.12 Motor neuron mitochondrial viability following 16 h proteasomal 
inhibition   
A PrestoBlue assay was performed to assess the reducing ability of iPSC derived 
motor neurons from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient 
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a SOD1E101G patient (SOD1), 
an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) 
as a neurodegenerative control, following treatment with a range of concentrations of 
proteasomal inhibitor MG132. Fluorescence was detected at 590 nm. Significance 
determined from Two-way ANOVA with Tukey’s post hoc test, denoted as 
*P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. N=5 independent 
differentiations. 
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Figure 4.13 Motor neuron mitochondrial viability following 48 h and 72 h 
proteasomal inhibition   
A PrestoBlue assay was performed to assess the reducing ability of iPSC derived 
motor neurons from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient 
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a SOD1E101G patient (SOD1), 
an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) 
as a neurodegenerative control, following treatment with a range of concentrations of 
proteasomal inhibitor MG132 for (A) 48 h and (B) 72 h. Fluorescence was detected 
at 590nm. Fluorescence was detected at 590nm. Significance determined from Two-
way ANOVA with Tukey’s post hoc test, denoted as *P<0.0332,  **P<0.0021, 
***P<0.0002, ****P<0.0001. N=5 independent differentiations. 
B 
A 
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4.7 Ubiquitin system function decreased in CCNFS621G motor 
neurons 
 
Following assessment of proteasomal stress on cellular viability and the relative 
exclusion of nitrosative stress in the cells (Appendices Figure 8.2), this study sought 
to assess the functionality of the UPS.  Using a degron assay, which engages a 
protein degradation (degron) signal fused to a GFP as an indicator of cellular UPS 
efficacy - cells are unable to degrade the GFP as efficiently when under UPS stress. 
The degron plasmid was co-transfected with a mCherry plasmid (to account for the 
transfection efficacy of the cells), and motor neuron precursors were monitored using 
live cell imaging for proteasomal activity.   A significant increase in fluorescence, 
indicating a decreased capacity to degrade cellular proteins, was found in the 
symptomatic CCNFS621G (CCNF2) derived iPSC-motor neuron precursors (Figure 
4.14).   
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Figure 4.14 Degron Assay in motor neurons following proteasomal inhibition  
GFP fluorescence detected by Incucyte Zoom analysis normalised to co-transfected 
mCherry plasmid expression in iPSC derived motor neurons a healthy donor (HC1), 
a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G 
ALS patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy 
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a 
neurodegenerative control.  Significance determined via One-way ANOVA, Tukey’s 
post hoc test * P>0.05, **P>0.01, ***P>0.001. N=3. 
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4.8 Discussion 
 
4.8.1 Endogenous ALS proteins TDP-43 and cyclin F expressed ALS patient 
derived motor neurons 
The ability to study endogenous protein is of great value to ALS research wherein 
protein overexpression systems can result in confounding, potentially misleading 
effects.  As hypothesized, the two ALS proteins examined, TDP-43 and cyclin F, 
were both detectable at endogenous concentrations in the iPSC derived motor neuron 
models generated in this study.  The detection of endogenous TDP-43 is inline with 
previous iPSC-ALS studies (Bilican et al., 2012; Burkhardt et al., 2013; Egawa et al., 
2012; Nishimura et al., 2014; Serio et al., 2013; Zhang et al., 2013), which have 
detected endogenous TDP-43 in iPSC derived motor neurons.  The detectable 
expression of endogenous cyclin F was not guaranteed based on the literature; Cyclin 
F is known to play different roles in different cell types (and is therefore likely to 
vary in expression) (Tetzlaff et al., 2004). Though endogenous cyclin F has been 
detected in mouse iPSCs (Buganim et al., 2012), proteasomal inhibition via MG132 
treatment has been previously required to detect endogenous levels of cyclin F in 
some models (D’Angiolella et al., 2013).  It is therefore greatly beneficial that 
detection of endogenous cyclin F was possible given the need for an ALS relevant 
model with detectable endogenous cyclin F. Particularly as the endogenous cyclin F 
in the existing zebrafish model varies from the human form of cyclin F and therefore 
requires transfection of the human form to study it in the context of ALS (Hogan et 
al., 2017).   
 
 204 
 
A limitation of the few previous studies examining cyclin F in the context of ALS 
(Williams et al (2016), Hogan et al (2017), and Lee et al (2017; 2018), is the 
investigation of a cyclin in mitotic cells such as the mouse neuroblastoma line, which 
remains mitotic in culture.  It would be unsurprising that the role of cyclin F change 
in different cell types - particularly in post-mitotic cells.  Indeed, these findings 
represent the first reporting of cyclin F expression and localisation in a non-
cancerous derived-human cell line, an important step in considering the function of 
cyclin F in post-mitotic motor neurons. 
 
4.8.2 Cyclin F may be decreased in iPSC derived motor neurons  
Cyclin F was decreased across all three of the ALS cell lines (CCNF1, CCNF2 and 
SOD1) compared to the three other controls (including significant differences 
between HC1, as well as a decrease compared to HC2 and SAD). This suggests that 
either Triton X soluble NSE is increased in ALS, or that Triton X soluble cyclin F 
was decreased (or reduced in solubility), or a combination of both.  The relative 
intensity and number of these aggregates did not decrease as per protein 
quantification (via western blots), and examination of correlation of these two 
features did not yield significantly distinct partitioning. Though this technique is not 
necessarily definitive, it may suggest that the decrease in cyclin F detected via 
western blot is due to an increased retention of NSE, which can occur as a result of 
UPS dysfunction, and has been reported to occur in ALS (Jain et al., 2008), despite 
being a commonly used normalising protein (Li et al., 2015).  Conversely, it may be 
speculated that cyclin F is self-regulating, and mutations to this protein may cause an 
increased propensity for either aggregation (thereby sequestering the soluble protein 
into undetectable aggregates) or degradation. The limited number of previous studies 
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into cyclin F expression have not detected differences in the expression of cyclin F 
compared to control, (Hogan et al., 2017; Lee et al., 2018; Y.-C. Lee et al., 2017; 
Williams et al., 2016), however, this study is the first study to examine the 
endogenous levels of cyclin F. Further examination into the regulation of cyclin F 
would be warranted to better evaluate if cyclin F is decreased.   
 
4.8.3 iPSC derived motor neurons express cyclin F in structures consistent with 
nuclear bodies 
The expression of cyclin F in these motor neurons was further analysed via 
immunocytochemistry. Motor neurons expressed nuclear cyclin F, localising 
predominantly in structures consistent with nuclear bodies.  There was no significant 
difference in the intensity or number of these structures amongst the different cell 
lines. There was, however, a trend for a decrease in a high number of high intensity 
cyclin F positive aggregates in the neurodegenerative cell lines, when compared to 
the two healthy controls. It could be speculated that this trend suggests a changing 
role of cyclin F in the nucleus (potentially a change in nuclear protein targets), or that 
there is a shift towards larger nuclear bodies in the neurodegenerative cell lines 
which may suggest sequestering of proteins, as would be seen in cells under UPS 
stress.  Assessing the size and number of these aggregate structures via a technique 
such as FloIT, a flow cytometric aggregate analysis would provide further high 
throughput quantification of these structures that may elucidate this potential shift in 
cyclin F positive nuclear bodies (Whiten et al., 2016).  This would be very useful in 
ascertaining the heterogeneity of the nuclear body-like structures, which would give 
a direction for assessing the type of nuclear bodies present. 
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 As an early study of the expression of cyclin F in these patient derived motor 
neurons, the ALS causing mechanism of a cyclin F mutation was also considered.  
Given the role of nuclear bodies in transcription and translation (Table 4.1), the 
expression of cyclin F in nuclear bodies suggests the cyclin F has a role in 
transcription or post - translational modifications.   It may be that cyclin F is included 
in multiple nuclear body functions, or may simply be involved in a limited number of 
processes.  Should this be the case, cyclin F positive bodies would likely be (which 
were present in at least four irregular bodies in each nucleus) nuclear speckle/granule 
clusters, nuclear stress bodies, or polycomb bodies (Table 4.6). The co-expression of 
specific nuclear body antibodies, examining expression of SC35 SF2/ASF (nuclear 
speckles), HSF1 (nuclear stress bodies) BMI1, and PC2 (polycomb) shoud be 
performed to determine if these nuclear body species are present (Spector, 2006).  
 
Table 4.6 Nuclear protein body characteristics corresponding to cyclin F nuclear 
bodies in iPSC motor neurons 
 
 
4.8.4 TDP-43 decreased in CCNFS621G patient derived motor neurons 
Western blot quantification of TDP-43 indicated a decrease in total endogenous 
TDP-43 in the two CCNFS621G patient derived lines compared to the other cell lines.  
This is in opposition with a majority of iPSC-ALS studies which have found 
increases in TDP-43 in ALS-iPSC derived motor neurons compared to healthy 
controls (Bilican et al., 2012; Burkhardt et al., 2013; Egawa et al., 2012; Nishimura 
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et al., 2014; Serio et al., 2013; Zhang et al., 2013).  The detected decrease in TDP-43 
and particularly phosphorylated TDP-43 in this study corroborates with the findings 
by Lee et al (2017), which proposed that mutant CCNFS621G caused an increase in 
degradation-associated ubiquitination in neuronal-like cell models (Neuro-2as and 
Sh-SY5Ys).  
 
Expression of TDP-43 in two of the four samples indicated additional banding at ~40 
kDa in both pre-symptomatic and symptomatic CCNFS621G patient derived motor 
neurons samples (CCNF1 and CCNF2).  TDP-43 is known to be ubiquitinated, and 
given the role of cyclin F as an E3 ubiquitin ligase, this line of investigation was 
probed further. iPSC derived motor neuron samples were divided upon collection 
and treated with either a deubiquitinating inhibitor, or a vehicle control. A change in 
the detected weight of TDP-43 following exclusion of DUB inhibitor suggests that 
this band is likely the ubiquitinated from of TDP-43.  This is in agreement with 
findings that indicate CCNFS621G transfected neuronal models experience an increase 
in ubiquitinated (Lys48) substrates (Lee et al., 2018). The variability (band was 
present in only two of the four replicates) would be interesting to investigate to 
determine what slight variations in experimental conditions lead to this variability. 
This band has been previously detected in ALS tissue. This previously detected band 
was removed by λ-phosphatase, which may indicate that this is in fact an alternate 
phosphorylated TDP-43 species, which should be considered for future analysis 
(Sorarú et al., 2009).  The presence of the Triton X insoluble TDP-43 in all cell lines 
suggests that careful buffer selection is required for future studies of the protein.  
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These preliminary findings in TDP-43 expression justify further studies to examine 
the less-soluble TDP-43 species to determine if, and what abnormal cellular 
aggregates are present in the ALS cell lines.  Previous studies have examined 
endogenous TDP-43 in iPSC derived motor neurons, and found a distinction in 
expression of TDP-43 and phosphorylated TDP-43 in the nucleus; TDP-43 showed a 
lower intensity overlap with the nuclear stain DAPI and was positive in only 
concentrated high intensity structures consistent with nuclear bodes, while co-stained 
phosphorylated TDP-43 was only expressed in these concentrated high intensity 
structures (Burkhardt et al., 2013).  An antibody for this same epitope (409/410 
phosphorylated TDP-43) was used in this study, however western blot results 
strongly suggest that this antibody was also able to detect other TDP-43 forms.  
Further studies using selective antibodies (including one specific for the 45 kDa 
fragment) would be advantageous in discerning what TDP-43 species are present in 
these abundant nuclear structures, and to accurately quantify if there are differences 
between ALS patient derived motor neurons and controls, or if this is an artifact of 
non specific binding.  The study by Burkhardt et al (2013) assumed that these nuclear 
structures were aggregates related to disease pathology, as these were only detected 
in the SALS patient derived motor neurons, compared to healthy control motor 
neurons, though interestingly were not observed in the FALS patient derived motor 
neurons, highlighting the need for further investigation into the purpose of these 
structures. Alternate methods of investigating these structures would also be 
valuable; similar to cyclin F, co-staining motor neurons with TDP-43 and nuclear 
body specific markers would work towards quantifying the potentially heterogeneous 
population. Again, using a technique such as FloIT would be useful in discerning the 
population of these nuclear structures in a bulk study. TDP-43 positive aggregates, 
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which did not show visual distinction to the extent at which they could be quantified 
in the motor neurons, could be further investigated using this technique (Whiten et 
al., 2016).  It would also be of value to further investigate these nuclear structures via 
increase biological sample size to determine if this is a true trend, or artefact of 
smaller biological sample size.  
 
4.8.5 An additional role for TDP-43 in iPSC motor neuron cultures 
TDP-43 was not only detected in the nucleus, but was also found in the cytosol, 
associating in a spindle - stress fibre-like pattern in select cells (Tojkander et al., 
2012). This phenotype was observed in select cells across every cell line, suggesting 
it is not an ALS phenotype.  As the cultures are not pure motor neurons, it is possible 
that this cytosolic TDP-43 indicates the presence of a different cell type in the 
cultures (Ederle and Dormann, 2017; Sephton et al., 2010).  Further investigation 
into the identity of these select cells would be of great value in understanding this 
variability in TDP-43 expression in these cultures, and further our understanding of 
the role of TDP-43 in ALS.  Cell specific protein markers expression and 
electrophysiology, which could discern specific cell types, would be of benefit to 
further examine any differences in TDP-43 distribution between cell types.  It would 
be important to examine co-expression of a motor neuron marker with both TDP-43 
and cyclin F in the future, potentially engaging a reporter vector, or simply co-
staining via immunocytochemistry. 
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4.8.6 UPS function decreased in CCNFS621G motor neurons 
UPS dysfunction was detected in one of the two CCNFS621G carrier derived motor 
neurons as indicated via the degron assay. The reporter protein destined for 
ubiquitination and degradation were retained at a greater concentration in the CCNF2 
line motor neuron precursors, derived from a symptomatic patient. This finding is 
validated by the findings that previously examined the effects of cyclin F 
overexpression in neuronal-like models, including NSC-34s, Neuro-2A and SH-
SY5Y cells (Lee et al., 2018; Lee et al., 2017; Williams et al., 2016).  NSC-34 cells 
overexpressing cyclin F with different ALS causing mutations were found to have an 
increased retention of the UPS reporter protein compared to controls. A proteasomal 
assay indicated mutation to cyclin F had no effect on proteasomal activity, thereby 
implicating the ubiquitination machinery of the UPS (Williams et al., 2016).  
Interestingly, the motor neuron precursors from the pre-symptomatic donor with the 
CCNFS621G mutation (CCNF1) did not show this level of UPS dysfunction. This 
discrepancy suggests that there may be alternate cellular influences that are either 
neuroprotective in the CCNF1 cells, or cause additional cellular stress in the 
symptomatic CCNFS621G (CCNF2) cell line. 
 
4.8.7 CCNFS621G likely increases degradation of substrates including TDP-43 
The decrease in TDP-43 further supports the previous findings that cyclin F 
associates with TDP-43.  Williams et al (2016) found that an increased abundance of 
TDP-43 pulled down with ubiquitin, indicating that TDP-43 is a possible substrate of 
cyclin F in its capacity as a substrate recognition subunit of an E3 ubiquitin ligase. 
Lee et al  (2017) indicated that the CCNFS621G resulted in an inability to be 
deactivated by phosphorylation, thereby leading to an increase in ubiquitination 
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activity. Together with the results of this study, which indicate a reduction of 
endogenous TDP-43, and a likely increase in the ubiquitinated form of TDP-43, 
would strongly suggest that TDP-43 is reduced as a consequence of increased TDP-
43 ubiquitination by cyclin F (as further discussed in Chapter 6).  
 
4.8.8 Motor neuron viability was inversely correlative to proteasomal inhibition  
Across all cell lines examined, motor neurons exhibited a decrease in viability as 
proteasomal inhibitor increased (from 1 µM to 250 µM MG132).  Overall, viability 
decreased over time (at the three time points examined: 16 h, 48 h, 72 h).  These 
findings did not show a clear difference in the viability of motor neurons from ALS 
patients and controls. The sporadic Alzheimer’s disease (SAD) derived cells showed 
the most consistent sensitivity to the proteasomal inhibition; this is consistent with 
the previously reported SAD phenotype (Balez et al., 2016).  It was hypothesized 
that the ALS patient derived motor neurons would show a similar decrease in 
viability, being more affected by the UPS stressed caused by the proteasomal 
inhibition than healthy controls.  At the time points measured, there was not a 
consistent pattern of the ALS derived motor neurons having a significantly reduced 
viability compared to both healthy controls.  Despite the lack of distinction between 
the healthy motor neurons and the ALS derived motor neurons in viability 
measurements, there was a significant difference in the function of the UPS in one of 
the two CCNFS621G derived motor neurons, following UPS stress. The symptomatic 
CCNFS621G patient (CCNF2) derived motor neurons exhibited a retention of reporter 
protein following proteasomal inhibition for 16 h, (10 µM MG132) at a increased 
level compared to the five other cell lines, consistent with UPS stress being an 
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upstream mechanism in motor neurons, prior to a loss of viability (and therefore a 
potential contributing factor).   
4.9 Summary and future directions 
 
Due to the very recent discovery of mutations in the CCNF gene as a cause of ALS, 
very limited information was available at the commencement of this study into the 
role of cyclin F in motor neurons.  Here, it was identified that endogenous levels of 
both cyclin F and TDP-43 were detectable in iPSC derived motor neurons, in both 
healthy donor- and patient derived motor neurons.  The detectability of the 
endogenous TDP-43 and cyclin F are of great importance for these models, which 
represent a dynamic system to examine the underlying mechanisms of ALS.  The 
ability to detect these endogenous proteins provided the means to quantify and 
further examine the localisation of these ALS associated proteins.  Cyclin F was 
found to decrease, via western blot though not by immunocytochemistry, requiring 
more analysis to determine if the decrease was an artefact of normalising to neuronal 
marker NSE.  Given the role of cyclin F as an E3 ubiquitin ligase substrate 
recognition subunit, which likely recognises a range of protein substrates, a non-bias 
investigatory approach would serve to bring great insight to why mutations in this 
protein cause ALS. 
 
TDP-43 was detected at a weight of 50 kDa (consistent with phosphorylated TDP-
43), 43 kDa (no post translational modifications), as well as a 45 kDa TDP-43 
(potentially a phosphorylated or ubiquitinated TDP-43) in only the CCNFS621G motor 
neurons.  As only four studies to date have examined the role of cyclin F, and its 
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interaction with TDP-43 in the context of ALS (Hogan et al., 2017; Lee et al., 2018; 
Lee et al., 2017; Williams et al., 2016), we can only draw comparisons to these 
studies.  This data supports the proposition that TDP-43 abundance is reduced in 
mutant CCNFS621G ; this reduction is likely the result of the inability to phosphorylate 
cyclin F, which results in abnormal activity of the cyclin F (Lee et al., 2017).  
However, together these studies serve to raise many questions. Future investigations 
are needed to establish the fundamental role of cyclin F in motor neurons, which 
would no longer serve the same purpose as it would in a mitotic cell.  A co-
localisation study with TDP-43 and cyclin F would be the next logical step in 
establishing if, and if so, how these two proteins interact, which has been previously 
alluded to in overexpression systems (Williams et al., 2016). It is critical to establish 
what type (or types) of cyclin F positive and TDP-43 positive nuclear structures are 
present in these motor neurons, which could be performed via co-expression with 
nuclear body specific antibodies, and flow cytometry techniques such as FloIT.  In 
addition, assays to further exacerbate UPS stress, such as proteasomal inhibitor 
treatments would likely accelerate this aggregation, and potentially other ALS 
pathology. 
 
This study also endeavoured to examine the relationship between mutations affecting 
the proteasome, the UPS and cellular viability.  Though there was not a clear 
difference in the susceptibility of motor neurons derived from ALS patients to UPS 
stress in terms of viability (compared to healthy controls), one of the two CCNFS621G 
patient derived motor neurons did exhibit an increased propensity to retain the UPS 
reporter protein compared to the other cell lines, suggesting this is upstream of a 
reduced viability in ALS motor neurons.  Overall, this study overcomes the first 
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hurdle in establishing viable models for probing ALS mechanisms, establishing 
measurable parameters, and identifying potential phenotypes from which future 
studies may measure improvements to disease pathogenesis; Identifying a testable 
phenotype is critical for trialling potential therapeutics.  
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Chapter Five:  
 
Ubiquitomes of iPSC Derived 
Motor Neurons and Related Cell 
Types 
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5 UBIQUITOMES OF IPSC DERIVED MOTOR NEURONS AND RELATED 
CELL TYPES 
 
5.1 Introduction 
Ubiquitin is required as an essential protein for healthy motor neuron function, and 
survival (Park and Ryu, 2014). Deficits in the ubiquitin system are detrimental to 
multiple facets of neuronal function (Tai and Schuman, 2008).  Many proteins 
associated with essential motor neuron functions have been shown to be modulated 
by ubiquitin, including proteins associated with the synapse (including vesicles), the 
spliceosome, and the UPS itself.  Despite the now widespread use of iPSC derived 
motor neurons in ALS research, our understanding of the role of the UPS in these 
models remains limited.   No study to date has collectively examined the global 
ubiquitinated proteome (ubiquitome) of human iPSCs, nor any human iPSC derived 
cells.  As aforementioned, deficits in the UPS are suggested to contribute to the 
susceptibility of motor neurons in ALS.  This susceptibility has been highlighted in a 
comparison between ocular and spinal motor neurons, wherein an upregulation of 
UPS component proteins correlated with neuroprotection (Brockington et al., 2013). 
The importance of this system in ALS has also been highlighted through the 
identification of ALS-causing mutation in UPS genes (Deng et al., 2011).  
 
Advances in mass spectrometry techniques now allow for specific qualification and 
subsequent quantification of ubiquitinated proteins via ubiquitinomics.  Examination 
of the ubiquitinated proteome (termed the ubiquitome) can be used to identify 
changes that occur in different cellular stages – for example through the different 
cellular stages in cellular modelling of neurons.   Despite the exponential increase in 
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iPSC disease modelling, little is known about the iPSC ubiquitome.  Buckley et al. 
(2012) have previously investigated the mouse iPSC ubiquitome in a comparison of 
these cells in cultures containing both embryonic stem cells and mouse embryonic 
fibroblasts (Buckley et al., 2012).  No studies have yet identified the ubiquitome of 
human iPSC-motor neuron or their derivative cells for comparison.  Such a study 
would be valuable in furthering our understanding of cellular differentiation, as well 
as motor neuron diseases.  
 
Differences in the pathways ubiquitin regulates can be elucidated using pathway 
analysis tools, such as Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING). Changes in protein-protein interactions can be grouped using a number 
of features including similar Molecular Functions, Cellular Components, Biological 
Process, and via the Kyoto Encyclopedia of Genes and Genomes (KEGG).  Once 
target pathways, and proteins of interest are identified through this technique, 
methods such as colourimeteric viability assays are effective probing techniques to 
ascertain the functional consequence of altering these pathways.  
 
Here, following the successful generation of iPSC derived motor neurons at a 
relatively high yield, and identification of an ALS relevant phenotype, we have 
employed high-throughput mass spectrometry to map the global ubiquitome of 
human donor derived fibroblasts, iPSCs and iPSC derived motor neurons. 
Quantitative mass spectrometry allowed for the evaluation of dynamic changes in the 
ubiquitome across these three cellular stages and four cell lines (Figure 5.1).  This 
comparison  examines the ubiquitomes from a pre-symptomatic CCNFS621G patient 
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(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a healthy donor (HC2), and a 
sporadic Alzheimer’s disease patient.  This data is available upon request. 
 
 
Figure 5.1 Schematic of ubiquitinomics workflow 
Lysate from fibroblasts, iPSCs and motor neurons were purified via affinity column, 
and detected via an LC-MS/MS for analysis. 
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5.2 Hypotheses 
 
1. Different cell types throughout the reprogramming and differentiation of 
fibroblasts, iPSCs and motor neurons will exhibit different ubiquitinated proteomes.   
 
2. Drug treatments affecting pathways identified in Aim 1 as being signficantly 
regulated will affect neuronal development and viability. 
 
3. iPSC derived motor neuron ubiquitomes will vary between individual cell lines. 
 
5.3 Aims 
 
1. To perform ubiquitinomic analysis on the cell types throughout the 
reprogramming and differentiation (fibroblasts, iPSCs and motor neurons). 
 
2. To use drug treatments to test whether significant pathways identified to be 
regulated by ubiquitin in Aim 1 affect neuronal development and viability. 
 
3. To compare ubiquitomes of iPSC derived motor neurons derived from different 
donors. 
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5.4 Ubiquitome changes through fibroblast-iPSC reprogramming 
5.4.1 Total ubiquitomes of samples correlated strongly between replicates and 
partitioned between cell types. 
To identify and quantify the ubiquitome during cellular reprogramming and 
differentiation, fibroblasts, iPSCs, and iPSC derived motor neuron lysates from ALS 
patient- and healthy control- derived cell lines were immunoprecipitated by ubiquitin 
affinity beads. Following overnight digestion with trypsin, samples were analysed 
using quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS).  
Replicate data was first evaluated for robustness via visualisation using heatmaps of 
both the filtered MaxQuant output, as well as the imputed data normalized using a z-
score scale (Appendices Figure 8.4).  Heatmaps of the Pearson’s Correlation values 
indicated similarity in replicates and distinct partitioning of datasets within cell lines 
by cell stage (Figure 5.2; Appendices Figures 8.5). Multiscatter plots of the total data 
sets of each cell line assured there was consistency in replicates (Figure 5.3, 
Appendices Supplementary 8.7 - 8.8).  
 
Similarity of samples was assessed via a Principal component analysis (PCA). This 
analysis, which uses a singular value decomposition to provide a scaled projection of 
the total data (please see Appendices Figure 8.9 for further explanation; Kassambara, 
2017) indicated distinct partitioning of samples by cell type (Figure 5.4).   
Interestingly, within this total grouping of all replicates analysed, the motor neuron 
samples from derived from a CCNFS621G patient (CCNF2), and from a sporadic 
Alzheimer’s disease patient (SAD) grouped closely to all the iPSC samples (which 
tightly clustered together regardless of sample). A PCA was performed for each of 
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the separate cell lines examined, to compare the ubiquitomes of fibroblasts, iPSCs 
and motor neurons derived from the same donors. These analyses also consistently 
indicated separate clustering of these cell types within each cell line; For example in 
comparing the cells from a CCNFS621G patient (CCNF1), the fibroblasts grouped 
separately from the iPSCs, and these grouped separately again from the motor 
neurons (Appendices Figures 8.10 - 8.11).  
 
The ubiquitinomics data was also grouped by cell type, to compare the similarity of 
the cell lines within a given cell type. These PCA consistently revealed clustering of 
all cell lines closely together, with the exception of one of the CCNFS621G patient 
derived cell lines (CCNF2) in the fibroblasts (Figure 5.5), iPSCs (Figure 5.6), and 
motor neurons (Figure 5.7), suggesting there is a consistent difference in the 
ubiquitomes of these cells, regardless of the effects of reprogramming or 
differentiation. 
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Figure 5.2 Representative heatmap of Pearson’s correlation values  
Pearson’s correlation values were calculated from the comparison of samples from 
pre-symptomatic CCNFS621G patient derived cell lines (CCNF1). Heatmaps were 
generated for each cell line to compare between replicates and between cell stages  
(See Appendices Figure 8.5).  
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Figure 5.3 Representative multiscatter correlation plots  
Multiscatter values were calculated from pre-symptomatic CCNFS621G patient derived ubiquitomes (CCNF1) as an additional measure for 
correlation of data within sample replicates and between cell types.  Multiscatter plots were generated for each cell line to compare between 
replicates and between cell stages  (See Appendices Figures 8.6 - 8.7).  
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Figure 5.4 Principle components analysis of all samples measured between cell lines 
Plot was generated from comparison of filtered ubiquitinomics data from fibroblasts, iPSCs and motor neurons from the different cell lines 
examined.  
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Figure 5.5 Principle components analysis of all fibroblast samples  
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from fibroblasts.  Cell lines 
were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient 
(CCNF2), and a sporadic Alzheimer’s disease patient (SAD).  
Fibroblasts 
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Figure 5.6 Principle components analysis of iPSC samples 
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from iPSCs.  Cell lines were 
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), 
and a healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control.  
iPSCs 
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Figure 5.7 Principle components analysis of iPSC derived motor neuron samples 
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from iPSC derived motor 
neurons. Cell lines were derived from a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), 
and a healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control. 
.  
Motor Neurons 
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5.4.2 Symptomatic CCNFS621G patient derived ubiquitome exhibits large abundance 
of ubiquitinated proteins 
The ubiquitomes from each cell line were quantified and compared at each of the 
three cell stages.  As would be expected, many of the cell lines expressed uniquely 
ubiquitinated proteins. The comparison of cell lines at the fibroblast stage indicated 
that over half of all the ubiquitinated proteins were common to all samples. 
Interestingly, in these fibroblasts, the ubiquitome of the CCNF2 cell line (originating 
from a patient with a symptomatic CCNFS621G mutation expressed three fold more 
ubiquitinated proteins compared to the other cell lines (Figure 5.8).  This pattern 
continued in the other cell types examined. In all iPSC samples, over half of the 
proteins ubiquitinated were common amongst the five cell lines; total ubiquitinated 
proteins were increased (1.30 - 1.36 fold) compared to the other cell lines examined. 
There was a large increase of ubiquitinated proteins present only in the CCNF2 
sample and not in any of the others (Figure 5.9).  In the iPSC derived motor neurons 
the uniquely ubiquitinated proteins were also more abundant in CCNF2 with a 65 
fold increase compared to healthy control (Figure 5.10).  Between 64% - 78% of all 
proteins examined in the iPSC derived motor neurons (collectively) were commonly 
ubiquitinated in all cell lines. 
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Figure 5.8 Venn analysis of ubiquitinated protein expression in fibroblasts 
Lysates were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G 
ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), and a 
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control. 
 
Fibroblasts 
 230 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Venn analysis of ubiquitinated protein expression in iPSCs 
Lysates were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G 
ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), and a healthy 
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a 
neurodegenerative control.
iPSCs 
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Figure 5.10 Venn analysis of ubiquitinated protein expression in iPSC derived motor 
neurons 
Lysates were derived from a pre-symptomatic CCNFS621G ALS patient (CCNF1), a 
symptomatic CCNFS621G patient (CCNF2), and a healthy donor (HC2) and a sporadic 
Alzheimer’s disease patient (SAD) as a neurodegenerative control.  
 
Motor Neurons 
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5.4.3 Comparison of the ubiquitinomic changes that occur following 
reprogramming fibroblasts to iPSCs in multiple cell lines 
Following the identification of ubiquitinated proteins, it was possible to quantify the 
changes in the ubiquitinated proteins identified between cell types (as well as cell 
lines). To examine the changes through the reprogramming and differentiation of 
iPSC derived motor neurons, the ubiquitinated proteins increased in abundance in 
each of these cell stages was compared via student T-test, and visualised via volcano 
plot (Appendices Figures 8.14 - 8.15). Proteins commonly increased amongst the cell 
lines were analysed via STRING, and the pathways that were significantly expressed 
(categorised Molecular Functions, Cellular Components, Biological Process, and 
KEGG as determined by STRING when set to Highest Confidence 0.900 Interaction 
Score) were examined. First, the significantly more abundant proteins from each cell 
type (I.e. 1. The ubiquitinated proteins increased in fibroblasts; and 2. Ubiquitinated 
proteins increased in iPSCs), were examined for a focused analysis of pathways 
common to the proteins in these cell types via STRING. Second, the network 
generated from all the proteins that were increased in abudance in the comparison 
(I.e. in fibroblasts and iPSCs), were exported to examine the changes to pathways 
involved in these processes (reprogramming and differentiation) via Cytoscape. 
 
STRING analysis of the significantly increased ubiquitinated proteins indicated the 
pathways that were commonly increasingly regulated by ubiquitin in all four of the 
cell lines examined in fibroblasts, when compared to iPSCs. The relative abundance 
of only 15 ubiquitinated proteins was commonly increased in abundance in all 
fibroblast four cell lines examined compared to iPSCs. An additional 14 proteins 
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were also commonly significantly more abundant in fibroblasts compared to iPSCs in 
all cell lines except fibroblasts from the symptomatic CCNFS61G patient (CCNF2).  
Together, these 29 proteins were combined for analysis. STRING analysis of the 
protein interactions by Biological Process indicated the enrichment of 62 biological 
processes. This included a significantly higher abundance in ECM and cytoskeletal 
associated proteins. For example a number of heat-shock associated proteins were 
also more abundantly ubiquitinated in fibroblasts compared to iPSCs, including heat 
shock protein 27, coded by HSPB1, which was significantly increased in the 
fibroblast samples, and annexin 2 (ANXA2), a calcium-regulated membrane-binding 
protein that has also been associated with heat-stress response were increased in 
abundance.   
 
Figure 5.11 Representative volcano plot analysis comparing iPSCs to fibroblasts 
Data represents ubiquitinated protein expression in CCNFS621G patient derived iPSCs 
compared to fibroblasts. Proteins significantly increased in abundance  (P<0.01) in 
fibroblasts and iPSCs indicated in red.  
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A small number of ubiquitinated proteins were increased in iPSCs (totalling 12 
proteins common amongst all four cell lines) compared to fibroblasts. An additional 
21 proteins were significantly increased in all cell lines excluding CCNF2. When 
combined with the proteins commonly increased in all five cell lines, these 33 
proteins, when analysed using STRING showed no KEGG pathway enrichments, 
however had strong enrichment for spliceosomal biological processes. One third of 
the proteins increased in iPSCs compared to fibroblasts were associated with the 
pathways RNA stabilization, processing and splicing. 
 
Cytoscape analysis of the collection of increased proteins in the comparison of 
fibroblasts and iPSCs (as visualised by volcano plot; Figure 5.11) indicated changes 
to the abundance of ubiquitinated ECM associated proteins (Figure 5.12).  Two 
collagen-associated proteins, collagen-6A1  (COL6A1) and -1A2 (COL1A2), along 
with CD44, Ras GTPase-activating-like protein (IQGAP1) and Lamin A/C (LMNA) 
were significantly more abundant in fibroblasts compared to iPSCs. Conversely, 
ubiquitinated Lamin B1 (LMNB1) was significantly more abundantly ubiquitinated 
in iPSCs (P>0.01).  These changes are consistent with a changed requirement for 
ECM proteins in the reprogrammed iPSCs (Figure 5.12).  The comparison of 
fibroblasts and iPSCs indicated a significant increase in the abundance of 
ubiquitinated poly(A) RNA binding proteins (12) in iPSCs, as well as base excision 
proteins (3), suggesting a significant shift in the role of ubiquitin in regulating these 
pathways in iPSCs.  Additionally, there was an increase in ubiquitinated proteins 
associated with immune response (4), and lysosomal proteins (3) in fibroblasts. 
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Figure 5.12 STRING map of ubiquitinated proteins commonly significantly different 
in fibroblasts compared to iPSCs in lysates examined 
Lysates compared were derived from a healthy donor (HC1), a CCNFS621G ALS 
patient (CCNF1), a CCNFS621G ALS patient (CCNF2), and a healthy donor (HC2) 
and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative control.  
Higher protein abundance in iPSCs indicated in magenta, fibroblasts in blue. 
Significance determined by Student T-test (Threshold cut-off setting P>0.01). 
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5.4.4 The ubiquitome of iPSC derived motor neurons is significantly different from 
their originating iPSCs 
A comparison of the ubiquitinated proteins of significantly higher abundance in 
iPSCs and iPSC derived motor neurons indicated significant changes to the 
ubiquitome following differentiation (as visualised by volcano plot; Figure 5.13).   
Eight proteins were commonly increased in iPSCs compared to iPSC derived motor 
neurons in all four cell lines compared. An additional 13 proteins were commonly 
increased in iPSCs compared to motor neurons in three of the four cell lines 
(excluding the symptomatic CCNFS621G patient line, CCNF2). Combined, the 
analysis of 21 proteins revealed the pathways that were significantly increased in 
iPSCs compared to motor neurons:  Biological Process analysis revealed 24 
pathways were signficantly more present, including RNA processing (including 
splicing). Cellular Component analysis of the protein interactions shared between 
these proteins indicated that in addition to an increase of DNA replication 
minichromosome maintenance (MCM) proteins -4, -5 and -7 (MCM4, MCM5 and 
MCM7) which are associated with DNA helicase (as classified by Molecular 
Function analysis), DNA replication and cell cycle (as classified via KEGG). 
Additionally nuclear speckle proteins were also increased in their ubiquitinated form, 
as well as spliceosomal proteins which were increasingly abundant in iPSCs 
compared to motor neurons, included serine/arginine-rich splicing factor (SRSF) -1, -
3, -6 (SRSF1, SRSF3, SRSF6) transformer 2 -alpha homolog (TRA2A), and -beta 
homolog (TRA2B), and apoptotic chromatin condensation inducer 1 (ACIN1). 
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Twenty ubiquitinated proteins were commonly significantly increased in motor 
neurons compared to iPSCs.  Comparison of these protein interactions as classified 
by Biological Process indicated that half (10) of these ubiquitinated proteins were 
associated with nervous system development, and these included roles in 
neurogenesis and regulation of axogenesis.   An additional 47 proteins were 
increased in abundance commonly in three of the four cell line iPSC derived motor 
neurons (excluding the symptomatic CCNFS621G patient line, CCNF2). Combined, 
these 67 proteins were also analysed for protein interactions via STRING. Biological 
Process analysis indicated that an additional 8 protein (totalling 18) were associated 
with nervous system development.  Almost two thirds (43) of the proteins increased 
in motor neurons were associated with vesicles, as classified by Cellular Component 
analysis.  Examining Cellular Component interactions revealed ECM and 
cytoskeletal proteins were increased in iPSC derived motor neurons compared to 
iPSCs; this included microtubule associated protein -2, -4, -1B, and -RE1 (MAP2, 
MAP4, MAP1B, MAPRE1) and annexin 1 and 6 (ANAX1, ANXA6).  Three 
proteins associated with the positive regulation of the endoplasmic reticulum 
(ubiquitin-dependent) protein catabolism, ubiquilin -1 (UBQLN1), -2 (UBQLN2) 
and ubiquitin-like 4A (UBL4A), were also increased in motor neurons. 
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Figure 5.13 Representative volcano plot comparing iPSCs to motor neurons 
Data represents ubiquitinated protein expression in CCNFS621G patient derived iPSCs 
compared to motor neurons. Proteins significantly increased  (P<0.01) in fibroblasts 
and iPSCs indicated in red.  
 
All increased ubiquitinated proteins from the comparison of iPSCs and iPSC derived 
motor neurons were analysed for network changes using Cytoscape (Figure 5.14).  
Examination of the collection of significantly different proteins reiterated the 
findings of the individual analyses performed via STRING, including the increased 
abundance of ubiquitinated spliceosomal proteins (6) and DNA replication proteins  
(3) in iPSCs.  This second analysis also highlighted the increased abundance of 
ubiquitinated proteins associated with axogenesis pathways (4), as well as and 
cytoplasmic transport proteins (5). Interestingly there was an increased abundance in 
ten ubiquitinated mitochondrial associated proteins in motor neurons, and one 
ubiquitinated mitochondrial associated protein (ATP Citrate Lyase; ACLY) in iPSCs, 
suggesting a change in mitochondrial activity in iPSC derived motor neurons. 
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Figure 5.14 STRING map of ubiquitinated protein significantly different in iPSCs 
compared to motor neurons in lysates examined 
Lysates compared were derived from a healthy donor (HC1), a pre-symptomatic 
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), 
and a healthy donor (HC2) and a sporadic Alzheimer’s disease male (SAD) as a 
neurodegenerative control.  Higher protein abundance in iPSCs indicated in magenta, 
motor neurons in cyan.  Significance determined by Student T-test (Threshold 
P<0.01). 
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A qualitative analysis of the proteins expressed in motor neurons was also performed 
to further validate the successful differentiation of motor neurons from iPSCs via 
expression of motor neuron specific proteins. Expression of ALS relevant proteins 
(as indicated by comparison to the ALS bioinformatics database ALSoD) including 
proteins such as profilin-1, ubiquilin-2, dynactin subunit 1 and tubulin proteins -β, -
β3, -β4, -β4A and -4B, in these iPSC derived motor neurons further supported the 
engagement of these cellular models in ALS research (Table 5.1; Abel et al., 2012). 
 
Table 5.1 ALS relevant ubiquitinated proteins detectable by ubiquitinomics in 
motor neuron lysates as listed in ALSoD bioinformatics database 
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Ubiquitinated ALS mutation proteins encoded by genes of which mutants 
are known to cause ALS  
Protein Gene UnitProt Protein Name 
DCTN1 DCTN1 Q14203 Dynactin subunit 1 
MATR3 MATR3 P43243 Matrin-3 
PROF1 PFN1 P07737 Profilin-1 
SQSTM SQSTM1 Q13501 Sequestosome-1 
TADBP TARDBP Q13148 TAR DNA-binding protein 43 
TERA VCP P55072 
Transitional endoplasmic reticulum ATPase (valosin-
containing protein) 
UBQL2 UBQLN2 Q9UHD9 Ubiquilin-2 
Ubiquitinated proteins associated with ALS and/or proteostasis related 
Protein Gene UnitProt Protein Name 
ATX10 ATXN10 Q9UBB4 Ataxin-10 
CAND1* CAND1 Q86VP6 Cullin-associated NEDD8-dissociated protein 1 
CLUS CLU P10909 Clusterin 
CUL3 CUL3 Q13618 Cullin-3 
NED4L NEDD4L Q96PU5 E3 ubiquitin-protein ligase NEDD4-like 
PSD12* PSMD12 O00232 26S proteasome non-ATPase regulatory subunit 12 
SAE2 UBA2 Q9UBT2 SUMO-activating enzyme subunit 2 
SRS10 SRSF10 O75494 Serine/arginine-rich splicing factor 10 
SUMO1 SUMO1 P63165 Small ubiquitin-related modifier 1 
SUMO2 SUMO2 P61956 Small ubiquitin-related modifier 2 
TBB3 TUBB3 Q13509 Tubulin beta-3 chain 
TBB4A TUBB4A P04350 Tubulin beta-4A chain 
TUBB TUBB P07437  Tubulin beta chain 
TUBB4B TUBB4B P68371 Tubulin beta-4B chain 
UBA1 UBA1 P22314 Ubiquitin-like modifier-activating enzyme 1 
UBA52 UBA52 P62987 Ubiquitin-60S ribosomal protein L40 
UBE2N UBE2N P61088 Ubiquitin-conjugating enzyme E2 N 
UBE3A UBE3A Q05086 Ubiquitin-protein ligase E3A 
UBP2L UBAP2L Q14157 Ubiquitin-associated protein 2-like 
UBP5 USP5 P45974 Ubiquitin carboxyl-terminal hydrolase 5 
UBP7 USP7 Q93009 Ubiquitin carboxyl-terminal hydrolase 7 
UBQL1* UBQLN1 Q9UMX0 Ubiquilin-1 
UBR5 UBR5 O95071 E3 ubiquitin-protein ligase UBR5 
UBXN1 UBXN1 Q04323 UBX domain-containing protein 1 
USP9X* USP9X Q93008 Probable ubiquitin carboxyl-terminal hydrolase FAF-X  
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5.4.5 The ubiquitinomics profile of the two terminally differentiated cell stages in 
multiple cell lines are significantly different 
A comparison of the ubiquitinated proteins of significantly higher abundance in 
fibroblasts and iPSC derived motor neurons further highlighted the cell type 
dependent regulation governed by the ubiquitome (as visualised by volcano plot; 
Figure 5.15).  STRING analysis indicated only eight ubiquitinated proteins were 
commonly increased in fibroblasts compared to motor neurons in all cell lines. Of 
these proteins, seven were extracellular exosomal proteins.  An additional 25 
ubiquitinated proteins were commonly increased in fibroblasts all lines except the 
CCNF2 line. Combined, these 33 proteins were associated with a range of protein-
interaction pathways.  Eight ubiquitinated spliceosomal proteins were significantly 
more abundant in fibroblasts.  Interestingly, four cytoskeleton proteins were 
increased in fibroblasts - tenascin C (TNC), CD44, fibronectin 1 (FN1), and 
thrombospondin 1, (THBS1), and 20 proteins were associated with the extracellular 
exosome/extracellular region cellular component.  By comparison, only 20 proteins 
were increased in all cell lines examined in motor neurons compared to fibroblasts 
The only commonality between these proteins was the Cellular Component in which 
they were increased - the cytosol. No Biological Component or KEGG protein 
interactions were shared in these commonly increased ubiquitinated proteins.  
 243 
 
 
 
Figure 5.15 Representative volcano plot comparing fibroblasts to motor neurons 
Data represents ubiquitinated protein expression in CCNFS621G patient derived in 
fibroblasts compared to motor neurons. Proteins significantly increased in abundance  
(P<0.01) indicated in red. 
 
 Sharing the same trend as other cell stage comparisons, the common proteins 
significantly increased in all cell lines except the symptomatic CCNFS621G patient 
(CCNF2) were far more numerous: 79 proteins were commonly increased in motor 
neurons compared to fibroblasts. Combined, these 99 proteins were examined for 
interactions.  When grouping the protein interactions by Biological Process (46 
pathways were identified), 16 of these ubiquitinated proteins increased in motor 
neurons compared to fibroblasts were associated with RNA processing, including 
splicing, and stabilisation. Five proteasomal proteins were also increased as 
ubiquitinated proteins in motor neurons including small ubiquitin-related modifier 2 
(SUMO2), ubiquitin-like protein-4A (UBL4A), clusterin (CLU), ubiquilin-1 
(UBQLN1) and ubiquilin-2 (UBQLN2).   Examination of the protein interactions by 
Molecular Function protein interactions revealed approximately one third of the 99 
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proteins were associated with poly(A) RNA binding. As mentioned, many of these 
proteins were also classified as neuron specific components such as neuronal cell 
body (10), neuron projection (13), myelin sheath (12), dendrite (8), microtubule (8), 
and vesicles (52) components.  Mitochondrial proteins (12) were also increased in 
this classification (Molecular Function) in motor neurons compared to fibroblasts.   
 
All increased ubiquitinated proteins from the comparison of fibroblasts and iPSC 
derived motor neurons were analysed for network changes using Cytoscape (Figure 
5.16).  Similar to the comparison between fibroblasts and iPSCs, ECM associated 
proteins changed, with an increased abundance in two proteins in motor neurons and 
three proteins in fibroblasts. Exosomal proteins also exhibited changes within this 
pathway comparison: 15 exosomal proteins increased abundance in motor neurons, 
and two exosomal proteins increased in fibroblasts, suggesting a change in the 
regulation required in the motor neurons comparatively. As would be expected 
axogenesis proteins (3) again increased in ubiquitination abundance in the motor 
neurons compared to fibroblasts, similar to the comparison with iPSCs and motor 
neurons.  Most pronounced, however were again changes to the spliceosome, which 
accounted for approximately one third of the significantly different ubiquitinated 
proteins in this comparison. Interestingly, there were significant differences in the 
abundance of spliceosomal proteins in both cell types, highlighting the cell specific 
role of the spliceosome; this strongly suggests that ubiquitin is an important regulator 
of this cellular mechanism.  
 245 
 
 
 
Figure 5.16 STRING map of ubiquitinated protein significantly different in 
fibroblasts compared to motor neurons in lysates examined 
Lysates compared were derived from a pre-symptomatic CCNFS621G ALS patient 
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), and a healthy donor 
(HC2) and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative 
control.  Higher protein abundance in fibroblasts indicated in blue, motor neurons in 
cyan.  Significance determined by Student T-test (Threshold P>0.01). 
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5.4.6 Proteasomal inhibition has greatest effect on iPSCs, followed by motor 
neurons, compared to fibroblasts 
 
Following the identification of the widespread involvement of the UPS in such a 
variety of cellular pathways at each of the three cell stages investigated, we sought to 
determine the effects of inhibition of the UPS on the maintenance of these cell stages 
and the course of differentiation.  We compared the viability of the cells from each 
cell stage (fibroblasts, iPSCs and motor neurons) to those treated with proteasome 
inhibitor MG132, treated concurrently, in six biological replicates (from the six 
individuals examined in this study) (Figure 5.17).   
 
Cells from all biological samples, from all cell stages showed a dose dependent 
decrease in viability, inversely correlating to MG132 concentration which ranged 
from 1 μM – 250 μM.  Fibroblasts showed the lowest rate of change in viability, with 
a TC50 calculated at 149.8 μM MG132. The iPSC derived motor neurons were more 
susceptible to MG132 compared to fibroblasts. A mean TC50 was calculated at 43.3 
μM MG132. Intriguingly, the highest susceptibility to proteasomal stress was 
exhibited in iPSCs.  MG132 treatment was lethal to 100% of iPSC colonies at all 
concentrations tested.  Vehicle controls and no treatment control exhibited normal 
proliferation, increasing confluence by ~140% over 16 hours (Figure 2A). The iPSC 
colonies detached in as little as three hours at 1 μM MG132, the lowest concentration 
tested.  This cell death was consistent amongst all of the six biological replicates, in 
100% of cells as measured by Trypan Blue following 16 hours of incubation.  By 
comparison, neither fibroblasts nor motor neurons showed this level of toxicity to 
MG132. 
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Figure 5.17 Cellular viability decrease was inversely correlated to increasing MG132 
concentration 
MG132 was incubation for 16 hour treatment in firboblasts, iPSCs and motor 
neurons, compared to vehicle control.  iPSC viability was severely affected by 
MG132 treatment at the same concentrations as fibroblast and motor neuron 
treatments. Following 16 hour treatment, no iPSCs remained attached to culture dish; 
detached cells were determined dead by Trypan Blue.  
TC50 = 43.3 μM 
TC50 = 149.8 μM 
A 
B 
C 
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5.4.7 E1 inhibition detrimental to motor neuron viability 
To further investigate the importance of the ubiquitin system in the development of 
motor neurons we inhibited E1 ubiquitin binding protein UBA1 during motor neuron 
differentiation. UBA1 is a central regulator of the UPS, and mutations in UBA1 have 
previously been identified to cause the motor neurone disease spinal muscular 
atrophy (Groen and Gillingwater, 2015; Ramser et al., 2008).  Neurite outgrowth was 
monitored 24 h following treatment with the UBA1-specific inhibitor PYR41 during 
motor neuron differentiation (Figure 5.18). Neurite analysis revealed a decrease in 
neurite length in motor neuron precursor cells in all six biological replicates when 
treated with 10 µM PYR41. Neurite length was significantly decreased in three of 
these cell lines compared to vehicle control (0 µM PYR41) treated motor neuron 
precursors (from both ALS derived and healthy control derived cells) with one donor 
cell line exhibiting an approximately two-fold decrease in neurite length.  
 
To determine the long-term effects of UBA1 inhibition, and thus ubiquitin system 
stress on motor neuron development, we treated motor neuron precursors with a low 
dose (1 µM PYR41) and a higher dose of UBA1 inhibitor (10 µM PYR41) over the 
course of differentiation (Figure 7.19; Appendices Figures 8.17 - 8.19). Motor 
neuron precursors were dosed and imaged on alternative days.  Over the course of 
three doses of 10 µM PYR41, motor neuron precursors showed decreased neurite 
outgrowth and decreased cellular integrity. Cell death was evident by day 6 of the 
differentiation in all motor neuron precursors.  Precursors treated with 1 µM PYR41 
exhibited no significant difference in neurite outgrowth following four weeks of 
treatment compared to the vehicle control.   
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Despite no morphological differences, there was a clear decrease in viability of cells 
following four weeks of treatment with 1 µM PYR41 (Figure 5.20). Cell viability 
assay of the motor neurons at the end stage of the treatment revealed a significant 
decrease in the viability of the cells in the five biological replicates (As indicated by 
Student T-test, t=2.642, 5. P= 0.0459). 
 
 
Figure 5.18 Neurite outgrowth of motor neuron precursors following 24 hour 
treatment with UBA1 inhibitor PYR41 
Concentrations ranging from 1 µM – 10 µM PYR41 elicited a dose dependent 
response across six biological replicates, derived from a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS 
patient (CCNF2), and a healthy donor (HC2) and a sporadic Alzheimer’s disease 
male (SAD). Significant difference determined by ANOVA *P<0.05, ***P<0.001.  
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Figure 5.19 Representative graph of neurite outgrowth in motor neurons precursors  
Neurite outgrowth was monitored for 4 weeks of culture with UBA1 inhibitor 
PYR41 at high (10 µM) and low (1 µM) concentrations in the six biological 
replicates. Neurite outgrowth was unaffected by long-term low dose PYR41 
treatment, high dose PYR41 (10 µM) treatment resulted in cell death. Data shown 
from the CCNF1 cell line, derived from a pre-symptomatic CCNFS621G ALS donor. 
Significant difference tested via ANOVA P>0.05.  
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Figure 5.20 Motor neuron viability following low concentration UBA1 inhibition 
Cellular viability of PrestoBlue assay in motor neurons following alternate day 
treatment with UBA inhibitor PYR41 (1 µM) during the maturation of motor neurons 
measured by fluorescence emission at 590 nm compared to vehicle control across six 
biological replicates, derived from a healthy donor (1; HC1), a CCNFS621G ALS 
patient (2; CCNF1), a CCNFS621G ALS patient (3; CCNF2), a SOD1E101G ALS patient 
(4; SOD1), and a healthy donor (5; HC2). Significant difference assessed via Student 
T-Test *P<0.05. 
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5.5 Comparison of motor neuron ubiquitomes 
 
To further investigate if there were significant differences in the ubiquitination of 
protein pathways in motor neurons derived from individuals (inlcuding ALS 
patients), analysis of the different motor neuron cell lines was performed.  An 
ANOVA analysis was performed comparing the quantified ubiquitinated proteins 
expressed in each cell line. STRING analysis for protein interactions was then 
performed for the significantly different proteins expressed in the CCNF2 line, which 
had repeatedly exhibited differences in UPS activity.  A group of 423 ubiquitinated 
proteins were significantly different in the CCNF2 cell line. These results could be 
further sub-grouped into ubiquitinated proteins that were significantly different only 
between the HC2 (22), proteins that were only significantly different between 
CCNF2 and all other cell line proteins only (92), significant differences between 
HC2 and all other cell lines only (50) and all other assorted combinations wherein 
CCNF2 are significantly different (259) (Table 5.2). 
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Table 5.2 Summary of analysis of all proteins significantly different between 
CCNF2 and HC2 
Significantly 
different 
between:  
Total 
HC2 vs 
CCNF2 
CCNF2 vs all 
cell lines 
exclusively 
Assorted 
CCNF2 
HC2 vs 
all cell 
lines 
Significant difference present (ANOVA comparisons) 
HC2 vs. CCNF2 Yes Yes Yes Yes Yes 
HC2 vs. CCNF1 Yes/No No No Yes/No Yes 
HC2 vs. SAD Yes/No No No Yes/No Yes 
CCNF1 vs. CCNF2 Yes/No No Yes Yes/No No 
CCNF1 vs. SAD Yes/No No No Yes/No No 
CCNF2 vs. SAD Yes/No No Yes Yes/No No 
Proteins significantly different (ANOVA) 
Number of proteins 423 22 92 259 50 
Pathways with Significant Interactions (indicated by STRING) 
KEGG  20 0 0 7 0 
Biological Process 372 0 29 232 14 
Cellular Component 134 4 34 84 11 
Molecular Function 55 0 7 45 1 
 
Analysis of the interactions of the 432 ubiquitinated proteins significantly different 
between lysates via KEGG analysis indicated 20 pathways were increasingly 
represented - this included 12 spliceosomal proteins, 5 proteasome proteins, 11 
phagosomal proteins, 4 TCA proteins, 9 tight junctions, 11 focal adhesion, and 
interestingly, 9 proteins previously associated with Parkinson’s disease (which are 
predominantly mitochondrial proteins, when classified by Cellular Component) were 
significantly different between motor neurons from the CCNFS621G derived motor 
neurons (CCNF2) and the healthy donor derived cell lines (HC2).  Of the nine 
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significantly different proteins identified as belonging to this network, six of these 
were mitochondrial proteins. Two of these proteins were subunits of mitochondrial 
ATP Synthase; the abundance of these proteins was varied between the healthy 
control motor neurons and the symptomatic CCNFS621G (CCNF2) line. Three proteins 
were NADH dehydrogenase subunit proteins; all of these proteins were significantly 
decreased in CCNF2 compared to the healthy control. The ubiquitinated cytochrome 
C oxidase subunit protein was significantly more abundant in the CCNF2 line 
compared to the healthy control.  
 
Examining the protein interactions via STRING, revealed over 370 different 
Biological Processes were differently ubiquitinated in the symptomatic CCNFS621G 
(CCNF2) cell line compared to the healthy control line.  The top ten processes 
included a number of processes that have already been associated with ALS - 
including cellular transport, cellular stress and gene expression processes, as well as 
neuronal differentiation (Table 5.3). 
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Table 5.3 Significantly different Biological Processes between the healthy control 
(HC2) and symptomatic CCNF2S621G (CCNF2) motor neurons 
Ten most abundant Biological Processes significantly different 
between the healthy donor-derived (HC2) and a CCNFS621G ALS 
patient-derived (CCNF2) motor neurons  
Biological Process  
Number of 
proteins 
False Discovery 
Rates 
Organelle organization 105	 1.78E-09	
Transport 102	 3.93E-05	
Response to stress 102	 4.45E-0.5	
Cell differentiation 100	 2.73E-06	
Gene expression 99	 0.0379	
Protein localization 72	 1.79E-08	
Intracellular transport 66	 2.08E-10	
Neurogenesis/generation of neurons 54	 4.58E-05	
Cellular response to stress 54	 0.00167	
Vesicle-mediated transport 50	 5.72E-06	  
 
Pathways previously associated with dysfunction in ALS were highlighted in this 
analysis - processes such as proteostasis associated processes, endoplasmic reticulum 
localization (15), RNA splicing (22), as well as synaptic processes (via synaptic 
vesicle associated; 19), and microtubule organization (39) were significantly 
different (Figures 5.22 - 5.29).   
 
When examining the Cellular Component protein interactions (grouped localisation 
of these signficantly increased ubiqutiinated proteins), proteins localised (not 
necessarily exclusively) in vesicles (46%), the nucleus (44.4%), in the 
endomembrane (25%), cytoskeleton (17.5%), and mitochondria (14%).  There were 
22 ubiquitinated proteins only significantly different in between only CCNF2 and the 
healthy control - these were enriched for four cellular components - 13 were 
associated with extracellular exosomes and the extracellular region (the same 13 
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proteins), and 20 were associated with membrane/membrane-bounded organelle 
components of the cell. Additionally, 11 membrane proteins were also classified as 
the extracellular component associated proteins.   
 
An ANOVA analysis revealed close to a quarter of the total ubiquitinated proteins 
were significantly different between CCNF2 and all other cell lines (exclusively).  
Examining only these proteins via STRING indicated 29 Biological Processes, 
including organelle organization (26 proteins), regulation of ER-associated ubiquitin-
dependent protein catabolic process including ubiquitin like protein 4A (UBL4A) 
ubiquilin 2 (UBQLN2), and ubiquitin-specific protease 14 (USP14), proteasomal 
ubiquitin-independent protein catabolic process including proteasome subunit -A1, -
A6 and B5 (PSMA1 PSMA6, PSMB5).  Interestingly, two mitochondrial proteins 
mitochondrial ATP-dependent protease lon (LONP1), and stomatin-like protein 2 
(STOML2) registered as the Biological Process of regulation of mitochondrial DNA 
replication.  Together, these proteins were associated with over 30 Cellular 
Compartments, and belonged to 7 molecular function-enriched groupings.   
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Figure 5.21 STRING map of ubiquitinated protein significantly different in iPSC 
derived motor neurons  
Comparison was between CCNFS621G ALS patient (CCNF2) and a healthy donor 
(HC2) and other cell lines. iPSC derived motor neuron lysates from motor neurons 
from a CCNFS621G ALS patient (CCNF1) and  a sporadic Alzheimer’s disease male 
(SAD) as a neurodegenerative control were also compared.  Significance determined 
via ANOVA minimum of P<0.05. 
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Figure 5.22 Dotplot of proteostasis associated proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared to 
pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001.   
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Figure 5.23 Dotplot of proteasomal proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared to 
pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.24 Dotplot of ubiquitin associated proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared 
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.25 Dotplot of spliceosomal proteins expressed in motor neurons significantly different in abundance. 
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared 
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).  N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.26 Dotplot of glycoxylate/dicarbocylate metabolism proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared 
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.27 Dotplot of focal adhesion proteins expressed in motor neurons significantly different in abundance  
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared 
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.28 Dotplot of synaptic vesicle associated proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared 
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via 
STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with 
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and 
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, ****P<0.0001. 
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Figure 5.29 Dotplot of synaptic vesicle associated proteins expressed in motor neurons significantly different in abundance 
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also 
compared to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were 
classified via STRING analysis (High Confidence setting).   N = 3 differentiation replicates minimum. All data shown significantly different via 
ANOVA with post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference 
between HC2 and CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332,  **P<0.0021, ***P<0.0002, 
****P<0.0001. 
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5.6 Discussion 
 
Despite the increasing use of both iPSCs and iPSC derived motor neurons in medical 
research no study has yet examined the changes to the human ubiquitome following 
cellular reprogramming of primary cells to iPSCs, or the effects of differentiation to 
motor neurons on this landscape.  By engaging ubiquitin-filtering techniques 
combined with tandem mass spectrometry this study has, for the first time, mapped 
the global ubiquitinated proteome of iPSC derived motor neurons and derivative cell 
types (iPSCs and fibroblasts).  Comparison of lysates from fibroblasts, iPSCs, and 
motor neurons following (I) reprogramming, and (II) differentiation, indicated 
significant changes in the ubiquitome in a broad range of pathways including heat 
shock, cytoskeletal, and the spliceosome system, which are undoubtedly important to 
the intrinsic properties of these cell types (Chen and Moore, 2015; Fan, 2012; Kim et 
al., 2017; Omori et al., 2014; Tai and Schuman, 2008). Further probing of the 
importance of the UPS in these cellular stages indicated significant decreases in 
viability following UPS inhibition.  This study also importantly, for the first time, 
detects significant differences between ubiquitomes of motor neurons derived from 
ALS patients and those derived from healthy individuals.  Comparison of the 
collective ubiquitomes at the three fundamental stages of iPSC-motor neuron 
modelling indicated significant cell stage specific differences in the pathways 
regulated by ubiquitin. Changes in abundance of ubiquitinated proteins essential to 
both pluripotency maintenance, as well as motor neuron differentiation reiterated the 
dynamic and central role of the ubiquitin proteasome system, in regulating a wide 
spanning network of systems (Hershko and Ciechanover, 1998). 
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5.6.1 The dynamic landscape of the ubiquitome changes following iPSC-
reprogramming 
Comparisons of iPSCs and the derivative fibroblast cell stage revealed numerous 
changes in the ubiquitinated protein landscape.   Reprogramming of fibroblasts to 
iPSCs led to changes in the abundance of ubiquitinated heat shock associated 
proteins, as well as a significant lowering in the abundance of ubiquitinated ECM 
proteins. Conversely, increases in the ubiquitinated spliceosomal and poly(A) RNA 
binding proteins were evident in iPSCs.  Together these highlight the changing role 
of these pathways in the generation of these pluripotent cells, and the likely changing 
requirement of the ubiquitome in regulating these systems.  
 
5.6.1.1 Regulation of heat shock protein changes upon reprogramming 
The ubiquitinated forms of Hsp27 (encoded by HSPB1), and Annexin 2 were 
significantly changed following reprogramming.  Regulation of the heat shock 
protein network by the UPS via HSF1 ubiquitination has been previously reported in 
human cell lines including neuroblastoma cells (Kim, 2017; San Gil et al., 2017), 
however little is known regarding the regulation of the heat shock proteins by 
ubiquitination in pluripotency. It is believed that many heat shock proteins have been 
associated with maintenance of pluripotency. Increased expression of the heat shock 
protein Hsp90 has been shown to decrease the ability of ESCs to differentiate to 
other cell types (Bradley et al., 2012; Cheng et al., 2016).  Similarly, Hsp70 has been 
shown to regulate pluripotency by facilitating OCT4 binding to DNA in human 
embryonic carcinoma cells (Geng et al., 2015).  Moreover, a previous study indicated 
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proteasomal inhibition in ESCs correlated with a reduction in HSP70 and 
pluripotency factors  - including OCT4 and nanog (Park et al., 2012). The increased 
levels of the ubiquitinated form of these heat shock proteins in iPSCs could therefore 
indicate that ubiquitin is not necessarily acting as a degradation signal in these cells, 
but as a conformational alteration, to change the function of the heat shock proteins. 
Following these results, it would be of value to better understand the role of 
ubiquitination of the heat shock proteins in the maintenance of iPSCs, and during 
neuronal differentiation. 
 
5.6.1.2 Cytoskeletal and ECM proteins decreased in iPSC ubiquitome 
The rapid detachment of the iPSCs following UPS inhibition was particularly 
noteworthy given the changes in abundance of ubiquitinated proteins associated with 
focal adhesion/ECM interactions. Ubiquitinated forms of both a fibrillar (type 1) and 
non-fibrillar collagen (type 6) were downregulated in iPSCs.  A reduction in these 
collagen levels may also be due to an overall decrease in the presence of these 
proteins, which has been previously reported in a comparison of mouse fibroblast 
and mouse iPSCs and ESCs (Hao et al., 2013). This previous work indicated mouse 
pluripotent stem cells had a lower abundance of cell adhesion and cytoskeletal 
proteins, compared to tail tip fibroblasts, from which the mouse iPSCs were derived 
(Hao et al., 2013).  Total proteomic analysis of the mouse lines also indicated that 
ANXA1, ILK, collagens 1 (A1) and 6 (A1 and A2), LGALS1 and LGALS3 were 
significantly decreased in mouse iPSCs compared to the fibroblasts from which they 
derived.  This is also corroborated by findings that mouse ESCs (2i) expressed a 
decrease in nine cell adhesion proteins and seven cytoskeletal proteins compared to 
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the mouse ESC being differentiated in serum (Taleahmad et al., 2016).  Collectively, 
the decrease observed suggests that the decreased levels of ubiquitination could be 
due to the ubiquitin mediated degradation of these proteins following 
reprogramming, or a that these proteins are decreased in iPSCs, regardless of 
ubiquitination.  It is not clear why these pathways are decreased in pluripotency. It is 
important to consider that ECM proteins are added to iPSC cultures; Matrigel, which 
has been analysed to be 30% collagen IV, as indicated by the analysis performed in 
1982 (Kleinman et al., 1982). More recent analysis by LC-MS identified collagen I, 
3A1, 6A1 and 6A2 were present in Matrigel composition (Hughes et al., 2010).  
Further understanding of how iPSCs regulate ECM associated proteins will 
undoubtedly prove valuable given that ECM proteins remain one of the major costs 
of stem cell maintenance, and remain a source of variability in cultures (Hughes et 
al., 2011).   
 
5.6.1.3 Ubiquitinated spliceosomal proteins increased in iPSCs upon 
reprogramming  
The ubiquitination of ten spliceosomal proteins were commonly significantly 
increased in iPSCs compared to both fibroblasts and motor neurons.  Two of the 
proteins identified as more abundant in iPSCs, TRA2A, TRA2B have been 
previously reported as being increased in iPSCs (Munoz et al., 2014). Whether this 
higher abundance in iPSCs indicates regulation of abundance via ubiquitin signalled 
degradation, or is the result ubiquitin-mediated of spliceosomal regulation is unclear.  
Spliceosomal proteins, by their very nature, are modulators of cellular identity 
(Matera and Wang, 2014). The depletion of specific spliceosomal proteins have been 
known to cause a loss of pluripotency (Kim et al., 2017), and are altered in the event 
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of differentiation.  The ubiquitination of spliceosomal factors is under-explored in 
the context of pluripotency and differentiation, compared to other post-translational 
modifications, despite the importance of the spliceosome in both these processes 
(Graveley, 2011; Tsuiji et al., 2013).  Mutant ubiquitin has been shown to inhibit 
splicing events (Bellare et al., 2008). Collectively, these findings present a strong 
argument for further investigation of the ubiquitin regulation of spliceosomal events 
in differentiation given the potential importance of spliceosomal pathways in 
managing cellular fate.   
 
Ubiquitinated poly(A) RNA binding proteins were also identified as also being 
increased in iPSCs following reprogramming from fibroblasts.  Poly(A) RNA 
binding proteins are responsible for the additional of adenosine stretches to RNA 
transcripts, referred to as RNA polyadenylation.  This polyadenylation of RNA has 
been linked to transcript stability, localization, and subsequent translation (Ye and 
Blelloch, 2014).  This adenylation may occur at more than one poly(A) site on a 
transcript (in a process known as alternate polyadenylation) (Elkon et al., 2013).  
Poly(A) tail length affects mRNA abundance thereby regulating cellular protein 
levels. Short tails are thought to result in transcript degradation (Sach, 1970), while 
longer tails are associated with cellular proliferation (Ye and Blelloch, 2014).  Given 
the increase in proteins associated with this process following reprogramming, 
further investigation into this protein regulating mechanism would be of great value - 
specifically, examining the poly(A) tail lengths of proteins, and the regulation of 
pluripotency by the UPS. 
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5.6.1.4 No ubiquitin modification detected in OSKM factors 
Only one other study to date has investigated the global changes to ubiquitin during 
iPSC reprogramming - Buckley et al. compared mouse embryonic fibroblasts 
(MEFs), mouse iPSCs, and mouse ESCs (Buckley et al., 2012). This study found 
some similarities in the proteins ubiquitinated in human iPSCs with the combined 
MEF-iPSC ubiquitome reported.  Species differences, as well as varying data 
filtering techniques may contribute to differences between the datasets. In addition, 
as stem cells in this study were cultured under feeder-free conditions, there is no 
contribution of the MEF ubiquitome to our human iPSC dataset. This was not 
possible for Buckley et al. as their datasets could not distinguish the ubiquitomes of 
iPSCs and MEFs, due to the requirement of co-culturing stem cells on MEFs.  
 
Buckley et al. (2012) identified novel ubiquitinated pluripotency regulating proteins, 
including the reprogramming transcription factors, Oct4 and Nanog, which were 
reported in mouse iPSCs-MEF dataset (Buckley et al., 2012). Ubiquitinated Oct4 and 
Nanog were not detected in human iPSCs in this study, despite confirmation of the 
expression of these proteins via immunocytochemistry and/or qRT-PCR.  The 
absence of these proteins in the ubiquitome suggests that the ubiquitination of 
pluripotency factors is not required to maintain pluripotency in human iPSCs. 
Instead, it may be that ubiquitination causes a downregulation of these proteins, 
required for differentiation. This was indeed reported in mice, whereby inhibiting 
polyubiquitination of N-myc and c-myc inhibited neural differentiation of mESC 
(Zhao et al., 2008).  The ubiquitination in this scenario is thus potentially promoting 
degradation of these pluripotency factors by the proteasome to permit differentiation.   
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5.6.2 Fundamental motor neuron pathways ubiquitinated in iPSC derived motor 
neurons 
Comparison of the collective ubiquitomes from iPSCs and motor neurons suggested 
a shift in the role of ubiquitin.  Differentiation of the stem cells resulted in a decrease 
in ubiquitinated cell cycle proteins, and an increase in the presence of ubiquitinated 
spliceosomal, cytoskeletal, and synaptic proteins. Qualitative analysis confirmed the 
presence of motor neuron proteins and ALS relevant proteins further validating the 
usefulness of these models. 
 
5.6.2.1 Ubiquitinated cell cycle proteins decreased in iPSC-motor neuron 
differentiation  
Ubiquitinated MCM proteins were significantly decreased following the 
differentiation of iPSCs to motor neurons.  These MCM proteins combine to form a 
DNA helicase. Accordingly, these proteins are associated with cell cycling, and 
activity is known to decrease upon differentiation (Matson et al., 2017).  This is not 
the first reporting of regulation of MCM proteins via ubiquitin.  Ubiquitination of 
MCM proteins has been indicated to influence the activity of these proteins, for 
example ubiquitination of MCM10 alters the binding affinity of this protein to DNA 
polymerase (Gilberto and Peter, 2017). MCM7 ubiquitination has been found to be 
restrictive for replication forks (Maculins et al., 2015). Ubiquitin is therefore likely to 
play an important role in the regulation of DNA replication.  Further studies will be 
required to indicate to what extent the ubiquitination of these MCM proteins is 
homogenous, and what to verify what purpose it serves in these cells.  Given that the 
ubiquitination is a known requirement for the regulation of MCM proteins, the 
absence of these ubiquitinated proteins in the motor neurons is consistent with the 
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expectation that DNA replication processes are no longer occurring in motor 
neurons, and suggests this is a decrease in this pathway as a whole (García-
Rodríguez et al., 2016). 
 
5.6.2.2 Microtubule and synaptic proteins increased upon differentiation 
Microtubule-associated proteins and tubulin proteins were detected at significantly 
higher abundances in the ubiquitome following differentiation, reiterating previous 
findings that ubiquitin is an important modulator of cytoskeletal structures (Hamilton 
and Zito, 2013). This is also likely a reflection of the general increase of these 
proteins in the differentiating cells.  Unsurprisingly, synaptic proteins were 
increasingly found in the motor neurons.  This regulation of synaptic proteins is 
particularly interesting as previous findings suggest that even small alterations to the 
ubiquitination of synaptic proteins can lead to motor neuron death (Liu, Y et al., 
2015).  The iPSC derived motor neurons therefore present a suitable model system 
for probing these pathways, which are fundamental to motor neuron function, and are 
affected in motor neurone diseases. 
 
5.6.2.3 Mitochondrial ubiquitination increases following differentiation 
When considering the comparison between cellular states, mitochondrial proteins 
were significantly more abundant in motor neurons than in iPSCs.  This is consistent 
with an overall increase in mitochondrial count following differentiation from a stem 
cell state; two previous reports examining the number of mitochondria in hESC 
compared to differentiated cell indicated an increase in the mitochondrial mass and 
mtDNA in differentiated cells (Lonergan et al., 2007).   This reflects the changing 
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demand of the cells - stem cells are maintained in a glycolytic state, whereas motor 
neurons rely on oxidative phosphorylation for the generation of ATP (Zhang et al., 
2018). 
 
5.6.2.4 Ubiquitinated spliceosomal protein profile shifts in motor neurons  
Comparison of ubiquitinated spliceosomal proteins in motor neurons with both other 
cell types indicated changes to this cellular process. A decrease in the number of 
ubiquitinated proteins following reprogramming, as well as a shift in the 
spliceosomal proteins ubiquitinated in fibroblasts is, again, a likely reflection of the 
cell stage specific activity of the spliceosomal system.  Changes to spliceosomal 
proteins and RNA splicing/processing/stabilising proteins were evident when 
comparing the terminally fated cell lines, motor neurons and fibroblasts. A variety of 
proteins were found to be increased in fibroblasts and motor neurons alike, indicating 
a shift in the RNA processing proteins required to maintain these cellular states. As 
aforementioned, spliceosomal and RNA processing proteins are crucial regulators of 
cellular fate (Papasaikas and Valcárcel, 2016); that this distinct shift is evident in 
these different cell types is a testament to the importance of the UPS in regulating 
cell fate. 
 
5.6.3 iPSCs and motor neurons more susceptible to UPS stress compared to 
fibroblasts 
Following previous reports of an increased sensitivity in motor neurons to UPS 
stress, and the known vulnerability of motor neurons ALS to proteostasis dysfunction 
(Tai and Schuman, 2008; Yerbury et al., 2016), in combination with the extensive 
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differences in the ubiquitome of the different cell stages examined in this study, we 
sought to investigate the effects of UPS stress in motor neurons and derivate cell 
stages.  The UPS is important in maintaining pluripotent stem cells in even the 
lowest doses. It was clear that the UPS is vital to iPSCs maintenance, as indicated by 
the fatal response in iPSCs to inhibition of the UPS. All six human iPSC lines 
examined in this study exhibited an extreme sensitivity to proteasomal inhibition via 
MG132 treatment, compared to simultaneously treated fibroblasts and iPSC derived 
motor neurons.  While fibroblast and motor neuron viability was inversely correlated 
to MG132 concentrations, indicating a dose dependent response, iPSCs showed a 
rapid deterioration following MG132 treatment, even at the lowest concentrations 
tested.  MG132 at 1 µM was sufficient to cause cell death of iPSCs in five biological 
replicates within 16 hours. Monitoring via live cell imaging indicated that cellular 
detachment was evident at concentrations of 1 µM in only three hours.   Further 
preliminary testing by others in the Ooi laboratory identified that iPSCs were 
sensitive at concentrations as low as 10 nM MG132, leading to 80% cell death within 
16 hours (data not shown). Interestingly, UPS inhibition has previously been reported 
to have this effect in mouse ESCs, with doses higher than 0.2 μM MG132 causing 
cytotoxic effects (Geis et al., 2017), together these findings highlight the importance 
of the UPS in stem cell survival.   
 
Previous reports have suggested that proteasomal activity is increased in stem cells 
compared to fibroblasts (Vilchez et al., 2012), which may suggest an increased 
reliance of iPSCs on the proteasomal system. Again, it would be interesting to 
identify the type of ubiquitination occurring in these cells, whether the ubiquitination 
of the subunits is a conformation/activity modifier, or if the ubiquitin modification is 
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a degradation signal due to an over-production of these proteins.  Vilchez et al. 
(2012) identified a lower level of polyubiquitin chains and an increase in protease 
activity when normalised to total protein in iPSCs compared to other cell types. An 
increase in polyubiquitination is not necessarily indicative of decreased proteasomal 
function, and the polyubiquitin signal may provide a range of complex functions, 
including regulating cellular signalling (Alfano et al., 2016). The ratio of 
proteasomes to total protein is also an interesting consideration when comparing 
different cell types.  The ratio of total protein to proteasome is crucially important, 
since total protein changes within cell types (Pontén et al., 2009); This changes the 
ratio of protein required to be degraded by the proteasome, and thus the required 
number of proteasomes per cell to maintain the same level percentage of protein 
degradation.   
 
5.6.3.1 Ubiquitinated proteasomal proteins most abundant in motor neurons  
In three of the four cell lines examined, five proteasomal proteins were significantly 
more abundant in motor neurons compared to fibroblasts; interestingly, some of 
these same proteins were also more abundant in motor neurons when compared to 
iPSCs.  This increase in proteasomal proteins may suggest a total increase in these 
proteins in motor neurons (not just the ubiquitinated form).  The increase in 
ubiquitinated proteasomal proteins did not correlate with the susceptibility to 
proteasomal stress as seen in iPSCs compared to the other two cell types.  
 
To further investigate the importance of the ubiquitin system in the development of 
motor neurons UBA1, an E1 ubiquitin binding protein, was inhibited during motor 
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neuron differentiation. UBA1 is a central regulator of  the UPS, and mutations in 
UBA1 have previously been identified to cause the motor neurone disease spinal 
muscular atrophy (Groen and Gillingwater, 2015; Ramser et al., 2008). Image 
analysis of neurite outgrowth following UBA1 inhibition revealed a decrease in 
neurite outgrowth in motor neuron precursor cells in all six biological replicates 
when treated with 10 µM PYR41; Neurite length was significantly decreased in three 
of these cell lines compared to vehicle control treated motor neuron precursors, with 
one donor cell line exhibiting an approximately two fold decrease in neurite length.  
Early characterisation via cell stage specific markers (pluripotency markers and 
motor neuron markers) did not indicate a difference in these cell stages suggesting 
this was not due to the capacity to differentiate. Admittedly however, it is 
increasingly evident in the field that high expression of cell type specific 
mRNA/protein expression may not fully indicate the ultimate state of these cells. 
Accordingly, further research is required to investigate the effects of these mutations 
on the cell lines, through dynamic physiological means such as electrophysiology.   
Combined, these data may inform an underlying cause of dysfunction to the UPS 
seen in these cells, and the potentially compensatory mechanisms.  
 
As the UPS is a two-part system it was also important to investigate the ubiquitin 
system specifically, by treating differentiating cells with an ubiquitin system 
inhibitor.  Neurite outgrowth following inhibition of apex E1 ubiquitin-binding 
enzyme UBA1 via 24 h monitoring following treatment with a concentration curve 
of PYR41 revealed a non-linear response in neurite outgrowth in neural precursors. 
Treatments ranging from 0 µM - 5 µM PYR41 showed no signficant difference in 
outgrowth, while 10 µM PYR41 significantly reduced the outgrowth. This was likely 
 278 
 
due to the redundancies of the ubiquitin proteasome system, allowing the cell to 
compensate for the inhibition at low doses (Tai and Schuman, 2008).  Long-term 
treatment options (selected from this short term study) followed this non-linear 
pattern. The total cell death in motor neuron precursors occurred following three 
treatments of 10 µM PYR41; low dose treatment of motor neuron precursors had no 
effect on neurite outgrowth viability.  This may suggest that the UPS system 
redundancies were overwhelmed at higher concentrations of the UBA1 inhibitor, 
which proved toxic to the cells. This would be unsurprising given the vast array of 
pathways we identified as being regulated by the ubiquitin system in motor neurons.  
Interestingly, though neurite length remained unaffected over a four-week low dose 
PYR41 treatment, this low level UBA1 inhibition by 1 µM PYR41 caused a decrease 
in cellular viability. This significant decrease in viability following 1 µM PYR41 
treatment coupled with an absence of difference in the neurite extension could 
indicate that a relatively normal development process is possible in the presence of 
mild UPS stress, though may still be detrimental to the long-term health of motor 
neurons.  This sensitivity to UBA1 inhibition may also be exacerbated in ALS-
derived motor neurons – further investigation into this would be of great value.  
 
5.6.4 Symptomatic CCNFS621G ALS patient derived motor neurons exhibit unique 
ubiquitome profile 
As a preliminary investigation into the ALS ubiquitome, the motor neuron lysates 
derived from a selection of the cell lines, including the motor neurons dervied from 
the two CCNFS621G patients, a healthy donor derived line, and a sporadic Alzheimer’s 
disease line were compared with two control lines (one healthy, one 
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neurodegenerative).  While the PCA of all samples examined indicated cellular 
lysates grouped primarily by cell stage, examination within cell stages indicated 
differences within the cell stages by cell type: in all three cell stages examined, the 
CCNF2 cell line, derived from a CCNFS621G ALS patient, grouped separate from the 
cell lines examined. The CCNF2 cell line showed a greater variety of ubiquitinated 
proteins than the other cell lines in all three of the cell stages, and exhibited a 
distinctly different ubiquitome. Commonalities between all cell lines examined were 
less numerous than expected, however when the CCNF2 cell line was excluded the 
number of commonly increased ubiquitinated proteins increased dramatically.  This 
could reflect differences in the capacity of the CCNF2 cells to reprogram and 
differentiate and in the future this should be probed by dynamic physiological 
methods.  This may also suggest that this cell line exhbits detectable differences in 
the ubiquitome of the fibroblasts, suggesting examination the ubiquitome in patients 
may present as a potential detection method for diagnosis, as previously suggested 
(Yang et al., 2015).  Increasing sample sizes, and additional clones originating from 
these same patient derived cells will be citical in further assessing this possibility.  
 
5.6.4.1 Mitochondrial differences in the symptomatic CCNFS621G patient derived 
cell line 
As the unique phenotype exhibited in CCNF2 was present in all three cell types, this 
may indicate a limited capacity of the mitochondria within these cells, which are 
retained following reprogramming.  In addition to changes in the abundance of 
ubiquitinated mitochondrial proteins in different cell stages, significant differences 
were also detected between the cell lines in motor neurons: Parkinson’s diseases 
associated proteins were identified by KEGG classification as being significantly 
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different in the symptomatic CCNFS621G patient derived cell line (CCNF2).  Two 
thirds of these Parkinson’s disease associated proteins were mitochondrial proteins.  
Ubiquitination of mitochondria signals autophagy (mitophagy) which can be the 
result of damage via reactive oxygen species (Harper et al., 2018).  Mitochondrial 
dysfunction can be retained through reprograming as unlike other organelles, which 
are simply degraded via cellular degradation pathways, mitochondria have a unique 
transmission process. While mitochondria are turned over via autophagy, they are 
more often renewed via mitochondrial fusion and fission (Terman et al., 2010).  This 
process provides the opportunity for daughter cells (and reprogrammed cells) to 
inherit defective mitochondria. Normally, defective mitochondria are signalled for 
degradation via parkin-induced ubiquitination of mitochondrial outer membrane 
proteins (that are yet to be fully defined in the field) (Narendra et al., 2008).  There is 
the potential that these mitochondrial proteins identified in this study may be 
involved in this process; Further verification in the ubiqitination of these 
mitochondrial proteins would therefore be pertinent. Together the dysfunction in the 
ALS line (regardless of cell stage) could indicate mitochondrial dysfunction is an 
early downstream pathways affected by UPS dysfunction.  A dysfunction in 
mitophagy is well documented in ALS (Desai et al., 2018), and linked to the 
accumulation of aberrant mitochondria seen in early ALS pathology  (Smith et al., 
2017); unsurprisingly reduced ATP production is common in ALS.   Mitochondrial 
dysfunction pathology has not been restricted to detection only in motor neurons - 
fibroblasts have been detected to have altered ATP production compared to healthy 
controls, and have been shown to have fragmentation in the mitochondrial network in 
C9ORF72 patient cells (Kirk et al., 2014; Onesto et al., 2016). It is premature to 
claim that the consistent differences in the UPS of the symptomatic CCNFS621G 
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patient derived cell line (CCNF2) throughout the cellular stages is linked with 
mitochondria. However, considering the inheritance of mitochondria through cellular 
stages due to transmission via mitochondrial fusion/fission (Scott and Youle, 2010), 
and the importance of ubiquitin in mitochondrial maintenance (Lavie et al., 2018), it 
would be greatly relevant to examine the mitochondrial network in these cells.  
Importantly, samples have been recently made available to the Ooi lab which were 
collected following symptom onset from the pre-symptomatic CCNFS621G patient 
(CCNF1), as well as CRISPR corrected clones, which for future investigations will 
be incredibly valuable in ascertaining the role of mitochondria in the CCNFS621G 
phenotype (Musunuru, 2013). 
 
5.6.4.2 Self-regulation of UPS differs in the symptomatic CCNFS621G patient 
derived cell line 
The ubiquitination of both ubiquitin and proteasomal proteins significantly differed 
in the symptomatic CCNFS621G patient (CCNF2) iPSC derived motor neurons.  Four 
of the five proteasomal proteins identified as being significantly different were 
decreased; this may suggest a decrease in total proteasomal proteins, and/or a 
decrease capacity to regulate the proteasome in the symptomatic CCNFS621G patient 
derived cell line (CCNF2).  A decrease in proteasomal function has been previously 
associated with ALS. In a comparison of spinal motor neurons collected at autopsy 
from ALS patients to both healthy controls and cerebral tissue (matched from the 
same patients), a decrease in activity in proteasomes, as well as a decrease in 
particular subunits (20SB5 and 19S5a) were detected (Kabashi et al., 2012). This 
decrease in the abundance of proteasomal proteins can broadly be labelled as a result 
of UPS dysfunction. It is however possible to speculate that the inappropriate 
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ubiquitination of these subunits leads to a decrease in the overall abundance of these 
units.  
 
5.6.4.3 Decreased abundance of ubiquitinated spliceosomal proteins in the 
symptomatic CCNFS621G patient derived cell line 
A decrease in eight of the nine spliceosomal proteins was evident in symptomatic 
CCNFS621G patient derived motor neurons (CCNF2) compared to the healthy control 
(HC2) motor neurons.  A loss of spliceosomal system integrity has previously been 
associated with ALS. Previous reports into the loss of spliceosomal system integrity 
in ALS found an increase in spliceosomal proteins - contrary to this study; these 
previous findings were however immunochemical findings in post mortem tissue, 
and therefore included proteins with a reduced solubility, which were not possible to 
detect through this ubiquitinomics method (Tsuiji et al., 2013).  Given the difference 
in the symptomatic CCNFS621G patient cell line (CCNF2), it will be important to 
further probe these differences using different detection techniques.  Nonetheless, 
these findings further implicate a dysfunction in the spliceosomal system in motor 
neurons derived from a CCNFS621G patient.  
 
The ninth protein identified to be significantly different in its ubiquitinated form 
compared to the healthy control was heat shock protein 8 (HSPA8), which was 
significantly more abundant in the symptomatic CCNFS621G patient derived motor 
neurons (CCNF2), as well as the sporadic Alzheimer’s disease patient derived motor 
neurons (SAD), compared to the healthy donor derived (HC2) motor neurons.  
Though, again, detection of this protein would need to be validated via alternate 
methods of protein quantification, this elevation does correlate with ALS patient 
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serum studies.  HSP70 levels have been detected to be elevated in serum derived 
from ALS patients compared to healthy control, warranting further investigation of 
this protein (Miyazaki et al., 2016). 
 
5.7 Summary and future directions  
 
This study provided the first step in identifying the much-needed characterisation of 
cell type specific ubiquitin modifications, which will be essential in identifying and 
understanding the role of the dynamic human ubiquitome.  This is the first reported 
human iPSC ubiquitome, and subsequently, the first comparison of fibroblasts, 
iPSCs, and iPSC derived motor neurons (the majority of which are derived from the 
same genetic pool).  The relative quantification of these ubiquitinated proteomes 
revealed significant shifts in the requirements of the ubiquitin system contingent of 
cellular stage.  Identification of a plethora of pathways further confirms the 
widespread reliance of cells on the UPS. Fundamental pathways including RNA 
splicing, heat shock, and ECM and cytoskeletal proteins, along with the ubiquitin 
proteasome itself were all detected to be regulated by ubiquitin., as well as a range of 
ALS associated proteins.  Further investigation into the role of ubiquitin in regulating 
these pathways may represent potential areas for improving reprogramming and 
differentiation protocols. Importantly, these pathways may highlight potential 
weaknesses for cells under UPS stress. Understanding the pathways that are most 
affected under conditions of cellular stress, and why, may provide invaluable insight 
into potential therapies from devastating neurodegenerative disease.  Motor neurons 
examined in this study were shown to be more sensitive to UPS stress compared to 
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their terminally matured fibroblast counterparts. Interestingly, this study highlighted 
the incredible sensitivity of iPSCs to proteasomal stress. iPSCs may represent a 
strong candidate for modelling the effects of therapeutics on the UPS so desperately 
required for neurodegenerative diseases such as ALS.  The investigation into the 
differences in individual motor neurons also provided the opportunity for a 
preliminary comparison of ALS motor neuron samples to controls. Differences were 
evident motor neurons derived from a symptomatic CCNFS621G patient.  Differences 
in the ubiquitination of pathways known to be dysfunctional in ALS further implicate 
the UPS as a central player in ALS pathology.  
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Chapter Six:  
 
The Ubiquitin Proteasome System 
in Patient iPSC Derived Motor 
Neurons and Derivative Cell 
Types 
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6 THE UBIQUITIN PROTEASOME SYTEM IN PATIENT IPSC DERIVED 
MOTOR NEURONS AND DERIVATIVE CELL TYPES 
 
6.1 Generating patient derived models to study ALS 
 
Here, for the first time, two CCNFS621G ALS patient derived motor neuron models, 
and an additional healthy control line have been generated using viral-free 
reprogramming.  These cells were characterised via conventional means including 
via the expression of pluripotent mRNA via qRT-PCR as well as the PluriTest, and 
via pluripotency factor expression detected via immunocytochemistry (Engel et al., 
2018; Muñoz et al., 2018). Additionally, as an ancillary benefit of the ubiquitinomics 
analysis performed later in this study, the lines were further validated by the 
detection of cell type specific pathways. For iPSCs this included pathways such as 
the cell cycle and cellular proliferation, which were significantly increased.  The 
characterisation of these three lines, along with a SOD1E101G iPSC line 
(reprogrammed by Rachelle Balez), indicate the successful generation of four novel 
cell lines which can be used to help understand the underlying mechanisms that 
cause ALS, as well as for drug screening for therapeutic development (Dimos et al., 
2008). 
 
Successful generation of motor neurons was characterised by motor neuron markers 
Hb9, Islet 1, and neurofilament heavy, via immunocytochemistry (Zeineddine et al., 
2015) and, similar to the iPSCs, via ubiquitinomics.  For the study of proteostasis, 
the novel patient iPSC derived motor neurons generated by this study provide an 
important tool; these iPSC derived motor neurons allow for the study for endogenous 
 287 
 
proteins in a patient derived motor neuron model.  The dynamic nature of the models 
allow for responsive studies, for example monitoring of cellular phenotypes 
following the inhibition of the UPS (Dimos et al., 2008).  As previously indicated, 
the ability to study endogenous proteins is particularly valuable when investigating 
the UPS, as protein overexpression systems are susceptible to results which may not 
be indicative of the true disease phenotype (Seminary et al., 2018).  This has been 
reported to occur in numerous disease associated proteins, with a variety of side 
effects (Hjerpe et al., 2016). These range from arresting the cell cycle to causing cell 
death (Matiuhin et al., 2008). Of particular importance when studying the UPS, is 
that overexpressing UBL-UBA domain proteins, such as ubiquitin domain-
containing protein DSK2, UV excision repair protein RAD23 homolog A, can have 
qualities of a proteasome inhibitor, preventing general degradation mechanisms 
(Chen and Madura, 2002; Funakoshi et al., 2002; Ortolan et al., 2000). Given the 
broad effect of proteasomal inhibition, it is difficult to discern native interactions of 
these proteins (which is of partcicular importance in reviewing the ubiquitome) under 
normal or disease conditions, in an overexpression model.  For examining cyclin F, 
the ability to monitor endogenous cyclin F is of great value to accompany models 
such as the zebrafish, which share only 61.4% nucleotide sequence similarity 
between the fish and human cyclin F (Hogan et al., 2017).   
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6.2 A UPS dysfunction phenotype is present in symptomatic 
CCNFS621G 
 
A crucial undertaking for establishing these patient derived models was to identify 
phenotypes from which to measure therapeutic outcomes, and to investigate the 
underlying ALS mechanisms. The iPSC derived motor neuron models expressed 
detectable levels of relevant endogenous proteins - including cyclin F, as well as the 
hallmark ALS protein TDP-43. The quantification of these proteins indicated that a 
measurable disease phenotype was present, even at low levels of stress (cell culture 
conditions alone) (Table 6.1).  Comparison of the ALS affected iPSC derived motor 
neurons saw a relative reduction in total TDP-43, and the increased presence of an 
additional TDP-43 species in both the CCNFS621G cell lines motor neurons suggesting 
the CCNFS621G mutation may cause an altered post-translational modification to 
TDP-43, consistent with a TDP-43 proteinopathy. These results, combined with the 
functional assays investigating the UPS dysfunction, and the ubiquitome of 
fibroblasts, iPSCs and motor neurons derived from a symptomatic CCNFS621G patient 
(CCNF2) indicate that the S621G mutation affects the global distribution 
ubiquitination of proteins (including TDP-43, as discussed in this section). 
Collectively, the findings of this study corroborate the proposition that this mutation 
to CCNF causes a toxic gain of function (Galper et al., 2017), further supported by 
the non-lethal effects of cyclin F knock out in mice (Tetzlaff et al., 2004).  It cannot 
be ruled out, however, that there may be a toxic loss of function, as the change in the 
substrate recognition detected in symptomatic CCNFS621G cells may also render 
cyclin F unable to bind to normal substrates. 
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Table 6.1 Comparative summary of phenotypes observed in cell lines analysed in 
this study 
Assay 
Cell lines 
HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
Endogenous Cyclin F 
Expression + + + + + + 
Soluble expression -    - - 
Localisation Nuclear Nuclear Nuclear Nuclear Nuclear Nuclear 
Nuclear body-like 
structures 
+ + + + + + 
Number and 
intensity of nuclear 
bodies 
- - - - - - 
Correlation - - - - - - 
Endogenous TDP-43 
Expression 43 kDa + + + + + + 
Quantification of 43 
kDa 
- - - - - - 
Expression 45 kDa - + + - - - 
Expression 50 kDa -   - - - 
Quantification of 50 
kDa 
-   - - - 
Localisation Nuclear Nuclear Nuclear Nuclear Nuclear Nuclear 
UPS Function 
Proteasomal Stress NS pattern NS pattern NS pattern NS pattern NS pattern NS pattern 
Protein retention - - + - - - 
Ubiquitome - - 
Increased 
number of 
substrates - - - 
- No significant difference, + Present  Decreased abundance 
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6.2.1 Increased ubiquitination of proteins including TDP-43 was evident in 
CCNFS621G motor neurons 
The data from the ubiquitinomics comparison of the symptomatic CCNFS621G motor 
neurons (CCNF2), compared to the healthy control (HC2), combined with the UPS 
dysfunction exhibited in the UPS reporter ‘degron’ assay in this same cell line 
(CCNF2), are consistent with the CCNFS621G mutation causing UPS dysfunction.  
This proposal is further supported by reduction in total endogenous TDP-43, and the 
presence of a likely ubiquitinated TDP-43 species in both CCNFS621G iPSC derived 
motor neurons cell lines (CCNF1 and CCNF2).  Ubiquitinated TDP-43 has 
previously been shown to be increased in abundance in cells expressed mutatnt 
cyclin F (Williams et al 2016), and cells expressing the CCNFS621G mutation have 
been shown to have an increased population of (Lys48) ubiquitinated protein species 
in neuronal-like models (Lee et al., 2018).  It could therefore be postulated that the 
inability to inactivate cyclin F, due to a reduced ability of phosphorylation at S621G 
(Lee et al., 2018), leads to an increased ubiquitination of cyclin F substrates and  the 
subsequent degradation of these substrates until the UPS is overwhelmed, causing 
the accumulation of ubiquitinated protein (Figure 6.1).  This increased ubiquitination 
would decrease the available free ubiquitin pool, stressing the UPS (Farrawell et al., 
2017). Additionally, decreasing the level of cyclin F would potentially have serious 
implications for cellular homeostasis. The ubiquitinomics comparison performed in 
this study indicate that pathways including mitochondrial, spliceosomal, and 
ribosomal pathways, vesicle and ECM associated pathways, and the UPS itself were 
differently ubiquitinated in the symptomatic CCNFS621G motor neurons (Figure 6.1).   
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Figure 6.1 Proposed suggested mechanism of toxic gain of function caused by 
CCNFS621G 
The phosphorylation of wild type (WT), represented by the asterisks (*), cyclin F is 
believed to prevent ubiquitination and regulating the E3 ubiquitin ligase activity of 
cyclin F to maintain homeostasis. Mutant cyclin F reduces phosphorylation, and 
therefore degradation of cyclin F; this increases the ubiquitination of substrates, and 
may alter the substrate recognition, resulting in a decreased specificity, leading to the 
dysfunction of a number of pathways. *Pathways previously identified by Lee et al., 
(2018). 
 
6.2.2 Protection against a UPS phenotype 
Interestingly, the lines derived from the pre-symptomatic and symptomatic 
CCNFS621G carriers did not have identical phenotypes. It is admittedly possible, 
though unlikely, that this phenotype is anomalous, having only one symptomatic 
replicate available at the time of this study. As discussed later in this chapter, the 
development of CRISPR CCNFS621G corrected motor neurons will be essential in 
 292 
 
confirming these phenotypes (Musunuru, 2013). The findings of this study, do 
however corroborate with the few mechanistic studies of cyclin F in ALS performed 
to date, and are in agreement with the general theme of UPS dysfunction reported in 
ALS research.  It is more likely that the fibroblasts collected from the pre-
symptomatic sibling were subject to a protective element that the patient with ALS 
symptoms at the time of collection (CCNF2; the UPS dysfunction phenotype) did not 
have, or had lost. There are two lines of inquiry that should be pursued to better 
understand the ALS causing mechanisms at play: Firstly, the possibility that 
reprogrammed iPSCs were able to retain a protective element from the pre-
symptomatic fibroblasts, or retain a detrimental element in the symptomatic (or 
both).  For example mitochondria are retained throughout the reprogramming process 
owing to the fusion/fission process unique to this organelle, or the epigenetic profile 
of these cells is retained. Both of these features have been previously documented to 
be issues affected in iPSCs (Hayden, 2011; Wahlestedt et al., 2014). Secondly, that 
there is a protective genetic component in the pre-symptomatic donor cells - or 
secondary detrimental factor in the non symptomatic (or both).  Specific genotypes 
of APOE, for example, are neuroprotective, neutral, or promote neurodegeneration in 
Alzheimer’s disease - ε2, ε3, ε4, respectively (Saunders et al., 1993; Huang 2017). 
Interestingly, the symptomatic CCNFS621G line (CCNF2) is APOE ε3/4, carrying the 
neurodegenerative-associated allele.  The pre-symptomatic CCNFS621G line (CCNF1) 
line is APOE ε3/3, and therefore does not have a neurodegenerative allele for APOE. 
Further research into these neuroprotective/neurodegenerative-enhancing agents 
would be of great benefit for therapeutic development, or even risk management.   
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If there is an element or genetic feature in the pre-symptomatic CCNFS621G patient 
derived cells that is neuroprotective in these motor neurons, it would be interesting to 
examine the differences in phenotypes of these cells. The pre-symptomatic 
CCNFS621G patient derived cells did not show the same level of UPS stress or the 
same level of changes to the ubiquitome as the symptomatic CCNFS621G patient 
derived cells. A trend of decreased TDP-43 and the presence of an additional TDP-
43 band were common to both these patient derived cells. Together, this may suggest 
that there is a compensatory element protecting the UPS, which is renown for 
redundancies  (Nagarajan et al., 2017), which may serve as a therapeutic target.  
Additional research into this disease mechanism is therefore critical to determine 
appropriate therapeutic interventions.  Excitingly, as aforemnetioned, the Ooi 
laboratory has recently been provided access to fibroblasts from multiple timepoints 
over the course of the patient’s diagnosis - including pre-symptomatic fibroblasts 
used in this study, early symptomatic and later stage symptomatic. Further 
investigation into these cells will no doubt provide important information for 
discerning the protective effects at play in these cells, which could prove incredibly 
useful for therapeutic development.  
 
6.2.3 Cyclin F may regulate the motor neuron spliceosome 
A recurring trend that arose through this investigation of the CCNFS621G phenotype 
was an association with the spliceosome.  Based on the localisation of cyclin F in 
nuclear bodies, commonly associated with spliceosomal function, as well as the 
significant differences in abundance of eight ubiquitinated spliceosomal proteins in 
symptomatic CCNFS621G motor neurons, it could be speculated that cyclin F has an 
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additional role in modulating the motor neuron spliceosome. This transcriptional 
regulation may be an indirect regulation by cyclin F.  Known substrates of cyclin F 
range in function (as indicated in Table 3.1). Notably, transcription factor B-Myb is a 
cyclin F substrate (Klein et al., 2015).  It would therefore be unsurprising that 
spliceosomal factors are regulated via cyclin F as well. TDP-43, which has been 
shown to be altered in abundance in cyclin F in overexpression systems, (Williams et 
al., 2016) is also known to be associated with mRNA splicing. Alterations to the 
abundance of TDP-43, such as that seen in this study, could induce changes to the 
spliceosomal landscape. (Ederle and Dormann, 2017). The spliceosome was also a 
pathway subject to changed ubiquitination following reporgramming and 
differentiation, indicating a changing reliance on this cellular mechanism in motor 
neurons. Increasing evidence has implicated spliceosomal dysfunction as a 
mechanism that contributes to ALS.  Spliceosomal dysfunction, including 
dysfunction of TDP43 (and another ALS associated protein FUS) is believed to 
cause abnormal splicing, as seen in motor neuron post mortem tissue (Tsuiji et al., 
2013). A study of 12 sporadic ALS post mortem motor neurons, collected by laser 
capture microdissection, indicated 411 proteins were abnormally spliced. 
Interestingly, these aberrantly spliced proteins showed a significant number of ECM 
proteins; further emphasising the great need to focus on these mechanisms identified 
in iPSC derived motor neuron models.  Further studies will be required to investigate 
this relationship between the cyclin F and spliceosomal mechanisms.  
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6.3 Ubiquitin in maintaining pluripotency and differentiation  
 
In addition to establishing novel ALS models, this study also represents the first 
reported human iPSC ubiquitome, as well as the first comparison of fibroblasts and 
differentiated iPSC derived motor neurons from the same genetic origin.  The 
relative quantification of these ubiquitinated proteomes revealed significant shifts in 
the requirements of the ubiquitin system contingent on cellular stage.  Further 
investigation into the role of ubiquitin in regulating these pathways, including ECM 
associated pathways may represent potential areas for improving reprogramming and 
differentiation protocols.  
 
Importantly, these pathways may highlight potential vulnerable mechanisms for cells 
under UPS stress. Understanding which pathways are most affected under conditions 
of cellular stress, and why, may provide invaluable insight into potential therapies for 
devastating neurodegenerative disease.  We have shown that motor neurons are more 
sensitive to UPS stress compared to their terminally matured fibroblast counterparts. 
This vulnerability of motor neurons to UPS stress has been suggested throughout 
motor neuron disease research (Brockington et al., 2013; Ferrari et al., 2016; Tam et 
al., 2019), though perhaps not yet addressed so directly as in this study wherein we 
have been able to compare multiple different cell types derived from the same 
donors.  Interestingly, this study highlighted the incredible sensitivity of iPSCs to 
proteasomal stress. iPSCs may represent a strong candidate for modelling the effects 
of therapeutics, especially those targeting the UPS, so desperately required for 
neurodegenerative diseases such as ALS. 
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6.4 Limitations 
 
As with all ALS-iPSC studies, and cell model studies, these studies are limited by the 
number of cell lines able to be examined at a given time; this limitation is due to the 
costly nature of using these cells, and the limited availability of donors. To date, only 
four studies have examined the prevalence of mutations in the CCNF gene in ALS 
patient populations - these studies have found the frequency of cyclin F mutations 
ranged from 0.6% - 3.3%, meaning there is a limited pool of donors available (Lee et 
al., 2017; Pan et al., 2017; Tian et al., 2018; Williams et al., 2016).  Engagement of 
control lines, including healthy controls and a neurodegenerative control engaged in 
this study provide a limited reference from which we can begin to draw insight on 
disease aetiology.  
 
As suggested earlier in this chapter, it is still not clear to what extent these cells are 
influences by epigenetic and mitochondrial inheritance.  The “age” of these motor 
neurons is thought to be reset during reprogramming to an extent.  It was initially 
thought that the reprogramming process cleared the epigenetic memory of the cells, 
however more recent evidence indicated that cells with multiple rounds of passaging 
were more epigenetically similar to ESCs compared to cells newly reprogrammed 
(Nishizawa et al., 2016). Whether this similarity in epigenetic profile was due to 
culture time, or passage round was unclear. In the studies presented here, cells were 
cultured for at least 20 passages prior to differentiation, reducing the likelihood of 
retaining an unwanted epigenetic state (Mallon et al., 2014).   
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In addition to the epigenetic influence retained during reprogramming, the 
mitochondria (thus the mitochondrial DNA) remains unchanged during 
reprogramming (Wahlestedt et al., 2014).  This may actually prove a strength for the 
model in regards to modelling ALS.  Mitochondrial dysfunction has been linked to 
ALS (Bannwarth et al., 2014). The retention of these fundamental organelles may 
therefore provide valuable insight in ALS mechanisms. Mitochondrial inheritance by 
the iPSCs would therefore be an interesting avenue to pursue in understanding this 
relationship and the consequences for ALS pathogenesis.   
 
Not only is the reprogramming ‘age’ an ongoing issue in the field, but the maturation 
of motor neurons is also still a highly contentious. Motor neuron differentiations vary 
in duration, and induction of neuronal development stages (Lee and Huang, 2017).  
The protein markers commonly used for motor neuron characterisation are HB9 and 
Islet 1, however HB9 is an early motor neuron marker.  Electrophysiology can be 
used to evaluate the functional properties of the cells, as a strong indicator of the 
maturation the cells (Bardy et al., 2016). Whole cell patch clamping as well as 
simpler techniques, such as calcium imaging, and multielectrode arrays would be of 
great benefit in further elucidating the level of maturity of these cells (Bianchi et al., 
2018; Tang et al., 2016). In order to best mimic the in vivo motor neurons, it would 
be advantageous to mature motor neurons alongside myoblasts and other cell types 
including astrocytes to provide a neuromuscular circuit that will even further 
replicate the in vivo system.  Previous co-culture studies of primary motor neuron 
precursors with myoblasts have indicated that the pairing of these cell types advances 
the maturation of the motor neurons (O’Brien and Fischbach, 1986; Prives et al., 
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1976).  Nonetheless, less mature motor neurons may provide critical information in 
the aetiology of ALS as shown in this study and others, as phenotypes can be 
detected at this ‘early age’. Indeed, these early phenotypes may represent early stage 
biomarkers and therefore good indicators of therapeutic intervention (Yoshida et al., 
2015). 
 
One such strategy for examining biomarkers could be via ubiquitinomics. As 
highlighted earlier, PCA indicated that cells derived from the CCNFS621G expressed a 
distinct ubiquitome to other cell lines in fibroblasts, iPSCs, and motor neurons. 
Defining a ‘normal’ ubiquitome would therefore be of great diagnostic value.  
Moreover, a recurring question raised in these ubiquitinomics studies is what are the 
types of ubiquitination post-translational modification amongst the redistributed 
proteins? Specific linkages of ubiquitin chains dictate the protein signalling 
properties of a ubiquitin modification (Xu and Jaffrey, 2011). Understanding which 
ubiqiutin linkages are involved, and potentially dysregulated will aid in determining 
the signalling and functional consequences of alterations.   Establishing the type, or 
types, of ubiquitination occurring on TDP-43 and other substrates of cyclin F will be 
important for establishing the disease mechanisms (and therefore therapeutics). 
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6.5 Future directions 
 
6.5.1.1 ALS causing mutations can be corrected in iPSCs 
Boulting et al. were the second group to ever describe iPSC-ALS motor neuron 
differentiation. This group made an astute observation that removal of an ALS 
mutation (A4V SOD1) would be the optimal method to determine the effects of the 
mutation.  At the time of publication, technologies limited their ability to validate 
this proposed idea (Boulting et al., 2011).  Tools now exist to edit the genome to 
correct or introduce disease-causing mutations, using a technique now referred to as 
genome editing.  Genetic sequences can be altered using tools such as the clustered 
regularly interspaced short palindromic repeats system (CRISPR), the transcription 
activator-like effector nuclease system (TALENS) and Zinc finger nucleases, which 
act a ‘molecular scissors’ cutting specific sites of DNA to allow the removal or 
insertion of DNA sequences.  These tools allow even single base pair changes, 
making it possible to determine the effects of small changes to a genome (Musunuru, 
2013).   
 
Multiple iPSC motor neuron studies have corrected mutations using genome editing 
to induce a reversal of disease phenotype in the same patient derived cell lines, 
creating isogenic controls.  Using such techniques, SOD1 corrections have become a 
reality, and have been successful in eliminating mutant SOD1 cellular phenotypes 
(Chen et al., 2014; Kiskinis et al., 2014; Wainger et al., 2014). For example, 
SOD1D90A patient iPSC derived motor neurons displayed neurofibrillary tangles, 
protein aggregates and cellular degeneration (Chen et al., 2014).  Upon correction of 
this mutation using TALENS, the aggregate formation and cellular stress was 
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alleviated in an isogenic control (same genome maintained however with the D90A 
mutation was reverted to D). Interestingly, the insertion of the D90A mutation into 
ESCs was also sufficient to cause cells to exhibit a similar disease phenotype as the 
D90A iPSC line.  
 
The ability to correct the known mutations provides a Koch's Principle-like method 
of assessing how mutations cause disease, linking mutant genotypes to disease 
phenotypes. The method of genome correction has three strengths in ALS research: 
First, these corrected mutations confirm the expression of an ALS specific phenotype 
in the iPSC motor neurons. Corrections to ALS causing mutations in disease affected 
cells and the introduction of these same mutations into healthy patient derived cells, 
further confirm the validity of these ALS-iPSC motor neuron models, for example in 
research by Chen et al. (2014) and Waigner et al. (2014).  Second, genetic 
engineering can identify and verify the effects of novel mutations.  For disease 
causing mutations, and perhaps genetic risk factors, this will be crucial in confirming 
true causation.  Third, the ability to remove and replace mutations enables us to 
elucidate the other genetic factors of ALS.  In many cases of neurodegeneration more 
than one genetic anomaly is required for disease presentation to occur. This ‘dual hit’ 
hypothesis would be easily validated using genetic engineering to remove or 
introduce one of the two mutations from a cell line, and determine if there is a 
phenotype change. Genetic engineering in ALS-iPSC lines is therefore a useful 
method to explore the additional effects of genetics in ALS, as it provides the ability 
to examine small changes to genotypes and their effects on disease phenotypes in a 
way that was not previously possible before (Musunuru, 2013).  
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6.5.1.2 Driving the latest model 
As is the fast paced nature of neuroscience, many new methods of research have 
been developed over the duration of this study, of which these cellular models can be 
applied.  The use of hydrogels and polymer scaffolds hold exciting new opportunities 
and challenges to ALS modelling, providing the ability to better model in vivo cells 
with 3D applications. Similar to co-culture systems, it is possible that the use of 3D 
systems would change the motor neuron differentiation - potentially changing the 
maturity of the cells (Kawada et al., 2017).  Better systems are now commercially 
available to mimic multicellular systems, including co-culture systems such as 
microfluidic chamber co-cultures with myoblasts, and potentially, following 
improved protocols and characterisations, motor neuron subtypes.  These systems, 
combined with gene editing such as CRISPR will undoubtedly provide powerful 
models to replicate “ALS in a dish”.  
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6.6 Conclusions 
 
In this study, iPSCs, and iPSC derived motor neurons have been generated from ALS 
patients and healthy donors to serve as viable models for ALS research. 
Characterisation of the cell types has laid the foundations for these cells to serve as 
tools to study the underlying mechanisms of ALS.  In examining the expression of 
ALS-associated proteins and vulnerable pathways in iPSC derived motor neurons, a 
number of measurable phenotypes were detected. These included expression of 
cyclin F and TDP-43 in the nucleus in aggregates consistent with nuclear bodies, a 
relative decrease in TDP-43 and cyclin F, UPS dysfunction measured via UPS 
reporter assay, as well as differences in the ubiquitome of a symptomatic CCNFS621G 
patient derived motor neurons, iPSCs, and fibroblasts. A range of ubiquitinated ALS 
associated proteins were detected at endogenous levels in the iPSC derived motor 
neurons were generated from the cells.  Importantly, this means the models generated 
from this study can be employed in ALS research, including in mechanistic studies, 
as well as translating to drug screening trials, to be used alongside traditional models. 
Additionally, this research has provided important information in the generation of 
patient derived motor neurons in both protocol development as well as defining the 
ubiquitinomic landscapes of the iPSC derived motor neurons and their derivative cell 
types, furthering our understanding of the UPS. Together these studies provide 
valuable information, which further our collective knowledge on the role of the UPS 
in iPSC maintenance, iPSC derived motor neuron differentiation, and the role of the 
UPS in the context of ALS. 
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8 APPENDICES 
 
8.1 Additional materials 
Table 8.1 Consumables utilised 
Consumable Brand Source 
Product 
Number 
Aerosol barrier pipette tips 10 µL Interpath Services Interpath 24300 
Aerosol barrier pipette tips 20 µL Interpath Services Interpath 24500 
Aerosol barrier pipette tips 100 µL Interpath Services Interpath 24600 
Aerosol barrier pipette tips 200 µL Interpath Services Interpath 24700 
Aerosol barrier pipette tips 1000 µL Interpath Services Interpath 24800 
Serological pipette tips 1 mL Greiner bio-one Interpath 604181 
Serological pipette tips 5mL Greiner bio-one Interpath 606180 
Serological pipette tips 10 mL Greiner bio-one Interpath 607180 
Serological pipette tips 25 mL Greiner bio-one Interpath 760180 
Serological pipette tips 50 mL Greiner bio-one Interpath 768180 
Cell scrapers Greiner bio-one Interpath 541070 
60 mm tissue culture dishes Greiner bio-one Interpath 628160 
60 mm petri dishes Interpath Services Interpath 628103 
6 well tissue culture plates Greiner bio-one Interpath 657160X 
12 well tissue culture plates Greiner bio-one Interpath 665180 
24 well tissue culture plates Greiner bio-one Interpath 662160X 
96 well tissue culture plates Greiner bio-one Interpath 655101 
96 well optical bottom black plates NUNC Thermo Fisher 160376 
96 well plates Greiner bio-one Interpath 655180X 
Cryovials Greiner bio-one Interpath 122263 
15 mL tubes Greiner bio-one Interpath 188271S 
50 mL tubes Greiner bio-one Interpath 227261S 
T25 tissue culture flasks Greiner bio-one Interpath 690175V 
T75 tissue culture flasks Greiner bio-one Interpath 658175V 
T175 tissue culture flasks Greiner bio-one Interpath 660175V 
Pipette tips (200 µL no filter) Greiner bio-one Interpath 739290 
Pipette tips (1000 µL no filter) Greiner bio-one Interpath 740290 
Reagent reservoirs Corning 
In Vitro 
Technologies 
cor4870 
Microtubes  (1.5 mL, low binding) Eppendorf 
Point of Care 
Diagnostics 
30120086 
Microtube (1.5 mL) Greiner bio-one Interpath 616201X 
Microtube (2 mL, low binding) Eppendorf 
Point of Care 
Diagnostics 
30120094 
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Microtube (.5 mL) Eppendorf 
Point of Care 
Diagnostics 
30121023 
PCR plate Roche Roche 4729692001 
PCR plate seal Roche Roche 4729757001 
Coverslips (13 mm) KNITTTEL ProSciTech G400-13 
Microscope slides Livingstone Thermo Fisher  
FN7101GRN
-A 
Aluminium foil Glad Foil OfficeMax 2549123 
Latex Gloves Skin Shield Livingstone 
GLVLPF100
M-T 
Glass bottle (250 mL) SIMAX Livingstone DB0250SB 
Inoculation loops Sarstedt Sarstedt 86.1562.010 
Petridish Interpath Services Interpath S9014S20 
Cell strainer (40  µm) Greiner BioOne Greiner 542040 
Cell strainer (70  µm) Greiner BioOne Greiner 542070 
Syringe Terumo Syringe Livingstone TSS50LZ 
Filter Millipore Merck Interpath SLGP033RS 
Objective Oil 
Leica 
Microsystems 
Leica 
Microsystems 
5682 
Ethanol (70% v/v)  POCD Healthcare 
Point of Care 
Diagnostics 
ETHABS701
PUW 
Spreader Sarstedt Sarstedt 83.1830 
Inoculation loop Sarstedt Sarstedt 85.1562.010 
23 G needle Livingstone Thermo Fisher  
DN23GX1.0
LV 
21 G needle Livingstone Thermo Fisher  
DN21GX1.0
LV 
18 G needle BD  
Bacto 
laboratories 
302032 
Criterion blot filter paper  Biorad Biorad 1704085 
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Figure 8.0 Representative brightfield images of endodermal progenitors 
Images of iPSC clone lines differentiated to endodermal progenitors which exhbited 
typical clustering morphology (indicatd by arrows) in a healthy donor (HC1), a pre-
symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient 
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy 
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD). N=2 Independent 
differentiations per cell line. Scale bar = 200 μm.  
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8.2 TDP-43 - Western blots 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Full western blots immunolabelled with TDP-43 
Demonstrate no TDP-43 fragmentation at low molecular weight was present in motor 
neuron samples in blots of  (A) Triton X only soluble motor neuron samples and (B) 
Triton X, 2% SDS, and 8M Urea soluble motor neuron samples. 
 
  
B 
A 
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8.3 Nitrosative stress assay (Griess) 
 
Following the evaluation of proteasomal stress in the motor neurons, we sought to 
determine if nitrosative stress was also exhibited.   To investigate cellular nitrosative 
stress in the motor neurons under normal culturing conditions, a Griess assay was 
first performed to determine the concentration of nitrosative stress product (nitrite) 
following normalisation to the total triton X soluble proteins of the culture, to 
account for any differences in cellular abundance-. While no significant difference 
was detected in the endogenous levels of supernatant, some interesting trends were 
observed: The mean level of nitrite detected in the supernatant of the CCNF2 and 
SOD1 motor neurons were lower than the four cell lines examined, including the 
SAD line.  
 
Following the evaluation of the levels of nitrosative stress under normal culture 
conditions, we sought to examine the effects of proteasomal stress; the supernatant of 
MG132 treated motor neurons were compared to DMSO control treated cells.  
Again, no significant difference was observed between the motor neuron 
supernatants.  Interestingly, the proteasomal stress of induced by MG132 appeared to 
have no effect on the supernatant nitrite levels, compared to the DMSO control. 
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Figure 8.2 Nitrogenous stress in motor neurons  
Concentrations of released nitrite from motor neurons cultured under normal 
conditions in supernatant reacted with Griess reagent as detected at absorbance 548 
nm taken from the following cell lines: healthy female (HC1), a CCNFS621G female 
(CCNF1), a CCNFS621G male (CCNF2), a SOD1E101G male (SOD1), a healthy male 
(HC2) and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative 
control. Concentrations were normalised to the concentration of total protein.  
 338 
 
 
The Griess assay harnesses the Griess diazotization reaction to colourimetrically 
determine the concentration of NO2 species against a standard curve.  First 
established by Griess in 1879, the assay selectively assesses the NO2 levels, however 
cannot account for other nitrosative stress species.  The over two fold difference in 
the mean concentration of NO2 species in the supernatant from the motor neurons 
derived from the positive ALS control SOD1E101G male donor, strongly suggests that 
NO2 may be further catalysed to ONOO
-, in the supernatant. The similarities in the 
motor neuron supernatant derived from the CCNFS21G male donor, and the reduced 
levels in the other CCNF mutant cell line, derived from the CCNFS21G female, and 
the neurodegenerative control SAD male donor derived motor neurons.   
 
Nitrosative stress following proteasomal stress was next monitored. As may be 
expected, no significant differences between DMSO treated motor neurons and 
MG132 treated motor neuron.  Suggests that proteasomal stress is an early disease 
even compared to nitrosative stress exhibited in ALS pathology.   Comparison of the 
non-treated cells and the DMSO/MG132 treatments indicated a difference between 
the comparative levels of SOD1, indicated that the vehicle, DMSO, may yield an 
increase in nitrosative stress.  
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Figure 8.3 Nitrogenous stress in motor neurons following proteasomal inhibition.  
Concentrations of released nitrite from motor neurons cultured following 
proteasomal inhibition (16 h treatment with 10 mM MG132) in supernatant reacted 
with Griess reagent as detected at absorbance 548 nm taken from the following cell 
lines: healthy female (HC1), a CCNFS621G female (CCNF1), a CCNFS621G male 
(CCNF2), a SOD1E101G male (SOD1), a healthy male (HC2) and a sporadic 
Alzheimer’s disease male (SAD) as a neurodegenerative control. Concentrations 
were normalised to paired vehicle (DMSO) treated motor neuron concentrations.  
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8.4 Motor neuron response to proteasomal inhibition 
 
Table 8.2 Fold change of mitochondrial viability following 16 h proteasomal 
inhibition at 1 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.74 0.97 0.61 0.83 1.43* 
CCNF1   1.00 1.31 0.82 1.12 1.93 
CCNF2     1.00 0.63 0.86 1.48* 
SOD1       1.00 1.36 2.34** 
HC2         1.00 1.72 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis.  
Significant difference denoted as *P<0.0332, **P<0.0021. 
 
Table 8.3 Fold change of mitochondrial viability following 16 h proteasomal 
inhibition at 2.5 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.79* 0.82 0.89** 0.88** 0.97 
CCNF1   1.00 1.03 1.13 1.11 1.23 
CCNF2     1.00 1.09 1.08 1.19** 
SOD1       1.00 0.98 1.09 
HC2         1.00 1.10 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference denoted as * P<0.0332, ** P<0.0021. 
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Table 8.4 Fold change of mitochondrial viability following 16 h proteasomal 
inhibition at 10 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.20 0.83 1.58 2.13* 1.62 
CCNF1   1.00 0.69 1.31 1.77 1.35 
CCNF2     1.00 1.91 2.58 1.96 
SOD1       1.00 1.35 1.25 
HC2         1.00 0.76 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference denoted as * P<0.0332.  
 
Table 8.5 Fold change of mitochondrial viability following 16 h proteasomal 
inhibition at 100 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.06** 1.11 2.39 2.91 5.54 
CCNF1   1.00 1.05 2.27** 2.76*** 5.25**** 
CCNF2     1.00 2.15 2.61 4.98**** 
SOD1       1.00 1.22 2.31 
HC2         1.00 1.90 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant difference 
determined from Two-way ANOVA with Tukey’s Post Hoc Test, 
denoted as **P<0.0021, ***P<0.0002, ****P<0.0001 
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Table 8.6 Fold change of mitochondrial viability following 16 h proteasomal 
inhibition at 250 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.50 1.07 1.52 2.50 3.65 
CCNF1   1.00 0.71 1.01 1.66 2.43 
CCNF2     1.00 1.42 2.34 3.43 
SOD1       1.00 1.65 2.41 
HC2         1.00 1.46 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant difference 
determined from Two-way ANOVA with Tukey’s Post Hoc Test. 
 
Table 8.7 Fold change of mitochondrial viability following 48 h proteasomal 
inhibition at 1 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 
1.00 1.47 1.12 1.43 1.59 1.19 
CCNF1 
  1.00 0.76 0.98 1.08 0.81 
CCNF2 
    1.00 1.28 1.42 1.06 
SOD1 
      1.00 1.11 0.83 
HC2 
        1.00 0.75 
SAD 
          1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant difference 
determined from Two-way ANOVA with Tukey’s Post Hoc Test. 
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Table 8.8 Fold change of mitochondrial viability following 48 h proteasomal 
inhibition at 2.5 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.30 1.14 0.81 1.22 1.16 
CCNF1   1.00 0.87 0.62* 0.94 0.89 
CCNF2     1.00 0.71 1.08 1.02 
SOD1       1.00 1.51 1.43 
HC2         1.00 0.95 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test denoted as *P<0.0332. 
 
Table 8.9 Fold change of mitochondrial viability following 48 h proteasomal 
inhibition at 10 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.32 0.91 0.97 1.27 1.14 
CCNF1   1.00 0.69 0.74 0.97 0.87 
CCNF2     1.00 1.07 1.40 1.25 
SOD1       1.00 1.31 1.17 
HC2         1.00 0.89 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test. 
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Table 8.10 Fold change of mitochondrial viability following 48 H proteasomal 
inhibition at 100 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.80 0.71 0.48 0.72 1.05 
CCNF1   1.00 0.88 0.60 0.90 1.31 
CCNF2     1.00 0.67 1.02 1.48 
SOD1       1.00 1.51 2.19 
HC2         1.00 1.45 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test. 
 
Table 8.11 Fold change of mitochondrial viability following 48 H proteasomal 
inhibition at 250 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.90 0.91 0.62 0.79 0.90 
CCNF1   1.00 1.00 0.69 0.87 0.99 
CCNF2     1.00 0.69 0.87 0.99 
SOD1       1.00 1.27 1.45 
HC2         1.00 1.14 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test. 
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Table 8.12 Fold change of mitochondrial viability following 72 H proteasomal 
inhibition at 1 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.78*** 1.22 1.19 1.47* 0.90 
CCNF1   1.00 0.68 0.67 0.83 0.51**** 
CCNF2     1.00 0.98 1.21 0.74 
SOD1       1.00 1.24 0.76 
HC2         1.00 0.61*** 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant difference 
determined from Two-way ANOVA with Tukey’s Post Hoc Test, 
denoted as *P<0.0332, ***P<0.0002, ****P<0.0001. 
 
Table 8.13 Fold change of mitochondrial viability following 72 H proteasomal 
inhibition at 2.5µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 1.29 1.87 0.70 1.19 0.80 
CCNF1   1.00 1.45 0.54 0.93 0.62 
CCNF2     1.00 0.37* 0.64 0.43* 
SOD1       1.00 1.71 1.15 
HC2         1.00 0.67 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant difference 
determined from Two-way ANOVA with Tukey’s Post Hoc 
Test, denoted as *P<0.0332. 
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Table 8.14 Fold change of mitochondrial viability following 72 H proteasomal 
inhibition at 10 µM.  
 HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.94 1.54 0.45* 1.29 1.22 
CCNF1  1.00 1.64 0.48 1.37 1.30 
CCNF2   1.00 0.29** 0.83 0.79 
SOD1    1.00 2.83** 2.68** 
HC2     1.00 0.95 
SAD      1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test, denoted as *P<0.0332, ***P<0.0002. 
 
Table 8.15 Fold change of mitochondrial viability following 72 H proteasomal 
inhibition at 100 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.46 0.62 0.32* 0.64 1.01 
CCNF1   1.00 1.33 0.70 1.39 2.18 
CCNF2     1.00 0.52 1.04 1.63 
SOD1       1.00 2.00 3.12* 
HC2         1.00 1.56 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test, denoted as *P<0.0332. 
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Table 8.16 Fold change of mitochondrial viability following 72 H proteasomal 
inhibition at 250 µM.  
  HC1 CCNF1 CCNF2 SOD1 HC2 SAD 
HC1 1.00 0.77 1.12 0.61 0.97 1.20 
CCNF1   1.00 1.46 0.80 1.26 1.56 
CCNF2     1.00 0.55 0.86 1.07 
SOD1       1.00 1.58 1.96 
HC2         1.00 1.24 
SAD           1.00 
Red indicates decrease, blue indicates increased viability 
compared to cell line indicated on Y axis. Significant 
difference determined from Two-way ANOVA with Tukey’s 
Post Hoc Test. 
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8.5 Heatmap of ubiquitinomes examined 
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Figure 8.4 Heat maps of total filtered ubiquitinomics  
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8.6 Pearson’s correlation heatmaps 
 
 
 
 
 
 
 
 
 
Figure 8.5 Heatmaps of Pearson’s correlation values  
Pearson’s correlation values calculated from the comparison of samples from (A) 
symptomatic CCNFS621G patient derived cell lines (CCNF2), (B) healthy control 
(HC2), and (C) sporadic Alzheimer’s disease (SAD). Heatmaps were generated for 
each cell line to compare between replicates and between cell stages. 
C 
B 
A 
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8.7 Multiscatter 
 
Figure 8.6 Multiscatter correlation plot of pre-symptomatic CCNFS621G patient derived ubiquitomes (CCNF1). 
Multiscatter plot was calculated as an additional measure for correlation of data within sample replicates and between cell types.  Multiscatter 
plots were generated for each cell line to compare between replicates and between cell stages.
 351 
 
 
 
Figure 8.7 Multiscatter correlation plot of healthy donor derived ubiquitomes (HC2) 
Multiscatter plot was calculated as an additional measure for correlation of data within sample replicates and between cell types.  Multiscatter 
plots were generated for each cell line to compare between replicates and between cell stages. 
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8.8  Principal component analyses 
 
 
Figure 8.9 Visualisation of principal component analysis (PCA).  
The PCA uses a singular value decomposition to provide a scaled projection of the 
total data.  The axis generated from the data two principal components are used to re-
plot data. Principal Component 1 (PC1) is plotted from the largest variation of the 
total data. Principal Component 2 (PC2) is plotted perpendicular to PC1.  Figure is 
from Kassambara (2017). 
 
 
Figure 8.10 Principle components analysis of samples from pre-symptomatic 
CCNFS621G patient derived ubiquitomes (CCNF1). 
PCA generated from comparison of filtered ubiquitinomic data from fibroblasts, 
iPSCs and motor neurons. Numbers indicate replicates. 
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Figure 8.11 Principle components analysis of cell types. 
Data is from (A) symptomatic CCNFS621G patient-derived ubiquitomes (CCNF2) and 
(B) sporadic Alzheimer’s disease patient-derived ubiquitomes. Principle components 
analysis generated from comparison of filtered ubiquitinomic data from fibroblasts, 
iPSCs and motor neurons. Numbers indicate replicates. 
 
A 
B 
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8.9 Qualitative ubiquitome venn analyses 
 
 
 
 
Figure 8.12 Venn analysis of ubiquitinated proteins in fibroblasts, iPSCs, and motor 
neurons  
Comparisons are within cell lines from samples from (A) a pre-symptomatic 
CCNFS621G (CCNF1), (B) a symptomatic CCNFS621G (CCNF2) and (C) sporadic 
Alzheimer’s disease (SAD). 
B 
C 
A 
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8.10 Volcano plots 
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Figure 8.14 Volcano plot comparisons of ubiquitomes derived from symptomatic 
CCNFS621G patient (CCNF2). Plots compare (A) fibroblast v iPSC, (B) iPSC v motor 
neurons, and (C) fibroblasts v motor neurons. 
A 
B 
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Figure 8.15 Volcano plot comparison of ubiquitomes derived from a healthy donors  
Volcano plots compare (A) fibroblast v iPSC (HC1) (B) iPSC v motor neurons 
(HC2). 
A 
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Figure 8.16 Volcano plot comparison of ubiquitomes derived from a sporadic 
Alzheimer’s disease donor (SAD)  
Volcano plots compare (A) fibroblast v iPSC, (B) iPSC v motor neurons, and (C) 
fibroblasts v motor neurons. 
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Figure 8.17 Neurite outgrowth following longitudinal UBA1 inhibition  
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10 
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth 
was unaffected by long-term low dose PYR41 treatment in healthy control iPSC-
derived motor neurons (A) HC1 and (B) a symptomatic CCNFS621G  (CCNF2). 
Significant difference tested via ANOVA P>0.05. 
A 
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Figure 8.18 Neurite outgrowth following longitudinal UBA1 inhibition  
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10 
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth 
was unaffected by long term low dose PYR41 treatment in healthy control iPSC-
derived motor neurons from (A) SOD1 and a (B) healthy control (HC2) patient 
iPSC-derived motor neurons. Significant difference tested via ANOVA P>0.05. 
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Figure 8.19 Neurite outgrowth following longitudinal UBA1 inhibition. 
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10 
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth 
was unaffected by long term low dose PYR41 treatment in healthy control iPSC-
derived motor neurons from a sporadic Alzheimer’s disease patient iPSC-derived 
motor neurons. Significant difference tested via ANOVA P>0.05. 
 
 
